Annotation Detail for ESR2
Basic Information Top
| Gene Symbol: | ESR2 ( ER-BETA,ESR-BETA,ESRB,ESTRB,Erb,NR3A2 ) |
|---|---|
| Gene Full Name: | estrogen receptor 2 (ER beta) |
| Band: | 14q23.2-q23.3 |
| Quick Links | Entrez ID:2100; OMIM: 601663; Uniprot ID:ESR2_HUMAN; ENSEMBL ID: ENSG00000140009; HGNC ID: 3468 |
| Relate to Another Database: | SFARIGene; denovo-db |
| No data |
| No data |
| Pathway ID | Pathway Name |
|---|---|
| Gene Expression |
| Pathway ID | Pathway Name |
|---|---|
| 200029 | Plasma membrane estrogen receptor signaling |
| No data |
| No data |
| No data |
| Desease ID | Desease Name |
|---|---|
| 1709 | Parkinson disease |
| 1740 | Alzheimer's disease |
| 1743 | Late pregnancy |
| 1888 | Myasthenia Gravis |
| 1891 | Ptosis |
| 1901 | Endometriosis |
| 1918 | Atherosclerosis |
| 1934 | Cancer |
| 1940 | Ovarian disease |
| 1979 | Testicular dysfunction |
| 1997 | Dental plaque |
| 2091 | Hypertension |
| 2060 | Glaucoma |
| 2069 | Schizophrenia |
| 2070 | Cholelithiasis |
| 2119 | Temporal arteritis |
| 2138 | Osteoporosis |
| Desease Name |
|---|
| bone density fractures, vertebral |
| menstrual disorders |
| Parkinson's disease |
| blood pressure, arterial |
| CARDIOVASCULAR |
| cholesterol cholesterol, HDL cholesterol, LDL fatty acid glucose insulin lipoprotein triacylglycerols |
| endometriosis |
| hypospadias |
| hormone disturbance |
| prostate cancer |
| bone mass |
| blood pressure |
| Bone Mineral Density |
| CANCER |
| PSYCH |
| homocysteine nitric oxide |
| bone density |
| breast cancer |
| NEUROLOGICAL |
| METABOLIC |
| bone density fracture risk osteoporosis, postmenopausal |
| Infertility, Male |
| dementia, vascular |
| bulimia |
| REPRODUCTION |
| No data |
| No data |
| Chemical ID | Chemical Name | Interaction | Interaction Action | Publication |
|---|---|---|---|---|
| C002591 | 16-ketoestrone | 16-ketoestrone binds to ESR2 protein | affects binding | 16728493 |
| C033729 | 1H,1H,2H,2H-perfluorodecanol | 1H,1H,2H,2H-perfluorodecanol promotes the reaction [ESR2 protein binds to NCOA2 protein] | affects binding|increases reaction | 17603182 |
| C033729 | 1H,1H,2H,2H-perfluorodecanol | 1H,1H,2H,2H-perfluorodecanol results in increased activity of ESR2 protein | increases activity | 17603182 |
| C508406 | 1H,1H,2H,2H-perfluorooctan-1-ol | 1H,1H,2H,2H-perfluorooctan-1-ol promotes the reaction [ESR2 protein binds to NCOA2 protein] | affects binding|increases reaction | 17603182 |
| C508406 | 1H,1H,2H,2H-perfluorooctan-1-ol | 1H,1H,2H,2H-perfluorooctan-1-ol results in increased activity of ESR2 protein | increases activity | 17603182 |
| C035476 | 2,2',4,4'-tetrahydroxybenzophenone | 2,2',4,4'-tetrahydroxybenzophenone binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16079615 |
| C035476 | 2,2',4,4'-tetrahydroxybenzophenone | 2,2',4,4'-tetrahydroxybenzophenone binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15458795 |
| C035476 | 2,2',4,4'-tetrahydroxybenzophenone | 2,2',4,4'-tetrahydroxybenzophenone results in decreased expression of ESR2 mRNA | decreases expression | 15458795 |
| C035476 | 2,2',4,4'-tetrahydroxybenzophenone | 2,2',4,4'-tetrahydroxybenzophenone results in increased expression of ESR2 mRNA | increases expression | 15458797 |
| C404910 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 15840436 10999957 11861976 10579340 |
| C404910 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15840436 |
| C404910 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Genistein binds to and results in increased activity of ESR2 protein] | affects binding|decreases reaction|increases activity | 11861976 |
| C404910 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased expression of ESR2 mRNA | decreases expression | 11509743 |
| C404910 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in increased expression of ESR2 mRNA | increases expression | 11509743 |
| C404910 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | [Estradiol co-treated with 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 11509743 |
| C404910 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | [Estradiol co-treated with 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 11509743 |
| C404910 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 10579340 |
| C404910 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 11509743 |
| C003585 | 22-hydroxycholesterol | 22-hydroxycholesterol binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 17873880 |
| C003585 | 22-hydroxycholesterol | 22-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17873880 |
| C104006 | 2',3',4',5'-tetrachloro-4-biphenylol | 2',3',4',5'-tetrachloro-4-biphenylol binds to ESR2 protein | affects binding | 10964929 |
| C104006 | 2',3',4',5'-tetrachloro-4-biphenylol | 2',3',4',5'-tetrachloro-4-biphenylol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 10964929 |
| C104006 | 2',3',4',5'-tetrachloro-4-biphenylol | 2',3',4',5'-tetrachloro-4-biphenylol promotes the reaction [ESR2 protein binds to NCOA1 protein] | affects binding|increases reaction | 10964929 |
| C104006 | 2',3',4',5'-tetrachloro-4-biphenylol | 2',3',4',5'-tetrachloro-4-biphenylol promotes the reaction [ESR2 protein binds to NCOA2 protein] | affects binding|increases reaction | 10964929 |
| C101851 | 2-(((3,5-dichlorophenyl)carbamoyl)oxy)-2-methyl-3-butenoic acid | 2-(((3,5-dichlorophenyl)carbamoyl)oxy)-2-methyl-3-butenoic acid binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16750840 |
| C486182 | 2,3-bis(4-hydroxyphenyl)-propionitrile | ESR2 protein affects the reaction [2,3-bis(4-hydroxyphenyl)-propionitrile results in increased expression of BCL2 mRNA] | affects reaction|increases expression | 19264808 |
| C486182 | 2,3-bis(4-hydroxyphenyl)-propionitrile | ESR2 protein affects the reaction [2,3-bis(4-hydroxyphenyl)-propionitrile results in increased expression of PDCD4 mRNA] | affects reaction|increases expression | 19264808 |
| C486182 | 2,3-bis(4-hydroxyphenyl)-propionitrile | 2,3-bis(4-hydroxyphenyl)-propionitrile binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15994857 20926581 17234159 17088409 |
| C067259 | 2,4,6-trichlorophenyl-4'-aminophenyl ether | 2,4,6-trichlorophenyl-4'-aminophenyl ether results in increased activity of ESR2 protein | increases activity | 15064155 |
| C121479 | 2,4-dihydroxybenzophenone | 2,4-dihydroxybenzophenone binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16079615 |
| C044563 | 24-hydroxycholesterol | 24-hydroxycholesterol binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 17873880 |
| C044563 | 24-hydroxycholesterol | 24-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17873880 |
| C007997 | 25-hydroxycholesterol | 25-hydroxycholesterol binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 17873880 |
| C007997 | 25-hydroxycholesterol | 25-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17873880 |
| C076996 | 27-hydroxycholesterol | 27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR2 protein | affects binding|affects folding|increases activity | 17872378 |
| C076996 | 27-hydroxycholesterol | 27-hydroxycholesterol binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 17873880 |
| C076996 | 27-hydroxycholesterol | 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17873880 |
| C076996 | 27-hydroxycholesterol | ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA] | affects reaction|decreases expression | 17873880 |
| C076996 | 27-hydroxycholesterol | ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA] | affects reaction|decreases expression | 17873880 |
| C076996 | 27-hydroxycholesterol | ESR2 protein affects the susceptibility to 27-hydroxycholesterol | affects response to substance | 17873880 |
| C004369 | 2-phenylphenol | 2-phenylphenol results in increased expression of ESR2 mRNA | increases expression | 12737316 |
| C041525 | 3,3',4,5'-tetrahydroxystilbene | 3,3',4,5'-tetrahydroxystilbene results in increased activity of ESR2 protein | increases activity | 17935960 |
| C041525 | 3,3',4,5'-tetrahydroxystilbene | fulvestrant inhibits the reaction [3,3',4,5'-tetrahydroxystilbene results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17935960 |
| C028451 | 3,4,3',4'-tetrachlorobiphenyl | 3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [nonylphenol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 16291559 |
| C028451 | 3,4,3',4'-tetrachlorobiphenyl | 3,4,3',4'-tetrachlorobiphenyl results in decreased expression of ESR2 mRNA | decreases expression | 17291011 |
| C028451 | 3,4,3',4'-tetrachlorobiphenyl | [4-nonylphenol co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 17291011 |
| C028451 | 3,4,3',4'-tetrachlorobiphenyl | alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in decreased expression of ESR2 mRNA] | decreases expression|decreases reaction | 17291011 |
| C028451 | 3,4,3',4'-tetrachlorobiphenyl | fulvestrant inhibits the reaction [[4-nonylphenol co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in decreased expression of ESR2 mRNA] | affects cotreatment|decreases expression|decreases reaction | 17291011 |
| C028451 | 3,4,3',4'-tetrachlorobiphenyl | Tamoxifen inhibits the reaction [[4-nonylphenol co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in decreased expression of ESR2 mRNA] | affects cotreatment|decreases expression|decreases reaction | 17291011 |
| C053286 | 3,4-dihydroxybenzaldoxime | 3,4-dihydroxybenzaldoxime analog binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 12954056 |
| C038939 | 3-(4'-methylbenzylidene)camphor | 3-(4'-methylbenzylidene)camphor binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16079615 |
| C038939 | 3-(4'-methylbenzylidene)camphor | 3-(4'-methylbenzylidene)camphor binds to ESR2 protein | affects binding | 15147785 |
| C101850 | 3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide | 3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16750840 |
| C026423 | 3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one | 3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one binds to and affects the activity of ESR2 protein | affects activity|affects binding | 16506809 |
| C511303 | 3-benzylidene camphor | 3-benzylidene camphor binds to ESR2 protein | affects binding | 15147785 |
| C047368 | 3-methylquercetin | 3-methylquercetin binds to ESR2 protein | affects binding | 14706564 |
| C496952 | 4-(2-chloro-4-(2-piperidin-1-ylethoxy)phenyl)-5-(2,6-dichloro-4-hydroxyphenyl)-2-imidazoline | 4-(2-chloro-4-(2-piperidin-1-ylethoxy)phenyl)-5-(2,6-dichloro-4-hydroxyphenyl)-2-imidazoline binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15658860 |
| C486184 | 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol | ESR2 protein affects the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol results in increased expression of BCL2 mRNA] | affects reaction|increases expression | 19264808 |
| C486184 | 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol | ESR2 protein affects the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol results in increased expression of PDCD4 mRNA] | affects reaction|increases expression | 19264808 |
| C009505 | 4,4'-diaminodiphenylmethane | 4,4'-diaminodiphenylmethane results in decreased expression of ESR2 mRNA | decreases expression | 18648102 |
| C477728 | 4-fluorobenzoyl-TN-14003 | 4-fluorobenzoyl-TN-14003 inhibits the reaction [SDF1 protein results in increased activity of ESR2 protein] | decreases reaction|increases activity | 19584281 |
| C477728 | 4-fluorobenzoyl-TN-14003 | 4-fluorobenzoyl-TN-14003 inhibits the reaction [SDF1 protein results in increased phosphorylation of ESR2 protein] | decreases reaction|increases phosphorylation | 19584281 |
| C024292 | 4-hydroxybenzophenone | 4-hydroxybenzophenone binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16079615 |
| C014036 | 4-hydroxyestradiol-17 beta | 4-hydroxyestradiol-17 beta binds to ESR2 protein | affects binding | 15993745 |
| C016601 | 4-hydroxytamoxifen | 4-hydroxytamoxifen affects the expression of ESR2 protein | affects expression | 15721411 |
| C016601 | 4-hydroxytamoxifen | 4-hydroxytamoxifen binds to ESR2 protein | affects binding | 9751507 17203231 |
| C016601 | 4-hydroxytamoxifen | 4-hydroxytamoxifen inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| C016601 | 4-hydroxytamoxifen | 4-hydroxytamoxifen inhibits the reaction [methoxyacetic acid promotes the reaction [Estradiol results in increased activity of ESR2 protein]] | decreases reaction|increases activity|increases reaction | 15103026 |
| C016601 | 4-hydroxytamoxifen | ESR2 protein results in increased susceptibility to 4-hydroxytamoxifen | increases response to substance | 15821116 |
| C016601 | 4-hydroxytamoxifen | 4-hydroxytamoxifen inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| C504750 | 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene | 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene affects the expression of ESR2 mRNA | affects expression | 20435109 |
| C041594 | 4-nonylphenol | 4-nonylphenol binds to ESR2 protein | affects binding | 11518614 |
| C041594 | 4-nonylphenol | 4-nonylphenol binds to ESR2 protein | affects binding | 15081833 |
| C041594 | 4-nonylphenol | 4-nonylphenol results in decreased expression of ESR2 mRNA | decreases expression | 16759644 |
| C041594 | 4-nonylphenol | [4-nonylphenol co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 17291011 |
| C041594 | 4-nonylphenol | fulvestrant inhibits the reaction [[4-nonylphenol co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in decreased expression of ESR2 mRNA] | affects cotreatment|decreases expression|decreases reaction | 17291011 |
| C041594 | 4-nonylphenol | Tamoxifen inhibits the reaction [[4-nonylphenol co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in decreased expression of ESR2 mRNA] | affects cotreatment|decreases expression|decreases reaction | 17291011 |
| C041594 | 4-nonylphenol | 4-nonylphenol results in increased expression of ESR2 mRNA | increases expression | 17258427 |
| C041594 | 4-nonylphenol | 4-nonylphenol results in increased activity of ESR2 protein | increases activity | 11403899 |
| C080417 | 4-octylphenol | 4-octylphenol binds to ESR2 protein | affects binding | 15081833 |
| C019046 | 4-phenylphenol | 4-phenylphenol results in increased expression of ESR2 mRNA | increases expression | 12737316 |
| C105260 | 4-tert-octylphenol | 4-tert-octylphenol binds to ESR2 protein | affects binding | 10964929 |
| C105260 | 4-tert-octylphenol | 4-tert-octylphenol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 10964929 |
| C105260 | 4-tert-octylphenol | 4-tert-octylphenol promotes the reaction [ESR2 protein binds to NCOA1 protein] | affects binding|increases reaction | 10964929 |
| C105260 | 4-tert-octylphenol | 4-tert-octylphenol promotes the reaction [ESR2 protein binds to NCOA2 protein] | affects binding|increases reaction | 10964929 |
| C105260 | 4-tert-octylphenol | 4-tert-octylphenol results in increased expression of ESR2 mRNA | increases expression | 12737316 |
| C105260 | 4-tert-octylphenol | 4-tert-octylphenol results in increased expression of ESR2 mRNA | increases expression | 17258427 |
| C120076 | 5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol | 5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 15465114 |
| C113977 | 5-octylphenol | 5-octylphenol binds to ESR2 protein | affects binding | 11518614 |
| C121707 | 7,3'-dihydroxy-4'-methoxyisoflavone | 7,3'-dihydroxy-4'-methoxyisoflavone binds to ESR2 protein | affects binding | 20686605 |
| C121707 | 7,3'-dihydroxy-4'-methoxyisoflavone | 7,3'-dihydroxy-4'-methoxyisoflavone inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 20686605 |
| C475050 | 7alpha-methyl-17alpha-ethynylestradiol | 7alpha-methyl-17alpha-ethynylestradiol binds to ESR2 protein | affects binding | 12117614 |
| C119737 | 8-prenylnaringenin | 8-prenylnaringenin analog binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 17149865 |
| C119737 | 8-prenylnaringenin | 8-prenylnaringenin binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16076101 |
| C119737 | 8-prenylnaringenin | 8-prenylnaringenin results in decreased expression of ESR2 mRNA | decreases expression | 16522720 |
| D000452 | Aldrin | Aldrin binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 16626760 |
| C103303 | alitretinoin | alitretinoin inhibits the reaction [Paclitaxel results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 19340624 |
| D013196 | Dihydrotestosterone | AR protein mutant form affects the reaction [Dihydrotestosterone results in decreased expression of ESR2 protein] | affects reaction|decreases expression | 18007998 |
| D013196 | Dihydrotestosterone | Dihydrotestosterone results in decreased expression of ESR2 mRNA | decreases expression | 18007998 |
| D013196 | Dihydrotestosterone | Dihydrotestosterone results in decreased expression of ESR2 protein | decreases expression | 18007998 |
| D013196 | Dihydrotestosterone | Dihydrotestosterone results in increased activity of ESR2 protein | increases activity | 15171712 |
| D013196 | Dihydrotestosterone | Dihydrotestosterone results in increased localization of ESR2 protein | increases localization | 15171712 |
| D013196 | Dihydrotestosterone | fulvestrant inhibits the reaction [Dihydrotestosterone results in increased activity of ESR2 protein] | decreases reaction|increases activity | 15171712 |
| D013196 | Dihydrotestosterone | fulvestrant inhibits the reaction [Dihydrotestosterone results in increased localization of ESR2 protein] | decreases reaction|increases localization | 15171712 |
| C040534 | alpha-hexachlorocyclohexane | alpha-hexachlorocyclohexane results in increased activity of ESR2 protein | increases activity | 15064155 |
| C011512 | alpha-naphthoflavone | alpha-naphthoflavone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in decreased expression of ESR2 mRNA] | decreases expression|decreases reaction | 17291011 |
| D000643 | Ammonium Chloride | Ammonium Chloride affects the expression of ESR2 mRNA | affects expression | 16483693 |
| D015113 | Androstane-3,17-diol | Androstane-3,17-diol analog binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 17003281 |
| D015113 | Androstane-3,17-diol | Androstane-3,17-diol binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 17003281 |
| D015113 | Androstane-3,17-diol | fulvestrant inhibits the reaction [Androstane-3,17-diol analog binds to and results in increased activity of ESR2 protein] | affects binding|decreases reaction|increases activity | 17003281 |
| D015113 | Androstane-3,17-diol | fulvestrant inhibits the reaction [Androstane-3,17-diol binds to and results in increased activity of ESR2 protein] | affects binding|decreases reaction|increases activity | 17003281 |
| D015113 | Androstane-3,17-diol | Androstane-3,17-diol binds to ESR2 protein | affects binding | 16452668 |
| D047310 | Apigenin | Apigenin binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 9751507 |
| D047310 | Apigenin | Apigenin inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| D047310 | Apigenin | Apigenin results in increased activity of ESR2 protein | increases activity | 16118406 17132221 16860978 |
| D001149 | Arsenates | [Arsenates co-treated with Atrazine] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 18585445 |
| D001149 | Arsenates | Arsenates results in increased expression of ESR2 mRNA | increases expression | 18585445 |
| D001280 | Atrazine | [Arsenates co-treated with Atrazine] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 18585445 |
| D001280 | Atrazine | Atrazine results in increased expression of ESR2 mRNA | increases expression | 18585445 |
| C447119 | bazedoxifene acetate | bazedoxifene acetate binds to ESR2 protein | affects binding | 15961563 |
| C020225 | benzohydrol | benzohydrol binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16079615 |
| C047723 | benzophenone | benzophenone binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16079615 |
| C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15207704 |
| D019207 | beta Carotene | beta Carotene inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17051425 |
| D019207 | beta Carotene | beta Carotene inhibits the reaction [Genistein results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17051425 |
| C023888 | beta-hexachlorocyclohexane | beta-hexachlorocyclohexane results in increased activity of ESR2 protein | increases activity | 15064155 |
| C004541 | biochanin A | biochanin A binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16076101 9751507 |
| C004541 | biochanin A | biochanin A binds to ESR2 protein | affects binding | 16566672 |
| C004541 | biochanin A | biochanin A inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 16566672 |
| C006780 | bisphenol A | AR protein mutant form affects the reaction [bisphenol A results in decreased expression of ESR2 mRNA] | affects reaction|decreases expression | 18007998 |
| C006780 | bisphenol A | bisphenol A analog binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 20427257 |
| C006780 | bisphenol A | bisphenol A analog binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 11335189 |
| C006780 | bisphenol A | bisphenol A analog inhibits the reaction [Estradiol binds to and results in increased activity of ESR2 protein] | affects binding|decreases reaction|increases activity | 20427257 |
| C006780 | bisphenol A | bisphenol A binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 11258963 9751507 14709801 |
| C006780 | bisphenol A | bisphenol A binds to ESR2 protein | affects binding | 10964929 11518614 |
| C006780 | bisphenol A | bisphenol A inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 11258963 9751507 10964929 |
| C006780 | bisphenol A | bisphenol A promotes the reaction [ESR2 protein binds to NCOA1 protein] | affects binding|increases reaction | 10964929 |
| C006780 | bisphenol A | bisphenol A promotes the reaction [ESR2 protein binds to NCOA2 protein] | affects binding|increases reaction | 10964929 |
| C006780 | bisphenol A | bisphenol A results in decreased expression of ESR2 mRNA | decreases expression | 18007998 |
| C006780 | bisphenol A | bisphenol A results in decreased expression of ESR2 protein | decreases expression | 18007998 |
| C006780 | bisphenol A | bisphenol A results in increased activity of ESR2 protein | increases activity | 19161236 16756374 14754635 |
| C006780 | bisphenol A | bisphenol A results in increased expression of ESR2 mRNA | increases expression | 12737316 |
| C006780 | bisphenol A | bisphenol A affects the activity of ESR2 protein | affects activity | 17222059 |
| C006780 | bisphenol A | bisphenol A results in decreased expression of ESR2 mRNA | decreases expression | 12505546 |
| C006780 | bisphenol A | bisphenol A results in decreased expression of ESR2 protein | decreases expression | 12505546 |
| C006780 | bisphenol A | bisphenol A results in increased expression of ESR2 mRNA | increases expression | 14967926 |
| C006780 | bisphenol A | bisphenol A results in increased expression of ESR2 protein | increases expression | 17222491 |
| C006780 | bisphenol A | bisphenol A results in decreased expression of ESR2 mRNA | decreases expression | 20621667 |
| C006780 | bisphenol A | bisphenol A results in increased expression of ESR2 protein | increases expression | 14652134 |
| C006780 | bisphenol A | bisphenol A binds to ESR2 protein | affects binding | 15458795 |
| C006780 | bisphenol A | bisphenol A inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| C006780 | bisphenol A | bisphenol A metabolite affects the expression of ESR2 mRNA | affects expression | 20435109 |
| C006780 | bisphenol A | bisphenol A results in increased expression of ESR2 mRNA | increases expression | 12810577 14605012 |
| C006780 | bisphenol A | bisphenol A results in increased expression of ESR2 mRNA | increases expression | 17258427 |
| C006780 | bisphenol A | bisphenol A affects the activity of ESR2 protein | affects activity | 20926581 |
| C006780 | bisphenol A | bisphenol A results in increased activity of ESR2 protein | increases activity | 11403899 |
| C100092 | bromophos | bromophos results in increased activity of ESR2 protein | increases activity | 15064155 |
| D002083 | Butylated Hydroxyanisole | Butylated Hydroxyanisole binds to ESR2 protein | affects binding | 12822488 |
| D002083 | Butylated Hydroxyanisole | Butylated Hydroxyanisole inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 12822488 |
| D002083 | Butylated Hydroxyanisole | Butylated Hydroxyanisole results in increased activity of ESR2 protein | increases activity | 16756374 |
| C027561 | butylbenzyl phthalate | butylbenzyl phthalate binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 15840436 |
| C027561 | butylbenzyl phthalate | butylbenzyl phthalate binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15840436 |
| C027561 | butylbenzyl phthalate | butylbenzyl phthalate results in increased activity of ESR2 protein | increases activity | 11403899 |
| D020148 | Butyric Acid | Butyric Acid promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 15103026 |
| C402943 | bu-zhong-yi-qi-tang | bu-zhong-yi-qi-tang inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 17089059 |
| D002104 | Cadmium | Cadmium results in increased activity of ESR2 protein | increases activity | 16635015 |
| D012721 | Carbaryl | Carbaryl binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 16626760 |
| D002251 | Carbon Tetrachloride | Carbon Tetrachloride affects the expression of ESR2 mRNA | affects expression | 17805973 |
| C450419 | CHF 4056 | CHF 4056 binds to ESR2 protein | affects binding | 11861784 |
| D002706 | Chlordan | Chlordan binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16626760 |
| D002706 | Chlordan | Chlordan results in increased activity of ESR2 protein | increases activity | 15064155 |
| D007631 | Chlordecone | Chlordecone binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 16626760 |
| D007631 | Chlordecone | Chlordecone binds to ESR2 protein | affects binding | 9751507 |
| D007631 | Chlordecone | Chlordecone inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| D020111 | Chlorodiphenyl (54% Chlorine) | Chlorodiphenyl (54% Chlorine) results in decreased expression of ESR2 mRNA | decreases expression | 16414171 |
| C004663 | chloropropylate | chloropropylate results in increased activity of ESR2 protein | increases activity | 15064155 |
| D002839 | Chromans | Chromans analog results in decreased activity of ESR2 protein | decreases activity | 15737489 |
| C043561 | chrysin | chrysin binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 9751507 |
| C475575 | Cimicifuga extract BNO 1055 | Cimicifuga extract BNO 1055 affects the expression of ESR2 mRNA | affects expression | 19350480 |
| C111332 | cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt | cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt results in increased expression of ESR2 protein | increases expression | 16837883 |
| D003375 | Coumestrol | Coumestrol binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15084758 9751507 |
| D003375 | Coumestrol | Coumestrol binds to ESR2 protein | affects binding | 16566672 11518614 |
| D003375 | Coumestrol | Coumestrol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 16566672 9751507 |
| D003375 | Coumestrol | Coumestrol results in increased activity of ESR2 protein | increases activity | 16118406 |
| D003375 | Coumestrol | ESR2 protein affects the susceptibility to Coumestrol | affects response to substance | 17275032 |
| D003375 | Coumestrol | Coumestrol inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| C002488 | cyanophenphos | cyanophenphos results in increased activity of ESR2 protein | increases activity | 15064155 |
| D003513 | Cycloheximide | Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15207704 |
| D003513 | Cycloheximide | Tetrachlorodibenzodioxin inhibits the reaction [Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]] | decreases reaction|increases expression|increases reaction | 15207704 |
| D003520 | Cyclophosphamide | [Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 16322899 |
| C037304 | cyhalothrin | cyhalothrin results in decreased expression of ESR2 mRNA | decreases expression | 18419197 |
| C037304 | cyhalothrin | cyhalothrin results in decreased expression of ESR2 protein | decreases expression | 18419197 |
| C004742 | daidzein | daidzein inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 20043933 |
| C004742 | daidzein | daidzein results in increased expression of ESR2 mRNA | increases expression | 20043933 |
| C004742 | daidzein | daidzein binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 9751507 16076101 |
| C004742 | daidzein | daidzein binds to ESR2 protein | affects binding | 15993745 16506809 16566672 16773531 |
| C004742 | daidzein | [daidzein co-treated with ESR2 protein] results in decreased expression of EGFR mRNA | affects cotreatment|decreases expression | 19347870 |
| C004742 | daidzein | [daidzein co-treated with ESR2 protein] results in decreased expression of EGFR protein | affects cotreatment|decreases expression | 19347870 |
| C004742 | daidzein | [daidzein co-treated with ESR2 protein] results in increased expression of BGLAP mRNA | affects cotreatment|increases expression | 19347870 |
| C004742 | daidzein | [daidzein co-treated with ESR2 protein] results in increased expression of BSP mRNA | affects cotreatment|increases expression | 19347870 |
| C004742 | daidzein | [daidzein co-treated with ESR2 protein] results in increased expression of PTGS2 mRNA | affects cotreatment|increases expression | 19347870 |
| C004742 | daidzein | daidzein inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 16566672 |
| C004742 | daidzein | daidzein metabolite binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15084758 |
| C004742 | daidzein | daidzein promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 16118406 |
| C004742 | daidzein | daidzein results in increased activity of ESR2 protein | increases activity | 19161236 18937077 16118406 |
| C004742 | daidzein | daidzein results in increased activity of ESR2 protein alternative form | increases activity | 17266178 |
| C004742 | daidzein | daidzein results in increased expression of ESR2 mRNA | increases expression | 16033089 |
| C004742 | daidzein | daidzein results in increased expression of ESR2 protein | increases expression | 16033089 |
| C004742 | daidzein | ESR2 gene polymorphism affects the reaction [[Genistein co-treated with daidzein] affects the expression of VCAM1 protein] | affects cotreatment|affects expression|affects reaction | 16332659 |
| C004742 | daidzein | ESR2 gene polymorphism affects the susceptibility to [Genistein co-treated with daidzein] | affects cotreatment|affects response to substance | 16332659 |
| C004742 | daidzein | Estradiol affects the reaction [daidzein metabolite affects the activity of ESR2 protein] | affects activity|affects reaction | 16965913 |
| C004742 | daidzein | daidzein results in increased activity of ESR2 protein | increases activity | 19495926 |
| C004742 | daidzein | daidzein affects the activity of ESR2 protein | affects activity | 20926581 |
| C004742 | daidzein | daidzein results in increased activity of ESR2 protein | increases activity | 11403899 |
| D003634 | DDT | DDT binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16626760 |
| D003634 | DDT | DDT results in increased activity of ESR2 protein | increases activity | 15064155 |
| C014347 | decitabine | [decitabine co-treated with trichostatin A] results in decreased methylation of ESR2 promoter | affects cotreatment|decreases methylation | 19331143 |
| C014347 | decitabine | [decitabine co-treated with trichostatin A] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 19331143 |
| C014347 | decitabine | decitabine promotes the reaction [trichostatin A results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 18092350 |
| C014347 | decitabine | decitabine promotes the reaction [trichostatin A results in increased expression of ESR2 protein] | increases expression|increases reaction | 18092350 |
| C014347 | decitabine | decitabine results in decreased methylation of ESR2 promoter | decreases methylation | 19331143 |
| C014347 | decitabine | decitabine results in increased expression of ESR2 mRNA | increases expression | 19331143 17625110 |
| D003687 | Dehydroepiandrosterone | Dehydroepiandrosterone binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15994348 |
| D003687 | Dehydroepiandrosterone | Dehydroepiandrosterone results in increased expression of ESR2 mRNA | increases expression | 17823450 18709148 |
| C086916 | delta-hexachlorocyclohexane | delta-hexachlorocyclohexane results in increased activity of ESR2 protein | increases activity | 15064155 |
| C492519 | diarylpropionitrile | diarylpropionitrile binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15585566 |
| C492519 | diarylpropionitrile | diarylpropionitrile results in increased activity of ESR2 protein | increases activity | 17935960 |
| C492519 | diarylpropionitrile | fulvestrant inhibits the reaction [diarylpropionitrile results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17935960 |
| C492519 | diarylpropionitrile | diarylpropionitrile binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15910780 |
| C492519 | diarylpropionitrile | diarylpropionitrile binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15615701 15912132 |
| D003993 | Dibutyl Phthalate | Dibutyl Phthalate analog binds to ESR2 protein | affects binding | 15464722 |
| D003993 | Dibutyl Phthalate | Dibutyl Phthalate binds to ESR2 protein | affects binding | 15458795 |
| C011445 | dichlofenthion | dichlofenthion results in increased activity of ESR2 protein | increases activity | 15064155 |
| D003632 | Dichlorodiphenyldichloroethane | Dichlorodiphenyldichloroethane analog results in increased activity of ESR2 protein | increases activity | 15064155 |
| D003633 | Dichlorodiphenyl Dichloroethylene | Dichlorodiphenyl Dichloroethylene analog results in increased activity of ESR2 protein | increases activity | 15064155 |
| D004010 | Dicofol | Dicofol results in increased activity of ESR2 protein | increases activity | 15064155 |
| C036042 | dicyclohexyl phthalate | dicyclohexyl phthalate binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 15840436 |
| D019259 | Lamivudine | [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 16931933 |
| D019259 | Lamivudine | [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 16931933 |
| D004026 | Dieldrin | Dieldrin binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 16626760 |
| D004026 | Dieldrin | Dieldrin promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15261991 |
| D004051 | Diethylhexyl Phthalate | Diethylhexyl Phthalate binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 15840436 |
| C007379 | diethyl phthalate | diethyl phthalate analog binds to ESR2 protein | affects binding | 15464722 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol binds to ESR2 protein | affects binding | 9751507 10964929 11518614 17287592 |
| D004054 | Diethylstilbestrol | [Diethylstilbestrol binds to ESR2 protein] which binds to NCOA2 protein | affects binding | 15123288 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 10964929 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol promotes the reaction [ESR2 protein alternative form binds to ESR2 protein alternative form] | affects binding|increases reaction | 16938840 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol promotes the reaction [ESR2 protein binds to HOXA10 promoter] | affects binding|increases reaction | 15236964 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol promotes the reaction [ESR2 protein binds to NCOA1 protein] | affects binding|increases reaction | 10964929 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol promotes the reaction [ESR2 protein binds to NCOA2 protein] | affects binding|increases reaction | 10964929 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol results in increased activity of ESR2 protein | increases activity | 19161236 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol affects the activity of ESR2 protein | affects activity | 15451043 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15465114 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol results in increased expression of ESR2 protein | increases expression | 16468032 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol results in increased expression of ESR2 mRNA | increases expression | 17823450 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol results in increased expression of ESR2 protein | increases expression | 14652134 |
| D004054 | Diethylstilbestrol | Diethylstilbestrol affects the activity of ESR2 protein | affects activity | 20926581 |
| C089799 | diheptyl phthalate | diheptyl phthalate analog binds to ESR2 protein | affects binding | 15464722 |
| C027387 | di-n-hexyl phthalate | di-n-hexyl phthalate analog binds to ESR2 protein | affects binding | 15464722 |
| C027387 | di-n-hexyl phthalate | di-n-hexyl phthalate binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 15840436 |
| C010715 | di-n-octyl phthalate | di-n-octyl phthalate analog binds to ESR2 protein | affects binding | 15464722 |
| C034171 | di-n-pentyl phthalate | di-n-pentyl phthalate analog binds to ESR2 protein | affects binding | 15464722 |
| C034171 | di-n-pentyl phthalate | di-n-pentyl phthalate binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 15840436 |
| C106479 | di-n-propylphthalate | di-n-propylphthalate analog binds to ESR2 protein | affects binding | 15464722 |
| C004839 | dioxybenzone | dioxybenzone binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16079615 |
| C109695 | dong quai | dong quai binds to ESR2 protein | affects binding | 11368622 |
| C109695 | dong quai | dong quai inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 11368622 |
| D004317 | Doxorubicin | [Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 16322899 |
| D004317 | Doxorubicin | Doxorubicin results in increased expression of ESR2 mRNA | increases expression | 16900372 |
| D004365 | Drugs, Chinese Herbal | Drugs, Chinese Herbal binds to and affects the folding of and results in increased activity of ESR2 protein | affects binding|affects folding|increases activity | 17095596 |
| D004365 | Drugs, Chinese Herbal | Drugs, Chinese Herbal promotes the reaction [ESR2 protein binds to KRT19 promoter] | affects binding|increases reaction | 17095596 |
| D004642 | Emodin | Emodin results in increased activity of ESR2 protein | increases activity | 19161236 |
| D004726 | Endosulfan | [Endosulfan affects the activity of ESR2 protein] promotes the reaction [LIF protein results in increased activity of STAT3 protein] | affects activity|increases activity|increases reaction | 14975756 |
| D004726 | Endosulfan | Endosulfan binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 16626760 |
| D004726 | Endosulfan | Endosulfan promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15261991 |
| D004726 | Endosulfan | Endosulfan results in increased activity of ESR2 protein | increases activity | 15064155 |
| D004732 | Endrin | Endrin binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 16626760 |
| C007610 | equol | equol binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15084758 |
| C007610 | equol | equol binds to ESR2 protein | affects binding | 15993745 |
| C007610 | equol | equol results in increased activity of ESR2 protein | increases activity | 16118406 |
| C007610 | equol | Estradiol affects the reaction [equol affects the activity of ESR2 protein] | affects activity|affects reaction | 16965913 |
| C007610 | equol | equol affects the activity of ESR2 protein | affects activity | 20926581 |
| C074283 | estradiol 3-benzoate | estradiol 3-benzoate affects the expression of ESR2 mRNA | affects expression | 19350480 |
| C074283 | estradiol 3-benzoate | estradiol 3-benzoate results in decreased expression of ESR2 | decreases expression | 15375486 |
| D004958 | Estradiol | Estradiol results in increased activity of ESR2 protein | increases activity | 12387416 |
| D004958 | Estradiol | daidzein inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 20043933 |
| D004958 | Estradiol | Estradiol results in increased expression of ESR2 mRNA | increases expression | 20043933 |
| D004958 | Estradiol | 22-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17873880 |
| D004958 | Estradiol | 2',3',4',5'-tetrachloro-4-biphenylol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 10964929 |
| D004958 | Estradiol | 24-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17873880 |
| D004958 | Estradiol | 25-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17873880 |
| D004958 | Estradiol | 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17873880 |
| D004958 | Estradiol | 4-hydroxytamoxifen inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| D004958 | Estradiol | 4-hydroxytamoxifen inhibits the reaction [methoxyacetic acid promotes the reaction [Estradiol results in increased activity of ESR2 protein]] | decreases reaction|increases activity|increases reaction | 15103026 |
| D004958 | Estradiol | 4-tert-octylphenol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 10964929 |
| D004958 | Estradiol | AHR protein inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 15207704 |
| D004958 | Estradiol | Apigenin inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| D004958 | Estradiol | benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15207704 |
| D004958 | Estradiol | beta Carotene inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17051425 |
| D004958 | Estradiol | biochanin A inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 16566672 |
| D004958 | Estradiol | bisphenol A analog inhibits the reaction [Estradiol binds to and results in increased activity of ESR2 protein] | affects binding|decreases reaction|increases activity | 20427257 |
| D004958 | Estradiol | bisphenol A inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 11258963 10964929 9751507 |
| D004958 | Estradiol | Butylated Hydroxyanisole inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 12822488 |
| D004958 | Estradiol | Butyric Acid promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 15103026 |
| D004958 | Estradiol | Chlordecone inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| D004958 | Estradiol | Coumestrol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 16566672 9751507 |
| D004958 | Estradiol | Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15207704 |
| D004958 | Estradiol | daidzein inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 16566672 |
| D004958 | Estradiol | daidzein promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 16118406 |
| D004958 | Estradiol | Dieldrin promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15261991 |
| D004958 | Estradiol | Diethylstilbestrol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 10964929 |
| D004958 | Estradiol | dong quai inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 11368622 |
| D004958 | Estradiol | Endosulfan promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15261991 |
| D004958 | Estradiol | ESR2 affects the reaction [Estradiol affects the expression of ESR1 mRNA] | affects expression|affects reaction | 19434490 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol affects the expression of CCNA2 mRNA] | affects expression|affects reaction | 19434490 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol promotes the reaction [NCOA1 protein binds to NKD1 gene]] | affects binding|affects reaction|increases reaction | 17962382 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol promotes the reaction [NCOA2 protein binds to CECR6 gene]] | affects binding|affects reaction|increases reaction | 17962382 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol promotes the reaction [NCOA2 protein binds to NKD1 gene]] | affects binding|affects reaction|increases reaction | 17962382 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in decreased expression of CDKN1A mRNA] | affects reaction|decreases expression | 19434490 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in decreased expression of FGFR2 mRNA] | affects reaction|decreases expression | 14699072 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in decreased expression of PTPRO mRNA] | affects reaction|decreases expression | 19095770 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of BCL2 mRNA] | affects reaction|increases expression | 19264808 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of IL24 mRNA] | affects reaction|increases expression | 14699072 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of KLK3 mRNA] | affects reaction|increases expression | 17131305 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of KRT19 mRNA] | affects reaction|increases expression | 14699072 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of MMP12 mRNA] | affects reaction|increases expression | 14699072 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of NKX3-1 mRNA] | affects reaction|increases expression | 17131305 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of PDCD4 mRNA] | affects reaction|increases expression | 19264808 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of RLN2 mRNA] | affects reaction|increases expression | 14699072 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of SMOX mRNA] | affects reaction|increases expression | 14699072 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of TANK mRNA] | affects reaction|increases expression | 14699072 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of WISP2 mRNA] | affects reaction|increases expression | 14699072 |
| D004958 | Estradiol | ESR2 protein affects the susceptibility to Estradiol | affects response to substance | 17275032 |
| D004958 | Estradiol | ESR2 protein promotes the reaction [Estradiol results in decreased abundance of Reactive Oxygen Species] | decreases abundance|increases reaction | 20463317 |
| D004958 | Estradiol | ESR2 protein promotes the reaction [Estradiol results in decreased expression of ITPR1 mRNA] | decreases expression|increases reaction | 19426747 |
| D004958 | Estradiol | ESR2 protein promotes the reaction [Estradiol results in increased phosphorylation of MAPK1 protein] | increases phosphorylation|increases reaction | 20372779 |
| D004958 | Estradiol | ESR2 protein promotes the reaction [Estradiol results in increased phosphorylation of MAPK3 protein] | increases phosphorylation|increases reaction | 20372779 |
| D004958 | Estradiol | Estradiol affects the reaction [daidzein metabolite affects the activity of ESR2 protein] | affects activity|affects reaction | 16965913 |
| D004958 | Estradiol | Estradiol affects the reaction [equol affects the activity of ESR2 protein] | affects activity|affects reaction | 16965913 |
| D004958 | Estradiol | Estradiol affects the reaction [kaempferol results in increased activity of ESR2 protein] | affects reaction|increases activity | 16118406 |
| D004958 | Estradiol | Estradiol affects the reaction [O-desmethylangolensin affects the activity of ESR2 protein] | affects activity|affects reaction | 16965913 |
| D004958 | Estradiol | Estradiol affects the reaction [Quercetin results in increased activity of ESR2 protein] | affects reaction|increases activity | 16118406 |
| D004958 | Estradiol | Estradiol affects the reaction [tetrahydrodaidzein affects the activity of ESR2 protein] | affects activity|affects reaction | 16965913 |
| D004958 | Estradiol | Estradiol analog binds to ESR2 protein | affects binding | 16728493 |
| D004958 | Estradiol | Estradiol binds to and affects the folding of and results in increased activity of ESR2 protein | affects binding|affects folding|increases activity | 17872378 |
| D004958 | Estradiol | Estradiol binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 14709801 17873880 16079615 20427257 20332105 15937998 |
| D004958 | Estradiol | Estradiol binds to ESR2 protein | affects binding | 12822488 15946813 11518614 10964929 11258963 17203231 16728493 15961563 11368622 16839579 |
| D004958 | Estradiol | [Estradiol binds to ESR2 protein] which affects the folding of ESR2 protein | affects binding|affects folding | 16216903 |
| D004958 | Estradiol | [Estradiol binds to ESR2 protein] which binds to NCOA2 protein | affects binding | 15123288 |
| D004958 | Estradiol | [Estradiol co-treated with ESR2 protein] results in decreased expression of EGFR mRNA | affects cotreatment|decreases expression | 19347870 |
| D004958 | Estradiol | [Estradiol co-treated with ESR2 protein] results in decreased expression of EGFR protein | affects cotreatment|decreases expression | 19347870 |
| D004958 | Estradiol | [Estradiol co-treated with ESR2 protein] results in increased expression of BGLAP mRNA | affects cotreatment|increases expression | 19347870 |
| D004958 | Estradiol | [Estradiol co-treated with ESR2 protein] results in increased expression of BSP mRNA | affects cotreatment|increases expression | 19347870 |
| D004958 | Estradiol | [Estradiol co-treated with ESR2 protein] results in increased expression of IGFBP4 mRNA | affects cotreatment|increases expression | 12399409 |
| D004958 | Estradiol | [Estradiol co-treated with ESR2 protein] results in increased expression of MT2 mRNA | affects cotreatment|increases expression | 12399409 |
| D004958 | Estradiol | [Estradiol co-treated with ESR2 protein] results in increased expression of NOS3 mRNA | affects cotreatment|increases expression | 14742696 |
| D004958 | Estradiol | [Estradiol co-treated with ESR2 protein] results in increased expression of PTGS2 mRNA | affects cotreatment|increases expression | 19347870 |
| D004958 | Estradiol | Estradiol inhibits the reaction [royal jelly binds to ESR2 protein] | affects binding|decreases reaction | 17287592 |
| D004958 | Estradiol | Estradiol metabolite binds to ESR2 protein | affects binding | 16728493 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR1 protein binds to ESR2 protein] | affects binding|increases reaction | 20061804 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR2 protein alternative form binds to ESR2 protein alternative form] | affects binding|increases reaction | 16938840 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR2 protein binds to CECR6 gene] | affects binding|increases reaction | 17962382 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR2 protein binds to HOXA10 promoter] | affects binding|increases reaction | 15236964 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR2 protein binds to IGF1 promoter] | affects binding|increases reaction | 17872375 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR2 protein binds to NCOA1 protein] | affects binding|increases reaction | 10964929 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR2 protein binds to NCOA2 protein] | affects binding|increases reaction | 10964929 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR2 protein binds to NKD1 gene] | affects binding|increases reaction | 17962382 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR2 protein binds to PTGS2 promoter] | affects binding|increases reaction | 17872375 |
| D004958 | Estradiol | Estradiol promotes the reaction [NCOA1 protein binds to ESR2 protein] | affects binding|increases reaction | 17135255 |
| D004958 | Estradiol | Estradiol results in decreased expression of ESR2 mRNA | decreases expression | 15130599 |
| D004958 | Estradiol | Estradiol results in decreased expression of ESR2 mRNA alternative form | decreases expression | 16596234 |
| D004958 | Estradiol | Estradiol results in decreased expression of ESR2 protein | decreases expression | 18997820 15118252 |
| D004958 | Estradiol | Estradiol results in increased activity of ESR2 protein | increases activity | 16756374 19584281 17935960 18486176 11335189 12387416 11875334 15064155 15171712 15103026 16118406 19161236 |
| D004958 | Estradiol | Estradiol results in increased activity of ESR2 protein alternative form | increases activity | 17266178 |
| D004958 | Estradiol | Estradiol results in increased expression of ESR2 mRNA | increases expression | 12737316 12377985 15207704 15261991 16596234 |
| D004958 | Estradiol | Estradiol results in increased expression of ESR2 mRNA alternative form | increases expression | 16596234 |
| D004958 | Estradiol | Estradiol results in increased expression of ESR2 mRNA mutant form | increases expression | 15207704 |
| D004958 | Estradiol | Estradiol results in increased expression of ESR2 protein | increases expression | 16739346 |
| D004958 | Estradiol | Estradiol results in increased localization of ESR2 protein | increases localization | 15171712 |
| D004958 | Estradiol | Estriol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| D004958 | Estradiol | fenarimol promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15261991 |
| D004958 | Estradiol | fulvestrant inhibits the reaction [[Estradiol co-treated with ESR2 protein] results in increased expression of NOS3 mRNA] | affects cotreatment|decreases reaction|increases expression | 14742696 |
| D004958 | Estradiol | fulvestrant inhibits the reaction [Estradiol results in decreased expression of ESR2 mRNA] | decreases expression|decreases reaction | 15130599 |
| D004958 | Estradiol | fulvestrant inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 15171712 17935960 |
| D004958 | Estradiol | fulvestrant inhibits the reaction [Estradiol results in increased localization of ESR2 protein] | decreases reaction|increases localization | 15171712 |
| D004958 | Estradiol | fulvestrant inhibits the reaction [methoxyacetic acid promotes the reaction [Estradiol results in increased activity of ESR2 protein]] | decreases reaction|increases activity|increases reaction | 15103026 |
| D004958 | Estradiol | Genistein inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 11368622 9751507 10964929 16566672 |
| D004958 | Estradiol | Genistein promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 16118406 |
| D004958 | Estradiol | kaempferol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| D004958 | Estradiol | lycopene inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17051425 |
| D004958 | Estradiol | methoxyacetic acid promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 18486176 15103026 |
| D004958 | Estradiol | Methoxychlor inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| D004958 | Estradiol | naringenin inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 16566672 |
| D004958 | Estradiol | [phytoene co-treated with phytofluene] inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | affects cotreatment|decreases reaction|increases activity | 17051425 |
| D004958 | Estradiol | Phytoestrogens inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 16566672 |
| D004958 | Estradiol | Plant Extracts inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 11368622 |
| D004958 | Estradiol | Polychlorinated Biphenyls metabolite inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 12377985 |
| D004958 | Estradiol | prochloraz promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15261991 |
| D004958 | Estradiol | resveratrol promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 16118406 |
| D004958 | Estradiol | royal jelly inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 15946813 |
| D004958 | Estradiol | Tamoxifen inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 12377985 |
| D004958 | Estradiol | Tetrachlorodibenzodioxin inhibits the reaction [Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]] | decreases reaction|increases expression|increases reaction | 15207704 |
| D004958 | Estradiol | Tetrachlorodibenzodioxin inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 15207704 |
| D004958 | Estradiol | Tetrachlorodibenzodioxin inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA mutant form] | decreases reaction|increases expression | 15207704 |
| D004958 | Estradiol | tri-(2-ethylhexyl)trimellitate promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 16756374 |
| D004958 | Estradiol | trichostatin A promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 15103026 |
| D004958 | Estradiol | Triclosan inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 17992702 |
| D004958 | Estradiol | Valproic Acid promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 15103026 |
| D004958 | Estradiol | bu-zhong-yi-qi-tang inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 17089059 |
| D004958 | Estradiol | ESR2 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA] | increases expression|increases reaction | 17974624 |
| D004958 | Estradiol | Estradiol binds to and affects the activity of ESR2 protein alternative form | affects activity|affects binding | 15924412 |
| D004958 | Estradiol | [Estradiol co-treated with 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 11509743 |
| D004958 | Estradiol | [Estradiol co-treated with 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 11509743 |
| D004958 | Estradiol | [Estradiol co-treated with Methoxychlor metabolite] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 11509743 |
| D004958 | Estradiol | [Estradiol co-treated with Methoxychlor metabolite] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 11509743 |
| D004958 | Estradiol | Estradiol inhibits the reaction [ESR2 protein alternative form results in increased expression of GNRH1 mRNA] | decreases reaction|increases expression | 16439454 |
| D004958 | Estradiol | Estradiol results in decreased expression of ESR2 mRNA | decreases expression | 11509743 |
| D004958 | Estradiol | Estradiol results in increased activity of ESR2 protein | increases activity | 19495926 |
| D004958 | Estradiol | Estradiol results in increased expression of ESR2 mRNA | increases expression | 16606610 17089059 |
| D004958 | Estradiol | Estradiol results in increased expression of ESR2 protein | increases expression | 15916834 19279558 |
| D004958 | Estradiol | fulvestrant inhibits the reaction [ESR2 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]] | decreases reaction|increases expression|increases reaction | 17974624 |
| D004958 | Estradiol | Progesterone inhibits the reaction [ESR2 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]] | decreases reaction|increases expression|increases reaction | 17974624 |
| D004958 | Estradiol | [Estradiol co-treated with Tamoxifen] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 17823450 |
| D004958 | Estradiol | Estradiol results in increased expression of ESR2 mRNA | increases expression | 18709148 17823450 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in decreased expression of MMP13 mRNA] | affects reaction|decreases expression | 17612627 |
| D004958 | Estradiol | Estradiol inhibits the reaction [ESR2 protein results in increased expression of MMP13 mRNA] | decreases reaction|increases expression | 17612627 |
| D004958 | Estradiol | 4-hydroxytamoxifen inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D004958 | Estradiol | bisphenol A inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D004958 | Estradiol | Coumestrol inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D004958 | Estradiol | ESR2 protein affects the reaction [Estradiol results in increased expression of SLC6A3 protein] | affects reaction|increases expression | 16451217 |
| D004958 | Estradiol | Estradiol binds to ESR2 protein | affects binding | 15458795 9492041 |
| D004958 | Estradiol | Estradiol binds to ESR2 protein alternative form | affects binding | 9492041 |
| D004958 | Estradiol | [Estradiol co-treated with Tamoxifen] results in increased expression of ESR2 protein | affects cotreatment|increases expression | 19460436 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR2 protein alternative form binds to ESR1 protein] | affects binding|increases reaction | 9492041 |
| D004958 | Estradiol | Estradiol promotes the reaction [[ESR2 protein binds to FHL1 promoter] which results in decreased expression of FHL1 mRNA] | affects binding|decreases expression|increases reaction | 20149813 |
| D004958 | Estradiol | Estradiol results in decreased expression of ESR2 mRNA | decreases expression | 16614383 15458797 12834913 16522720 15979666 15458795 16414171 |
| D004958 | Estradiol | Estradiol results in increased activity of ESR2 protein | increases activity | 14662790 15901789 |
| D004958 | Estradiol | Estradiol results in increased expression of ESR2 mRNA | increases expression | 15458797 16311018 |
| D004958 | Estradiol | Estriol inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D004958 | Estradiol | Estrone inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D004958 | Estradiol | Genistein inhibits the reaction [Estradiol affects the expression of ESR2 mRNA] | affects expression|decreases reaction | 17049845 |
| D004958 | Estradiol | Genistein inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D004958 | Estradiol | Methoxychlor inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D004958 | Estradiol | pentabromodiphenyl ether promotes the reaction [Estradiol results in decreased expression of ESR2 mRNA] | decreases expression|increases reaction | 16414171 |
| D004958 | Estradiol | Tamoxifen inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D004958 | Estradiol | Estradiol results in increased activity of ESR2 protein | increases activity | 17539551 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR1 protein binds to ESR2 protein] | affects binding|increases reaction | 15891078 |
| D004958 | Estradiol | Estradiol promotes the reaction [ESR2 protein binds to ESR2 protein] | affects binding|increases reaction | 15891078 |
| D004958 | Estradiol | Estradiol affects the expression of ESR2 protein | affects expression | 15653758 16680078 |
| D004958 | Estradiol | Estradiol results in increased expression of ESR2 mRNA | increases expression | 17258427 |
| D004958 | Estradiol | 7,3'-dihydroxy-4'-methoxyisoflavone inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 20686605 |
| D004958 | Estradiol | Estradiol binds to ESR2 protein | affects binding | 20686605 |
| D004964 | Estriol | Estriol binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 12547825 |
| D004964 | Estriol | Estriol binds to ESR2 protein | affects binding | 16728493 11518614 9751507 |
| D004964 | Estriol | Estriol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| D004964 | Estriol | Estriol inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D004967 | Estrogens | ESR2 protein affects the reaction [Estrogens results in increased expression of VDR mRNA] | affects reaction|increases expression | 15664452 |
| D004966 | Estrogens, Conjugated (USP) | Estrogens, Conjugated (USP) affects the expression of ESR2 protein | affects expression | 15653758 16680078 |
| D004970 | Estrone | Estrone binds to ESR2 protein | affects binding | 11518614 |
| D004970 | Estrone | Estrone inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D004970 | Estrone | Estrone results in increased activity of ESR2 protein | increases activity | 17539551 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased activity of ESR2 protein | increases activity | 12387416 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol binds to ESR2 protein | affects binding | 11518614 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of ESR2 protein] | decreases expression|decreases reaction | 10633228 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol promotes the reaction [ESR2 protein alternative form binds to ESR2 protein alternative form] | affects binding|increases reaction | 16938840 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased activity of ESR2 protein | increases activity | 12387416 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased expression of ESR2 protein | increases expression | 10633228 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased expression of ESR2 mRNA | increases expression | 16606610 |
| D004997 | Ethinyl Estradiol | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 17942748 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in decreased expression of ESR2 mRNA | decreases expression | 17222921 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol affects the expression of ESR2 mRNA | affects expression | 16551644 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in decreased expression of ESR2 mRNA | decreases expression | 12834913 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in decreased expression of ESR2 protein | decreases expression | 14709816 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased expression of ESR2 mRNA | increases expression | 16183386 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol affects the expression of ESR2 | affects expression | 17539551 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in decreased expression of ESR2 mRNA | decreases expression | 17875331 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol analog binds to ESR2 protein | affects binding | 15041288 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol binds to ESR2 protein | affects binding | 15041288 |
| C100038 | ethion | ethion results in increased activity of ESR2 protein | increases activity | 15064155 |
| C041062 | ethyl bromophos | ethyl bromophos results in increased activity of ESR2 protein | increases activity | 15064155 |
| C451418 | ethyl cinnamate | ethyl cinnamate binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16079615 |
| D015025 | Zearalenone | Zearalenone binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 15084758 |
| D015025 | Zearalenone | Zearalenone binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 9751507 |
| D015025 | Zearalenone | Zearalenone binds to ESR2 protein | affects binding | 15169976 |
| C033789 | fenarimol | fenarimol promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15261991 |
| C033789 | fenarimol | fenarimol results in increased activity of ESR2 protein | increases activity | 15064155 |
| C033789 | fenarimol | fenarimol results in increased expression of ESR2 mRNA | increases expression | 15261991 |
| C504383 | fenbuconazole | fenbuconazole binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16626760 |
| C017690 | fenvalerate | fenvalerate binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16626760 |
| D005485 | Flutamide | Flutamide results in decreased expression of ESR2 mRNA | decreases expression | 11509743 |
| D005485 | Flutamide | Flutamide results in increased expression of ESR2 mRNA | increases expression | 11509743 |
| D005485 | Flutamide | Flutamide affects the expression of ESR2 mRNA | affects expression | 17222921 |
| D005485 | Flutamide | Flutamide results in increased expression of ESR2 mRNA | increases expression | 16003321 |
| D005485 | Flutamide | Flutamide results in increased expression of ESR2 protein | increases expression | 16003321 |
| C007768 | formononetin | formononetin binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16076101 9751507 |
| C007768 | formononetin | formononetin binds to ESR2 protein | affects binding | 16773531 |
| C070081 | fulvestrant | ESR2 protein results in increased susceptibility to fulvestrant | increases response to substance | 17638070 |
| C070081 | fulvestrant | fulvestrant binds to ESR2 protein | affects binding | 17203231 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [3,3',4,5'-tetrahydroxystilbene results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17935960 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [Androstane-3,17-diol analog binds to and results in increased activity of ESR2 protein] | affects binding|decreases reaction|increases activity | 17003281 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [Androstane-3,17-diol binds to and results in increased activity of ESR2 protein] | affects binding|decreases reaction|increases activity | 17003281 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [diarylpropionitrile results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17935960 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [Dihydrotestosterone results in increased activity of ESR2 protein] | decreases reaction|increases activity | 15171712 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [Dihydrotestosterone results in increased localization of ESR2 protein] | decreases reaction|increases localization | 15171712 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [[Estradiol co-treated with ESR2 protein] results in increased expression of NOS3 mRNA] | affects cotreatment|decreases reaction|increases expression | 14742696 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [Estradiol results in decreased expression of ESR2 mRNA] | decreases expression|decreases reaction | 15130599 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17935960 15171712 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [Estradiol results in increased localization of ESR2 protein] | decreases reaction|increases localization | 15171712 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [methoxyacetic acid promotes the reaction [Estradiol results in increased activity of ESR2 protein]] | decreases reaction|increases activity|increases reaction | 15103026 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [Plant Preparations results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17935960 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [prochloraz results in decreased expression of ESR2 mRNA] | decreases expression|decreases reaction | 15130599 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [resveratrol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17935960 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [rhapontigenin analog results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17935960 17692514 |
| C070081 | fulvestrant | fulvestrant promotes the reaction [ESR1 protein binds to ESR2 protein] | affects binding|increases reaction | 20061804 |
| C070081 | fulvestrant | fulvestrant results in decreased expression of ESR2 protein | decreases expression | 15950373 16202921 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [ESR2 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]] | decreases reaction|increases expression|increases reaction | 17974624 |
| C070081 | fulvestrant | fulvestrant binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 19570671 |
| C070081 | fulvestrant | fulvestrant inhibits the reaction [[4-nonylphenol co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in decreased expression of ESR2 mRNA] | affects cotreatment|decreases expression|decreases reaction | 17291011 |
| C419708 | gefitinib | gefitinib results in increased expression of ESR2 protein | increases expression | 20005069 |
| D019833 | Genistein | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [Genistein binds to and results in increased activity of ESR2 protein] | affects binding|decreases reaction|increases activity | 11861976 |
| D019833 | Genistein | beta Carotene inhibits the reaction [Genistein results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17051425 |
| D019833 | Genistein | ESR2 gene polymorphism affects the reaction [[Genistein co-treated with daidzein] affects the expression of VCAM1 protein] | affects cotreatment|affects expression|affects reaction | 16332659 |
| D019833 | Genistein | ESR2 gene polymorphism affects the susceptibility to [Genistein co-treated with daidzein] | affects cotreatment|affects response to substance | 16332659 |
| D019833 | Genistein | ESR2 protein affects the susceptibility to Genistein | affects response to substance | 17275032 |
| D019833 | Genistein | Genistein binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 9751507 15937998 12547825 11861976 16076101 11502892 15084758 |
| D019833 | Genistein | Genistein binds to ESR2 protein | affects binding | 10964929 16566672 11518614 15887952 11368622 16506809 |
| D019833 | Genistein | [Genistein binds to ESR2 protein] which binds to NCOA2 protein | affects binding | 15123288 |
| D019833 | Genistein | [Genistein co-treated with ESR2 protein] results in decreased expression of EGFR mRNA | affects cotreatment|decreases expression | 19347870 |
| D019833 | Genistein | [Genistein co-treated with ESR2 protein] results in decreased expression of EGFR protein | affects cotreatment|decreases expression | 19347870 |
| D019833 | Genistein | [Genistein co-treated with ESR2 protein] results in increased expression of BGLAP mRNA | affects cotreatment|increases expression | 19347870 |
| D019833 | Genistein | [Genistein co-treated with ESR2 protein] results in increased expression of PTGS2 mRNA | affects cotreatment|increases expression | 19347870 |
| D019833 | Genistein | [Genistein co-treated with ESR2] results in increased expression of BSP mRNA | affects cotreatment|increases expression | 19347870 |
| D019833 | Genistein | Genistein inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 11368622 10964929 16566672 |
| D019833 | Genistein | Genistein promotes the reaction [ESR2 protein binds to NCOA1 protein] | affects binding|increases reaction | 10964929 |
| D019833 | Genistein | Genistein promotes the reaction [ESR2 protein binds to NCOA2 protein] | affects binding|increases reaction | 10964929 |
| D019833 | Genistein | Genistein promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 16118406 |
| D019833 | Genistein | Genistein results in decreased expression of ESR2 mRNA | decreases expression | 15968319 |
| D019833 | Genistein | Genistein results in increased activity of ESR2 protein | increases activity | 16118406 17132221 18955141 19161236 18937077 |
| D019833 | Genistein | Genistein results in increased activity of ESR2 protein alternative form | increases activity | 17266178 |
| D019833 | Genistein | Genistein results in increased expression of ESR2 mRNA | increases expression | 16596234 16033089 |
| D019833 | Genistein | Genistein results in increased expression of ESR2 mRNA alternative form | increases expression | 16596234 |
| D019833 | Genistein | Genistein results in increased expression of ESR2 protein | increases expression | 16033089 |
| D019833 | Genistein | Methoxychlor metabolite inhibits the reaction [Genistein binds to and results in increased activity of ESR2 protein] | affects binding|decreases reaction|increases activity | 11861976 |
| D019833 | Genistein | Genistein results in increased activity of ESR2 protein | increases activity | 19495926 |
| D019833 | Genistein | Genistein results in increased expression of ESR2 mRNA | increases expression | 16857750 18359623 |
| D019833 | Genistein | Genistein binds to ESR2 protein | affects binding | 11880592 |
| D019833 | Genistein | [Genistein co-treated with Methoxychlor] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 16443925 |
| D019833 | Genistein | Genistein inhibits the reaction [Estradiol affects the expression of ESR2 mRNA] | affects expression|decreases reaction | 17049845 |
| D019833 | Genistein | Genistein inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D019833 | Genistein | Genistein results in increased expression of ESR2 mRNA | increases expression | 17341692 |
| D019833 | Genistein | Genistein binds to and affects the activity of ESR2 protein | affects activity|affects binding | 12950458 |
| D019833 | Genistein | Genistein results in increased activity of ESR2 protein | increases activity | 11403899 |
| D005947 | Glucose | Glucose results in decreased expression of ESR2 mRNA | decreases expression | 16621514 |
| D005947 | Glucose | Glucose results in increased expression of ESR2 mRNA | increases expression | 16621514 |
| D006064 | Gonadotropins, Equine | ESR2 protein results in increased susceptibility to Gonadotropins, Equine | increases response to substance | 15831568 |
| D055768 | Halogenated Diphenyl Ethers | Halogenated Diphenyl Ethers binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 11335189 |
| D006533 | Heptachlor | Heptachlor results in increased activity of ESR2 protein | increases activity | 15064155 |
| D006534 | Heptachlor Epoxide | Heptachlor Epoxide results in increased activity of ESR2 protein | increases activity | 15064155 |
| C475919 | hydroxytamoxifen | ESR2 protein inhibits the reaction [hydroxytamoxifen results in increased expression of FARP1 mRNA] | decreases reaction|increases expression | 16849584 |
| C475919 | hydroxytamoxifen | ESR2 protein inhibits the reaction [hydroxytamoxifen results in increased expression of IER3 mRNA] | decreases reaction|increases expression | 16849584 |
| C475919 | hydroxytamoxifen | ESR2 protein inhibits the reaction [hydroxytamoxifen results in increased expression of RAB30 mRNA] | decreases reaction|increases expression | 16849584 |
| C475919 | hydroxytamoxifen | ESR2 protein inhibits the reaction [hydroxytamoxifen results in increased expression of SOCS1 mRNA] | decreases reaction|increases expression | 16849584 |
| D007189 | Indans | Indans analog results in decreased activity of ESR2 protein | decreases activity | 15737489 |
| D007189 | Indans | Indans analog results in increased activity of ESR2 protein | increases activity | 15737489 |
| C047437 | indenestrol | indenestrol binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15465114 |
| D019469 | Indinavir | [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 16931933 |
| D007211 | Indoles | Indoles analog binds to and affects the activity of ESR2 protein | affects activity|affects binding | 15911274 |
| C018986 | ipriflavone | ipriflavone binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 9751507 |
| D007529 | Isoflavones | ESR2 gene SNP affects the susceptibility to Isoflavones | affects response to substance | 16522905 |
| C038267 | isopropyl 4,4'-dibromobenzilate | isopropyl 4,4'-dibromobenzilate results in increased activity of ESR2 protein | increases activity | 15064155 |
| C113642 | JK 1624F2-1 | JK 1624F2-1 results in decreased expression of ESR2 mRNA | decreases expression | 16406510 |
| C006552 | kaempferol | Estradiol affects the reaction [kaempferol results in increased activity of ESR2 protein] | affects reaction|increases activity | 16118406 |
| C006552 | kaempferol | kaempferol binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15182386 9751507 |
| C006552 | kaempferol | kaempferol binds to ESR2 protein | affects binding | 14706564 |
| C006552 | kaempferol | kaempferol inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| C006552 | kaempferol | kaempferol results in increased activity of ESR2 protein | increases activity | 18937077 16118406 |
| D010773 | Leptophos | Leptophos results in increased activity of ESR2 protein | increases activity | 15064155 |
| D001556 | Lindane | Lindane results in increased activity of ESR2 protein | increases activity | 15064155 |
| D008043 | Linseed Oil | Linseed Oil inhibits the reaction [Tamoxifen results in decreased expression of ESR2 mRNA] | decreases expression|decreases reaction | 21138602 |
| D047311 | Luteolin | Luteolin results in increased activity of ESR2 protein | increases activity | 16860978 |
| C504960 | LY2066948 | LY2066948 binds to ESR2 protein | affects binding | 16002528 |
| C115121 | LY 353381 | LY 353381 analog results in decreased activity of ESR2 protein | decreases activity | 17654759 |
| C115121 | LY 353381 | LY 353381 binds to ESR2 protein | affects binding | 16780356 11731420 |
| C115121 | LY 353381 | LY 353381 results in decreased activity of ESR2 protein | decreases activity | 17654759 |
| C015329 | lycopene | lycopene inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17051425 |
| D008628 | Mercury | Mercury results in increased expression of ESR2 mRNA | increases expression | 16823088 |
| D008714 | Methiocarb | Methiocarb results in increased activity of ESR2 protein | increases activity | 15064155 |
| D008714 | Methiocarb | Methiocarb results in increased expression of ESR2 mRNA | increases expression | 15130599 |
| C013598 | methoxyacetic acid | 4-hydroxytamoxifen inhibits the reaction [methoxyacetic acid promotes the reaction [Estradiol results in increased activity of ESR2 protein]] | decreases reaction|increases activity|increases reaction | 15103026 |
| C013598 | methoxyacetic acid | fulvestrant inhibits the reaction [methoxyacetic acid promotes the reaction [Estradiol results in increased activity of ESR2 protein]] | decreases reaction|increases activity|increases reaction | 15103026 |
| C013598 | methoxyacetic acid | methoxyacetic acid promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 15103026 18486176 |
| C013598 | methoxyacetic acid | methoxyacetic acid results in increased expression of and results in increased activity of ESR2 protein | increases activity|increases expression | 14662790 |
| C013598 | methoxyacetic acid | methoxyacetic acid results in increased expression of ESR2 mRNA | increases expression | 14662790 |
| D008731 | Methoxychlor | [Methoxychlor affects the activity of ESR2 protein] promotes the reaction [LIF protein results in increased activity of STAT3 protein] | affects activity|increases activity|increases reaction | 14975756 |
| D008731 | Methoxychlor | Methoxychlor analog binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 10999957 |
| D008731 | Methoxychlor | Methoxychlor binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 16626760 |
| D008731 | Methoxychlor | Methoxychlor binds to ESR2 protein | affects binding | 9751507 |
| D008731 | Methoxychlor | Methoxychlor inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 |
| D008731 | Methoxychlor | Methoxychlor metabolite binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 11861976 10579340 |
| D008731 | Methoxychlor | Methoxychlor metabolite inhibits the reaction [Genistein binds to and results in increased activity of ESR2 protein] | affects binding|decreases reaction|increases activity | 11861976 |
| D008731 | Methoxychlor | Methoxychlor affects the activity of ESR2 protein | affects activity | 15451043 |
| D008731 | Methoxychlor | [Estradiol co-treated with Methoxychlor metabolite] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 11509743 |
| D008731 | Methoxychlor | [Estradiol co-treated with Methoxychlor metabolite] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 11509743 |
| D008731 | Methoxychlor | Methoxychlor metabolite results in decreased expression of ESR2 mRNA | decreases expression | 11509743 |
| D008731 | Methoxychlor | Methoxychlor metabolite results in increased expression of ESR2 mRNA | increases expression | 11509743 |
| D008731 | Methoxychlor | [Genistein co-treated with Methoxychlor] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 16443925 |
| D008731 | Methoxychlor | Methoxychlor inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D008731 | Methoxychlor | Methoxychlor metabolite binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 10579340 |
| D008731 | Methoxychlor | Methoxychlor metabolite binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 11509743 |
| C008493 | methylselenic acid | methylselenic acid affects the expression of ESR2 mRNA | affects expression | 16928829 |
| C008493 | methylselenic acid | methylselenic acid results in increased expression of ESR2 mRNA | increases expression | 15833885 |
| D008797 | Metyrapone | Metyrapone results in increased expression of ESR2 mRNA | increases expression | 16713641 |
| C517398 | MF101 extract | MF101 extract binds to and affects the folding of and results in increased activity of ESR2 protein | affects binding|affects folding|increases activity | 17095596 |
| C517398 | MF101 extract | MF101 extract promotes the reaction [ESR2 protein binds to KRT19 promoter] | affects binding|increases reaction | 17095596 |
| C005273 | naringenin | naringenin binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 9751507 |
| C005273 | naringenin | naringenin binds to ESR2 protein | affects binding | 16566672 |
| C005273 | naringenin | naringenin inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 9751507 16566672 |
| C005273 | naringenin | naringenin results in increased activity of ESR2 protein | increases activity | 16118406 |
| C052753 | nebivolol | nebivolol affects the activity of ESR2 protein | affects activity | 19330906 |
| C001870 | nonachlor | nonachlor binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16626760 |
| C025256 | nonylphenol | nonylphenol binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 14709801 9751507 |
| C025256 | nonylphenol | nonylphenol results in increased activity of ESR2 protein | increases activity | 14754635 16756374 |
| C025256 | nonylphenol | 3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [nonylphenol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 16291559 |
| C025256 | nonylphenol | nonylphenol results in increased expression of ESR2 mRNA | increases expression | 16291559 |
| D009640 | Norethindrone | Norethindrone results in increased activity of ESR2 protein | increases activity | 10836199 |
| D009641 | Norethynodrel | Norethynodrel results in increased activity of ESR2 protein | increases activity | 10836199 |
| D009644 | Norgestrel | Norgestrel results in increased activity of ESR2 protein | increases activity | 10836199 |
| D016912 | Levonorgestrel | Levonorgestrel results in increased activity of ESR2 protein | increases activity | 10836199 |
| C088673 | octocrylene | octocrylene binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16079615 |
| C050052 | O-desmethylangolensin | Estradiol affects the reaction [O-desmethylangolensin affects the activity of ESR2 protein] | affects activity|affects reaction | 16965913 |
| C016340 | o,p'-DDT | o,p'-DDT binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16626760 9751507 |
| C016340 | o,p'-DDT | o,p'-DDT results in increased activity of ESR2 protein | increases activity | 15064155 |
| C508548 | ormeloxifene | ormeloxifene inhibits the reaction [ESR2 protein binds to NCOA1 protein] | affects binding|decreases reaction | 19460436 |
| C005290 | oxybenzone | oxybenzone binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16079615 |
| D017239 | Paclitaxel | alitretinoin inhibits the reaction [Paclitaxel results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 19340624 |
| D017239 | Paclitaxel | Paclitaxel results in increased expression of ESR2 mRNA | increases expression | 19340624 |
| C030856 | pendimethalin | pendimethalin results in increased activity of ESR2 protein | increases activity | 15064155 |
| C086401 | pentabromodiphenyl ether | pentabromodiphenyl ether promotes the reaction [Estradiol results in decreased expression of ESR2 mRNA] | decreases expression|increases reaction | 16414171 |
| C086401 | pentabromodiphenyl ether | pentabromodiphenyl ether results in increased expression of ESR2 mRNA | increases expression | 16414171 |
| C023036 | perfluorooctanoic acid | perfluorooctanoic acid results in increased expression of ESR2 mRNA | increases expression | 18709148 |
| C031181 | phenanthrene | phenanthrene analog binds to ESR2 protein | affects binding | 12672240 |
| C006166 | phenothrin | phenothrin results in decreased expression of ESR2 protein | decreases expression | 15118252 |
| D004849 | Phenylphosphonothioic Acid, 2-Ethyl 2-(4-Nitrophenyl) Ester | Phenylphosphonothioic Acid, 2-Ethyl 2-(4-Nitrophenyl) Ester results in increased activity of ESR2 protein | increases activity | 15064155 |
| D010693 | Phloretin | Phloretin binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 9751507 |
| C032279 | phthalic acid | phthalic acid metabolite binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 15840436 |
| C100185 | phytoene | [phytoene co-treated with phytofluene] inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | affects cotreatment|decreases reaction|increases activity | 17051425 |
| D048789 | Phytoestrogens | ESR2 promoter SNP affects the susceptibility to Phytoestrogens | affects response to substance | 16921512 |
| D048789 | Phytoestrogens | Phytoestrogens analog binds to ESR2 protein | affects binding | 15887952 |
| D048789 | Phytoestrogens | Phytoestrogens binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16076101 |
| D048789 | Phytoestrogens | Phytoestrogens binds to ESR2 protein | affects binding | 16566672 |
| D048789 | Phytoestrogens | Phytoestrogens inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 16566672 |
| D048789 | Phytoestrogens | Phytoestrogens results in increased expression of ESR2 mRNA | increases expression | 16033089 |
| D048789 | Phytoestrogens | Phytoestrogens results in increased expression of ESR2 protein | increases expression | 16033089 |
| C003140 | phytofluene | [phytoene co-treated with phytofluene] inhibits the reaction [Estradiol results in increased activity of ESR2 protein] | affects cotreatment|decreases reaction|increases activity | 17051425 |
| D010936 | Plant Extracts | Plant Extracts binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16076101 |
| D010936 | Plant Extracts | Plant Extracts binds to ESR2 protein | affects binding | 14706564 11368622 |
| D010936 | Plant Extracts | Plant Extracts inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 11368622 |
| D010936 | Plant Extracts | Plant Extracts inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 20559769 |
| D010936 | Plant Extracts | Plant Extracts promotes the reaction [Tamoxifen inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ESR2 mRNA]] | decreases reaction|increases expression|increases reaction | 20559769 |
| D028321 | Plant Preparations | fulvestrant inhibits the reaction [Plant Preparations results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17935960 |
| D028321 | Plant Preparations | Plant Preparations results in increased activity of ESR2 protein | increases activity | 17935960 |
| D028321 | Plant Preparations | Plant Preparations results in decreased expression of ESR2 protein | decreases expression | 17398067 |
| D011078 | Polychlorinated Biphenyls | Polychlorinated Biphenyls metabolite inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 12377985 |
| C045362 | prochloraz | fulvestrant inhibits the reaction [prochloraz results in decreased expression of ESR2 mRNA] | decreases expression|decreases reaction | 15130599 |
| C045362 | prochloraz | prochloraz promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 15261991 |
| C045362 | prochloraz | prochloraz results in decreased expression of ESR2 mRNA | decreases expression | 15130599 |
| D011374 | Progesterone | Progesterone metabolite results in increased expression of ESR2 mRNA | increases expression | 17683929 |
| D011374 | Progesterone | Progesterone inhibits the reaction [ESR2 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]] | decreases reaction|increases expression|increases reaction | 17974624 |
| D011435 | Propyl Gallate | Propyl Gallate results in increased activity of ESR2 protein | increases activity | 16756374 |
| C467746 | propyl pyrazole triol | propyl pyrazole triol results in increased expression of ESR2 mRNA | increases expression | 15207704 |
| C032072 | prothiophos | prothiophos results in increased activity of ESR2 protein | increases activity | 15064155 |
| C033607 | puerarin | puerarin results in decreased activity of ESR2 protein | decreases activity | 18937077 |
| C031280 | pyrazole | pyrazole analog binds to ESR2 protein | affects binding | 17909483 |
| D011720 | Pyrazoles | Pyrazoles analog binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 19772920 |
| D011794 | Quercetin | Estradiol affects the reaction [Quercetin results in increased activity of ESR2 protein] | affects reaction|increases activity | 16118406 |
| D011794 | Quercetin | Quercetin binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 9751507 15182386 15937998 11502892 |
| D011794 | Quercetin | Quercetin binds to ESR2 protein | affects binding | 14706564 |
| D011794 | Quercetin | Quercetin results in increased activity of ESR2 protein | increases activity | 18955141 16118406 |
| D011794 | Quercetin | Quercetin results in increased expression of ESR2 mRNA | increases expression | 15182386 |
| C009145 | quinalphos | quinalphos results in increased activity of ESR2 protein | increases activity | 15064155 |
| D020849 | Raloxifene | ESR2 protein affects the reaction [Raloxifene results in decreased expression of EDN3 mRNA] | affects reaction|decreases expression | 14699072 |
| D020849 | Raloxifene | ESR2 protein affects the reaction [Raloxifene results in decreased expression of FLNB mRNA] | affects reaction|decreases expression | 14699072 |
| D020849 | Raloxifene | ESR2 protein affects the reaction [Raloxifene results in decreased expression of IER3 mRNA] | affects reaction|decreases expression | 14699072 |
| D020849 | Raloxifene | ESR2 protein affects the reaction [Raloxifene results in decreased expression of KLRC2 mRNA] | affects reaction|decreases expression | 14699072 |
| D020849 | Raloxifene | ESR2 protein affects the reaction [Raloxifene results in decreased expression of MSMB mRNA] | affects reaction|decreases expression | 14699072 |
| D020849 | Raloxifene | ESR2 protein affects the reaction [Raloxifene results in decreased expression of NCF2 mRNA] | affects reaction|decreases expression | 14699072 |
| D020849 | Raloxifene | ESR2 protein affects the reaction [Raloxifene results in increased expression of GABRR1 mRNA] | affects reaction|increases expression | 14699072 |
| D020849 | Raloxifene | ESR2 protein affects the reaction [Raloxifene results in increased expression of METTL7A mRNA] | affects reaction|increases expression | 14699072 |
| D020849 | Raloxifene | ESR2 protein promotes the reaction [Raloxifene results in increased activity of TERT protein] | increases activity|increases reaction | 16798746 |
| D020849 | Raloxifene | ESR2 protein results in increased susceptibility to Raloxifene | increases response to substance | 17638070 |
| D020849 | Raloxifene | Raloxifene binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of ABCC1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of ACSL1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of AKAP1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of ARL4C mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of ASB13 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of C14ORF132 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of C2CD2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CA12 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CALM1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CASKIN2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CASP7 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CCND1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CDK5R1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CEBPB mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CLCN4 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CRISPLD2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CSDC2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CUEDC1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CXCR7 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CYP19A1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CYP24A1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of CYP26B1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of DOCK9 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of EDNRA mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of EIF2C2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of ELF3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of ENDOD1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of EVI2A mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of FADD mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of FAM134B mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of FGD6 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of FGFR2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of FHL2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of FLNB mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of FOSL2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of FOXO1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of FST mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of GOLSYN mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of GPRC5C mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of HEG1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of HK1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of HMOX1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of HPCAL1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of HSPB8 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of HTR3A mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of INPP5A mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of IVL mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of KAZN mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of KCTD12 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of KIF3C mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of KLRC3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of KLRK1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of LASS6 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of LBH mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of LMNB2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of LRIG1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of LRRC20 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of LYSMD4 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MAFF mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MAGEA8 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MAP3K5 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MAP3K8 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MAPKAPK2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MBNL2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MDFIC mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MEF2A mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MMP12 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MN1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MPPED2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of MYT1L mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NAV2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NCF2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NCOA1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NCOA4 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NDRG4 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NFATC1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NFIL3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NFKBIA mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NINJ1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NPR2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NR1D1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NR2F6 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of NUAK1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of OSBPL3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of OTUB2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of PCTP mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of PDLIM3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of PHC2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of PHF11 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of PITPNC1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of PRKCZ mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of PTGER3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of PTGES mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of RCOR3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of RET mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of RFTN1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of RGL1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of RHOF mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of RPS6KA2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of SALL1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of SCNN1A mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of SEMA3F mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of SERPINB6 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of SLC18A3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of SREBF1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of SSH1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of ST3GAL1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of STK24 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of SYNJ2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of SYNPO mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of TACC1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of TACC2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of TBXA2R mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of TGFA mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of TMOD1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of TNS3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of TOB1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of TRAF3IP2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of UPF1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of WNT5A mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of ZCCHC24 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of ZMIZ1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in decreased expression of ZNF395 mRNA | affects cotreatment|decreases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of ADAM19 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of ADORA2B mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of AMIGO2 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of ANKRD1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of AREG mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of ATF3 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of BIRC3 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of C18ORF1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of C8ORF4 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of CCL20 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of CCL2 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of CDH2 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of CDO1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of CXCL12 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of DACT1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of DCBLD2 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of DUSP2 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of DUSP5 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of EGR1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of ENC1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of FUT9 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of GAD1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of GRB10 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of GYG1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of HBEGF mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of ID4 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of IFNGR2 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of IL8 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of INHBA mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of JAG1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of KRT17 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of KRT34 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of LMCD1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of MAP2K3 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of NAB1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of NFKBIE mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of NR3C1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of NR4A3 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of OCLN mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of PCDH7 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of PDP1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of PTGS2 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of PTP4A3 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of PTX3 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of RASGRP1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of RCAN2 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of RFK mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of RGS4 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of RRAD mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of SERPINE1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of SLCO4C1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of SOD2 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of TGFB2 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of TGFBI mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of TMEM158 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of TNC mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of TNFRSF11B mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of TNFRSF21 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of TNIK mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of TRAF5 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of TRIB1 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | [Raloxifene co-treated with ESR2 protein] results in increased expression of TRIM36 mRNA | affects cotreatment|increases expression | 19059307 |
| D020849 | Raloxifene | Raloxifene promotes the reaction [ESR2 protein binds to IGF1 promoter] | affects binding|increases reaction | 17872375 |
| D020849 | Raloxifene | Raloxifene promotes the reaction [ESR2 protein binds to PTGS2 promoter] | affects binding|increases reaction | 17872375 |
| D020849 | Raloxifene | Raloxifene results in decreased activity of ESR2 protein | decreases activity | 17654759 |
| D020849 | Raloxifene | Raloxifene results in increased activity of ESR2 protein | increases activity | 17962382 |
| D020849 | Raloxifene | Raloxifene binds to and affects the activity of ESR2 protein alternative form | affects activity|affects binding | 15924412 |
| D020849 | Raloxifene | Raloxifene affects the expression of ESR2 mRNA | affects expression | 19350480 |
| D020849 | Raloxifene | Raloxifene affects the expression of ESR2 protein | affects expression | 16680078 15653758 |
| D017382 | Reactive Oxygen Species | ESR2 protein promotes the reaction [Estradiol results in decreased abundance of Reactive Oxygen Species] | decreases abundance|increases reaction | 20463317 |
| C059514 | resveratrol | fulvestrant inhibits the reaction [resveratrol results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17935960 |
| C059514 | resveratrol | resveratrol binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 15084758 |
| C059514 | resveratrol | resveratrol promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 16118406 |
| C059514 | resveratrol | resveratrol results in increased activity of ESR2 protein | increases activity | 16118406 17935960 |
| C059514 | resveratrol | resveratrol results in increased expression of ESR2 protein | increases expression | 17675339 |
| C059514 | resveratrol | resveratrol binds to ESR2 protein | affects binding | 16614383 |
| C431126 | rhapontigenin | fulvestrant inhibits the reaction [rhapontigenin analog results in increased activity of ESR2 protein] | decreases reaction|increases activity | 17692514 17935960 |
| C431126 | rhapontigenin | rhapontigenin analog results in increased activity of ESR2 protein | increases activity | 17935960 17692514 |
| D012293 | Rifampin | Rifampin results in increased expression of ESR2 mRNA | increases expression | 16713641 |
| C058787 | royal jelly | Estradiol inhibits the reaction [royal jelly binds to ESR2 protein] | affects binding|decreases reaction | 17287592 |
| C058787 | royal jelly | royal jelly binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15946813 |
| C058787 | royal jelly | royal jelly binds to ESR2 protein | affects binding | 17287592 |
| C058787 | royal jelly | royal jelly inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 15946813 |
| C005704 | salicylaldoxime | salicylaldoxime analog binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 12954056 |
| D019258 | Saquinavir | [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 16931933 |
| C440975 | silybin | silybin results in increased activity of [ESR1 protein binds to ESR2 protein] | affects binding|increases activity | 16076518 |
| C440975 | silybin | silybin results in increased activity of [ESR1 protein binds to ESR2 protein] | affects binding|increases activity | 16076518 |
| D012838 | Silymarin | Silymarin results in increased activity of [ESR1 protein binds to ESR2 protein] | affects binding|increases activity | 16076518 |
| D012838 | Silymarin | Silymarin results in increased activity of [ESR1 protein binds to ESR2 protein] | affects binding|increases activity | 16076518 |
| C025473 | sitosterol | sitosterol binds to ESR2 protein | affects binding | 11518614 |
| D018038 | Sodium Selenite | Sodium Selenite affects the expression of ESR2 mRNA | affects expression | 16928829 |
| D013629 | Tamoxifen | ESR2 protein affects the reaction [Tamoxifen results in decreased expression of F13A1 mRNA] | affects reaction|decreases expression | 14699072 |
| D013629 | Tamoxifen | ESR2 protein affects the reaction [Tamoxifen results in decreased expression of IVL mRNA] | affects reaction|decreases expression | 14699072 |
| D013629 | Tamoxifen | ESR2 protein affects the reaction [Tamoxifen results in decreased expression of KLRC3 mRNA] | affects reaction|decreases expression | 14699072 |
| D013629 | Tamoxifen | ESR2 protein affects the reaction [Tamoxifen results in decreased expression of MAFF mRNA] | affects reaction|decreases expression | 14699072 |
| D013629 | Tamoxifen | ESR2 protein affects the reaction [Tamoxifen results in decreased expression of PTPRH mRNA] | affects reaction|decreases expression | 14699072 |
| D013629 | Tamoxifen | ESR2 protein affects the reaction [Tamoxifen results in increased expression of NNMT mRNA] | affects reaction|increases expression | 14699072 |
| D013629 | Tamoxifen | ESR2 protein affects the reaction [Tamoxifen results in increased expression of PTPRO mRNA] | affects reaction|increases expression | 19095770 |
| D013629 | Tamoxifen | ESR2 protein affects the susceptibility to Tamoxifen | affects response to substance | 19434490 |
| D013629 | Tamoxifen | ESR2 protein promotes the reaction [Tamoxifen results in increased expression of BIK protein] | increases expression|increases reaction | 17638070 |
| D013629 | Tamoxifen | ESR2 protein results in decreased susceptibility to Tamoxifen | decreases response to substance | 16010412 |
| D013629 | Tamoxifen | ESR2 protein results in increased susceptibility to Tamoxifen | increases response to substance | 15821116 17638070 |
| D013629 | Tamoxifen | Plant Extracts promotes the reaction [Tamoxifen inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ESR2 mRNA]] | decreases reaction|increases expression|increases reaction | 20559769 |
| D013629 | Tamoxifen | SDF1 protein promotes the reaction [Tamoxifen promotes the reaction [ESR2 protein binds to CCND1 promoter]] | affects binding|increases reaction | 19584281 |
| D013629 | Tamoxifen | Tamoxifen binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 19059307 |
| D013629 | Tamoxifen | Tamoxifen binds to ESR2 protein | affects binding | 11518614 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of ABCC1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of ACSL1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of AKAP1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of ARL4C mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of ASB13 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of C14ORF132 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of C2CD2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CA12 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CALM1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CASKIN2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CASP7 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CCND1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CDK5R1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CEBPB mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CLCN4 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CRISPLD2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CSDC2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CUEDC1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CXCR7 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CYP19A1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CYP24A1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of CYP26B1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of DOCK9 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of EDNRA mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of EIF2C2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of ELF3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of ENDOD1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of EVI2A mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of FADD mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of FAM134B mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of FGD6 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of FGFR2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of FHL2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of FLNB mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of FOSL2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of FOXO1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of FST mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of GOLSYN mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of GPRC5C mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of HEG1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of HK1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of HMOX1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of HPCAL1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of HSPB8 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of HTR3A mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of INPP5A mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of IVL mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of KAZN mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of KCTD12 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of KIF3C mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of KLRC3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of KLRK1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of LASS6 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of LBH mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of LMNB2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of LRIG1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of LRRC20 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of LYSMD4 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MAFF mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MAGEA8 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MAP3K5 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MAP3K8 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MAPKAPK2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MBNL2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MDFIC mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MEF2A mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MMP12 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MN1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MPPED2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of MYT1L mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NAV2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NCF2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NCOA1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NCOA4 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NDRG4 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NFATC1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NFIL3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NFKBIA mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NINJ1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NPR2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NR1D1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NR2F6 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of NUAK1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of OSBPL3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of OTUB2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of PCTP mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of PDLIM3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of PHC2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of PHF11 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of PITPNC1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of PRKCZ mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of PTGER3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of PTGES mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of RCOR3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of RET mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of RFTN1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of RGL1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of RHOF mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of RPS6KA2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of SALL1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of SCNN1A mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of SEMA3F mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of SERPINB6 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of SLC18A3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of SREBF1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of SSH1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of ST3GAL1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of STK24 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of SYNJ2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of SYNPO mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of TACC1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of TACC2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of TBXA2R mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of TGFA mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of TMOD1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of TNS3 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of TOB1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of TRAF3IP2 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of UPF1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of WNT5A mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of ZCCHC24 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of ZMIZ1 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of ZNF395 mRNA | affects cotreatment|decreases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of ADAM19 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of ADORA2B mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of AMIGO2 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of ANKRD1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of AREG mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of ATF3 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of BIRC3 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of C18ORF1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of C8ORF4 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of CCL20 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of CCL2 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of CDH2 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of CDO1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of CXCL12 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of DACT1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of DCBLD2 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of DUSP2 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of DUSP5 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of EGFR mRNA | affects cotreatment|increases expression | 19347870 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of EGFR protein | affects cotreatment|increases expression | 19347870 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of EGR1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of ENC1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of FUT9 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of GAD1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of GRB10 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of GYG1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of HBEGF mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of ID4 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of IFNGR2 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of IL8 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of INHBA mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of JAG1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of KRT17 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of KRT34 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of LMCD1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of MAP2K3 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of NAB1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of NFKBIE mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of NR3C1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of NR4A3 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of OCLN mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of PCDH7 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of PDP1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of PTGS2 mRNA | affects cotreatment|increases expression | 19059307 19347870 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of PTP4A3 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of PTX3 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of RASGRP1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of RCAN2 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of RFK mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of RGS4 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of RRAD mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of SERPINE1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of SLCO4C1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of SOD2 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of TGFB2 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of TGFBI mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of TMEM158 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of TNC mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of TNFRSF11B mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of TNFRSF21 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of TNIK mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of TRAF5 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of TRIB1 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | [Tamoxifen co-treated with ESR2 protein] results in increased expression of TRIM36 mRNA | affects cotreatment|increases expression | 19059307 |
| D013629 | Tamoxifen | Tamoxifen inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 12377985 |
| D013629 | Tamoxifen | Tamoxifen inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 20559769 |
| D013629 | Tamoxifen | Tamoxifen metabolite binds to ESR2 protein | affects binding | 15135306 |
| D013629 | Tamoxifen | Tamoxifen promotes the reaction [ESR1 protein binds to ESR2 protein] | affects binding|increases reaction | 20061804 |
| D013629 | Tamoxifen | Tamoxifen promotes the reaction [ESR2 protein binds to CCND1 promoter] | affects binding|increases reaction | 19584281 |
| D013629 | Tamoxifen | Tamoxifen promotes the reaction [ESR2 protein binds to [[FOS protein binds to JUN protein] which binds to PTPRO promoter]] | affects binding|increases reaction | 19095770 |
| D013629 | Tamoxifen | Tamoxifen results in decreased expression of ESR2 protein | decreases expression | 16202921 |
| D013629 | Tamoxifen | Tamoxifen results in increased expression of ESR2 protein | increases expression | 16739346 |
| D013629 | Tamoxifen | Linseed Oil inhibits the reaction [Tamoxifen results in decreased expression of ESR2 mRNA] | decreases expression|decreases reaction | 21138602 |
| D013629 | Tamoxifen | Tamoxifen results in decreased expression of ESR2 mRNA | decreases expression | 21138602 |
| D013629 | Tamoxifen | Tamoxifen results in increased expression of ESR2 protein | increases expression | 19279558 |
| D013629 | Tamoxifen | [Estradiol co-treated with Tamoxifen] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 17823450 |
| D013629 | Tamoxifen | Tamoxifen results in increased expression of ESR2 mRNA | increases expression | 17823450 |
| D013629 | Tamoxifen | [Estradiol co-treated with Tamoxifen] results in increased expression of ESR2 protein | affects cotreatment|increases expression | 19460436 |
| D013629 | Tamoxifen | Tamoxifen inhibits the reaction [ESR2 protein binds to H19 gene] | affects binding|decreases reaction | 19683557 |
| D013629 | Tamoxifen | Tamoxifen inhibits the reaction [ESR2 protein binds to NCOA1 protein] | affects binding|decreases reaction | 19460436 |
| D013629 | Tamoxifen | Tamoxifen inhibits the reaction [Estradiol binds to ESR2 protein alternative form] | affects binding|decreases reaction | 9492041 |
| D013629 | Tamoxifen | Tamoxifen results in increased expression of ESR2 mRNA | increases expression | 12834913 |
| D013629 | Tamoxifen | Tamoxifen inhibits the reaction [[4-nonylphenol co-treated with 3,4,3',4'-tetrachlorobiphenyl] results in decreased expression of ESR2 mRNA] | affects cotreatment|decreases expression|decreases reaction | 17291011 |
| D013739 | Testosterone | Testosterone results in decreased expression of ESR2 protein | decreases expression | 15916834 |
| D013739 | Testosterone | Testosterone results in increased expression of ESR2 protein | increases expression | 15916834 |
| D013739 | Testosterone | Testosterone results in increased expression of ESR2 mRNA | increases expression | 15917159 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]] | decreases reaction|increases expression|increases reaction | 15207704 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [ESR1 protein binds to ESR2 promoter] | affects binding|decreases reaction | 15207704 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 15207704 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA mutant form] | decreases reaction|increases expression | 15207704 |
| D013749 | Tetrachlorodibenzodioxin | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 17942748 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased activity of ESR2 protein | decreases activity | 17991765 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of ESR2 mRNA | increases expression | 12223220 17611358 11500237 |
| D013755 | Tetradecanoylphorbol Acetate | Ethinyl Estradiol inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of ESR2 protein] | decreases expression|decreases reaction | 10633228 |
| D013755 | Tetradecanoylphorbol Acetate | Plant Extracts inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 20559769 |
| D013755 | Tetradecanoylphorbol Acetate | Plant Extracts promotes the reaction [Tamoxifen inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ESR2 mRNA]] | decreases reaction|increases expression|increases reaction | 20559769 |
| D013755 | Tetradecanoylphorbol Acetate | Tamoxifen inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ESR2 mRNA] | decreases reaction|increases expression | 20559769 |
| D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate results in decreased expression of ESR2 protein | decreases expression | 10633228 |
| D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate results in increased expression of ESR2 mRNA | increases expression | 20559769 |
| C433164 | tetrahydrodaidzein | Estradiol affects the reaction [tetrahydrodaidzein affects the activity of ESR2 protein] | affects activity|affects reaction | 16965913 |
| C095210 | tetralin | tetralin analog results in decreased activity of ESR2 protein | decreases activity | 15737489 |
| C095210 | tetralin | tetralin analog results in increased activity of ESR2 protein | increases activity | 15737489 |
| C009424 | tetramethrin | tetramethrin results in increased expression of ESR2 protein | increases expression | 16326440 |
| C027385 | tibolone | tibolone metabolite results in increased activity of ESR2 protein | increases activity | 16720731 |
| C027385 | tibolone | tibolone results in increased activity of ESR2 protein | increases activity | 16720731 |
| C426783 | tolclofos-methyl | tolclofos-methyl results in increased activity of ESR2 protein | increases activity | 15064155 |
| D017312 | Toremifene | Toremifene results in increased expression of ESR2 mRNA | increases expression | 12079510 |
| D014112 | Toxaphene | Toxaphene binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16626760 |
| C036101 | tri-(2-ethylhexyl)trimellitate | tri-(2-ethylhexyl)trimellitate promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 16756374 |
| C036101 | tri-(2-ethylhexyl)trimellitate | tri-(2-ethylhexyl)trimellitate results in increased activity of ESR2 protein | increases activity | 16756374 |
| C012589 | trichostatin A | [decitabine co-treated with trichostatin A] results in decreased methylation of ESR2 promoter | affects cotreatment|decreases methylation | 19331143 |
| C012589 | trichostatin A | [decitabine co-treated with trichostatin A] results in increased expression of ESR2 mRNA | affects cotreatment|increases expression | 19331143 |
| C012589 | trichostatin A | decitabine promotes the reaction [trichostatin A results in increased expression of ESR2 mRNA] | increases expression|increases reaction | 18092350 |
| C012589 | trichostatin A | decitabine promotes the reaction [trichostatin A results in increased expression of ESR2 protein] | increases expression|increases reaction | 18092350 |
| C012589 | trichostatin A | trichostatin A promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 15103026 |
| C012589 | trichostatin A | trichostatin A results in decreased methylation of ESR2 promoter | decreases methylation | 19331143 |
| C012589 | trichostatin A | trichostatin A results in increased expression of ESR2 mRNA | increases expression | 19331143 18092350 |
| C012589 | trichostatin A | trichostatin A results in increased expression of ESR2 protein | increases expression | 18092350 |
| D014260 | Triclosan | Triclosan inhibits the reaction [Estradiol binds to ESR2 protein] | affects binding|decreases reaction | 17992702 |
| C482068 | TS 108 | TS 108 binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 15671561 |
| C482068 | TS 108 | TS 108 binds to ESR2 protein | affects binding | 15671561 |
| D014635 | Valproic Acid | Valproic Acid promotes the reaction [Estradiol results in increased activity of ESR2 protein] | increases activity|increases reaction | 15103026 |
| C025643 | vinclozolin | vinclozolin binds to and results in increased activity of ESR2 protein | affects binding|increases activity | 16626760 16750840 |
| C025643 | vinclozolin | vinclozolin results in decreased expression of ESR2 mRNA | decreases expression | 16504050 |
| C025643 | vinclozolin | vinclozolin results in decreased expression of ESR2 mRNA | decreases expression | 17980475 |
| C025643 | vinclozolin | vinclozolin results in increased expression of ESR2 mRNA | increases expression | 17980475 |
| C017963 | vinyl carbamate | vinyl carbamate results in decreased expression of ESR2 mRNA | decreases expression | 17849452 |
| C518540 | Y134 compound | Y134 compound binds to and results in decreased activity of ESR2 protein | affects binding|decreases activity | 17115070 |
| D015215 | Zidovudine | [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 16931933 |
| D015215 | Zidovudine | [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ESR2 mRNA | affects cotreatment|decreases expression | 16931933 |
| Disease ID | Disease Name | Direct Evidence | Inference Chemical Name | Inference Score | Publication |
|---|---|---|---|---|---|
| MESH:D000008 | Abdominal Neoplasms | Tamoxifen | 3.25 | 14745880 | |
| MESH:D000014 | Abnormalities, Drug-Induced | Diethylhexyl Phthalate | 10.32 | 6734493 | |
| MESH:D000014 | Abnormalities, Drug-Induced | methoxyacetic acid | 10.32 | 1761404 3652986 12805644 1761407 15959878 | |
| MESH:D000014 | Abnormalities, Drug-Induced | Tetrachlorodibenzodioxin | 10.32 | 15322242 11752688 14514962 | |
| MESH:D000014 | Abnormalities, Drug-Induced | Valproic Acid | 10.32 | 8875741 | |
| MESH:D000015 | Abnormalities, Multiple | Valproic Acid | 2.76 | 19490988 | |
| MESH:D000038 | Abscess | Drugs, Chinese Herbal | 5.01 | 15043669 | |
| MESH:D000052 | Acanthosis Nigricans | diethyl phthalate | 6.13 | 12616302 | |
| MESH:D000138 | Acidosis | Ammonium Chloride | 2.30 | 18287403 | |
| MESH:D000152 | Acne Vulgaris | Ethinyl Estradiol | 2.65 | 17505938 | |
| MESH:D000163 | Acquired Immunodeficiency Syndrome | Zidovudine | 3.58 | 9612607 | |
| MESH:D058186 | Acute Kidney Injury | resveratrol | 2.72 | 16538975 | |
| MESH:D000230 | Adenocarcinoma | marker/mechanism | 17639508 | ||
| MESH:D000230 | Adenocarcinoma | daidzein | 9.55 | 11473722 | |
| MESH:D000230 | Adenocarcinoma | Doxorubicin | 9.55 | 17418594 | |
| MESH:D000230 | Adenocarcinoma | Estradiol | 9.55 | 11473722 | |
| MESH:D000230 | Adenocarcinoma | Ethinyl Estradiol | 9.55 | 14692618 | |
| MESH:D000230 | Adenocarcinoma | Genistein | 9.55 | 11473722 | |
| MESH:D000230 | Adenocarcinoma | vinyl carbamate | 9.55 | 16247444 17363558 | |
| MESH:D000236 | Adenoma | 4,4'-diaminodiphenylmethane | 3.84 | 3712494 | |
| MESH:D000236 | Adenoma | resveratrol | 3.84 | 15688382 | |
| MESH:D018248 | Adenoma, Liver Cell | DDT | 14.90 | 12597452 | |
| MESH:D018248 | Adenoma, Liver Cell | diethyl phthalate | 14.90 | 12616302 | |
| MESH:D018248 | Adenoma, Liver Cell | Tetrachlorodibenzodioxin | 14.90 | 16835633 | |
| MESH:D018248 | Adenoma, Liver Cell | vinyl carbamate | 14.90 | 12371669 | |
| MESH:D000309 | Adrenal Insufficiency | Dehydroepiandrosterone | 4.51 | 17302879 | |
| MESH:D000382 | Agricultural Workers' Diseases | Atrazine | 21.12 | 11874814 | |
| MESH:D000382 | Agricultural Workers' Diseases | DDT | 21.12 | 16487989 12584743 | |
| MESH:D000382 | Agricultural Workers' Diseases | Dichlorodiphenyl Dichloroethylene | 21.12 | 16487989 | |
| MESH:D000382 | Agricultural Workers' Diseases | Dicofol | 21.12 | 12584743 | |
| MESH:D000382 | Agricultural Workers' Diseases | Heptachlor | 21.12 | 12661182 | |
| MESH:D000382 | Agricultural Workers' Diseases | Lindane | 21.12 | 12661182 | |
| MESH:D000382 | Agricultural Workers' Diseases | Toxaphene | 21.12 | 16132792 | |
| MESH:D000419 | Albuminuria | Doxorubicin | 7.39 | 21441931 | |
| MESH:D000419 | Albuminuria | Raloxifene | 7.39 | 17308373 17451421 | |
| MESH:D019973 | Alcohol-Related Disorders | puerarin | 5.30 | 17887948 | |
| MESH:D000505 | Alopecia | Isoflavones | 3.63 | 17569567 | |
| MESH:D000544 | Alzheimer Disease | 24-hydroxycholesterol | 6.80 | 14523054 | |
| MESH:D000544 | Alzheimer Disease | 27-hydroxycholesterol | 6.80 | 20157255 14523054 | |
| MESH:D000544 | Alzheimer Disease | Plant Extracts | 6.80 | 16962711 | |
| MESH:D000544 | Alzheimer Disease | Raloxifene | 6.80 | 15800139 | |
| MESH:D000544 | Alzheimer Disease | resveratrol | 6.80 | 16162502 16183991 | |
| MESH:D000550 | Amblyopia | Valproic Acid | 3.94 | 17688650 | |
| MESH:D000686 | Amyloidosis | Diethylstilbestrol | 3.26 | 15469931 | |
| MESH:D000740 | Anemia | Drugs, Chinese Herbal | 5.24 | 17963324 15504547 | |
| MESH:D000740 | Anemia | Tetrachlorodibenzodioxin | 5.24 | 11748828 | |
| MESH:D000743 | Anemia, Hemolytic | Quercetin | 3.07 | 17084956 | |
| MESH:D000787 | Angina Pectoris | Drugs, Chinese Herbal | 4.13 | 11477813 | |
| MESH:D000987 | Antisocial Personality Disorder | Testosterone | 4.56 | 7506515 | |
| MESH:D001004 | Anus Diseases | Drugs, Chinese Herbal | 4.67 | 15043669 | |
| MESH:D001008 | Anxiety Disorders | Valproic Acid | 5.24 | 17497229 | |
| MESH:D001008 | Anxiety Disorders | vinclozolin | 5.24 | 19015723 | |
| MESH:D001161 | Arteriosclerosis | Cyclophosphamide | 10.22 | 15014928 | |
| MESH:D001161 | Arteriosclerosis | Ethinyl Estradiol | 10.22 | 11256880 | |
| MESH:D001161 | Arteriosclerosis | tibolone | 10.22 | 11256880 | |
| MESH:D001169 | Arthritis, Experimental | Ethinyl Estradiol | 6.88 | 15885639 | |
| MESH:D001169 | Arthritis, Experimental | Plant Extracts | 6.88 | 14686799 | |
| MESH:D001169 | Arthritis, Experimental | resveratrol | 6.88 | 17115116 | |
| MESH:D015210 | Arthritis, Gouty | Drugs, Chinese Herbal | 4.47 | 19655406 | |
| MESH:D001260 | Ataxia Telangiectasia | Quercetin | 3.70 | 15336622 | |
| MESH:D050197 | Atherosclerosis | 27-hydroxycholesterol | 5.97 | 9059518 11166758 | |
| MESH:D050197 | Atherosclerosis | Cadmium | 5.97 | 15687053 | |
| MESH:D050197 | Atherosclerosis | resveratrol | 5.97 | 17967414 16873680 | |
| MESH:D001284 | Atrophy | fulvestrant | 3.63 | 11514358 | |
| MESH:D001321 | Autistic Disorder | Mercury | 2.70 | 17497416 | |
| MESH:D001321 | Autistic Disorder | Valproic Acid | 2.70 | 15238991 19232924 18316065 18775368 18985861 18396377 20603192 17688650 18558336 17157402 19460635 16609825 17507914 18940202 18177632 | |
| MESH:D001327 | Autoimmune Diseases | Mercury | 6.88 | 16634805 | |
| MESH:D001327 | Autoimmune Diseases | Quercetin | 6.88 | 19761891 | |
| MESH:D001660 | Biliary Tract Diseases | 4,4'-diaminodiphenylmethane | 3.72 | 1440618 11289319 | |
| MESH:D001714 | Bipolar Disorder | Valproic Acid | 2.25 | 20046352 17594078 | |
| MESH:D001778 | Blood Coagulation Disorders | Tetrachlorodibenzodioxin | 1.89 | 12125929 | |
| MESH:D001836 | Body Weight Changes | Tetrachlorodibenzodioxin | 2.50 | 15340226 | |
| MESH:D001848 | Bone Diseases, Developmental | Tetrachlorodibenzodioxin | 4.77 | 15746008 | |
| MESH:D001848 | Bone Diseases, Developmental | Valproic Acid | 4.77 | 8888407 | |
| MESH:D019046 | Bone Marrow Neoplasms | Doxorubicin | 3.41 | 14601052 | |
| MESH:D001859 | Bone Neoplasms | Paclitaxel | 3.37 | 15867366 | |
| MESH:D001862 | Bone Resorption | bisphenol A | 5.95 | 11985600 | |
| MESH:D001862 | Bone Resorption | Drugs, Chinese Herbal | 5.95 | 9881647 | |
| MESH:D020201 | Brain Hemorrhage, Traumatic | Progesterone | 4.04 | 17868700 | |
| MESH:D001930 | Brain Injuries | Progesterone | 6.84 | 15665606 15845082 15380490 | |
| MESH:D001930 | Brain Injuries | Raloxifene | 6.84 | 16580743 | |
| MESH:D002545 | Brain Ischemia | beta Carotene | 14.15 | 16157235 | |
| MESH:D002545 | Brain Ischemia | Plant Extracts | 14.15 | 16041641 | |
| MESH:D002545 | Brain Ischemia | puerarin | 14.15 | 16041641 | |
| MESH:D002545 | Brain Ischemia | resveratrol | 14.15 | 17600658 | |
| MESH:D001932 | Brain Neoplasms | Doxorubicin | 2.69 | 17150277 | |
| MESH:D001943 | Breast Neoplasms | marker/mechanism|therapeutic | 19548127 19434490 17132221 | ||
| MESH:D001943 | Breast Neoplasms | 4-hydroxyestradiol-17 beta | 35.95 | 16675129 | |
| MESH:D001943 | Breast Neoplasms | alitretinoin | 35.95 | 16344269 | |
| MESH:D001943 | Breast Neoplasms | Apigenin | 35.95 | 17132221 16541309 | |
| MESH:D001943 | Breast Neoplasms | beta-hexachlorocyclohexane | 35.95 | 17640349 12948864 | |
| MESH:D001943 | Breast Neoplasms | bisphenol A | 35.95 | 17123778 | |
| MESH:D001943 | Breast Neoplasms | Cyclophosphamide | 35.95 | 11325840 16978400 17388661 12006526 18234424 15093573 17020986 18323546 15136595 | |
| MESH:D001943 | Breast Neoplasms | DDT | 35.95 | 16792888 12709520 | |
| MESH:D001943 | Breast Neoplasms | decitabine | 35.95 | 18320071 19208741 | |
| MESH:D001943 | Breast Neoplasms | Dichlorodiphenyl Dichloroethylene | 35.95 | 15061365 | |
| MESH:D001943 | Breast Neoplasms | Dieldrin | 35.95 | 15770527 11859874 | |
| MESH:D001943 | Breast Neoplasms | Diethylstilbestrol | 35.95 | 15324884 17129689 | |
| MESH:D001943 | Breast Neoplasms | Doxorubicin | 35.95 | 15668708 16595493 16826403 16264153 15634643 18628466 15994142 15939500 18382427 18695136 17426702 16935488 15692762 19526202 18234424 15136595 15567936 16115903 15993339 16096432 16322301 17983394 11325840 17369602 | |
| MESH:D001943 | Breast Neoplasms | equol | 35.95 | 16898868 | |
| MESH:D001943 | Breast Neoplasms | Estradiol | 35.95 | 19861407 17018787 14630087 18497071 16675129 17289903 17261762 12948864 | |
| MESH:D001943 | Breast Neoplasms | fulvestrant | 35.95 | 18984771 | |
| MESH:D001943 | Breast Neoplasms | Genistein | 35.95 | 17200150 16873071 16541309 | |
| MESH:D001943 | Breast Neoplasms | Heptachlor | 35.95 | 8738476 | |
| MESH:D001943 | Breast Neoplasms | Heptachlor Epoxide | 35.95 | 15770527 8738476 | |
| MESH:D001943 | Breast Neoplasms | kaempferol | 35.95 | 16756079 | |
| MESH:D001943 | Breast Neoplasms | Lindane | 35.95 | 14688026 | |
| MESH:D001943 | Breast Neoplasms | Linseed Oil | 35.95 | 21138602 | |
| MESH:D001943 | Breast Neoplasms | LY 353381 | 35.95 | 19477949 | |
| MESH:D001943 | Breast Neoplasms | Paclitaxel | 35.95 | 18223236 15136595 16115903 16244791 11325840 16273361 18234424 18323546 | |
| MESH:D001943 | Breast Neoplasms | Phytoestrogens | 35.95 | 17158751 17176212 | |
| MESH:D001943 | Breast Neoplasms | Plant Preparations | 35.95 | 17398067 | |
| MESH:D001943 | Breast Neoplasms | Progesterone | 35.95 | 16175315 15562024 17614352 | |
| MESH:D001943 | Breast Neoplasms | Quercetin | 35.95 | 18628248 | |
| MESH:D001943 | Breast Neoplasms | Raloxifene | 35.95 | 15775269 17595753 17893378 15572757 15758505 16912660 17440819 17952589 17242785 17261762 17049068 16837676 | |
| MESH:D001943 | Breast Neoplasms | resveratrol | 35.95 | 17534123 16393696 17651959 | |
| MESH:D001943 | Breast Neoplasms | Tamoxifen | 35.95 | 18855134 16873071 11161223 19059307 19221464 17242785 19115204 19487384 15565566 21138602 20135344 18821012 19189212 19142967 19189210 18984771 20544844 20005174 19155303 19103187 18629630 17261762 17893378 19200415 18351453 20065188 18815881 16202921 19288272 17049068 15668708 21152245 19011961 20390343 20859285 16818667 19084267 16273361 18997820 17440819 19066611 18425577 19244106 19410462 19289846 | |
| MESH:D001943 | Breast Neoplasms | Testosterone | 35.95 | 17261762 | |
| MESH:D001943 | Breast Neoplasms | Tetrachlorodibenzodioxin | 35.95 | 20435547 | |
| MESH:D001943 | Breast Neoplasms | Toremifene | 35.95 | 16273361 | |
| MESH:D002057 | Burns, Chemical | Plant Extracts | 4.05 | 9625245 | |
| MESH:D002105 | Cadmium Poisoning | Quercetin | 4.25 | 16962696 | |
| MESH:D002181 | Candidiasis, Vulvovaginal | Estradiol | 3.19 | 16111702 | |
| MESH:D002252 | Carbon Tetrachloride Poisoning | Carbon Tetrachloride | 2.55 | 10355542 15700767 3786805 16227642 16097048 15673190 16124888 15721981 16011737 16050911 18705752 16192424 | |
| MESH:D002276 | Carcinoid Tumor | Doxorubicin | 3.52 | 16051944 | |
| MESH:D002277 | Carcinoma | Tetrachlorodibenzodioxin | 1.74 | 16835633 | |
| MESH:D018270 | Carcinoma, Ductal, Breast | Tamoxifen | 3.25 | 19066611 | |
| MESH:D006528 | Carcinoma, Hepatocellular | 4,4'-diaminodiphenylmethane | 24.52 | 7296757 3581430 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Carbon Tetrachloride | 24.52 | 18788625 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Cyclophosphamide | 24.52 | 19701751 | |
| MESH:D006528 | Carcinoma, Hepatocellular | DDT | 24.52 | 12597452 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Diethylstilbestrol | 24.52 | 15948411 16924424 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Doxorubicin | 24.52 | 16023760 18059187 17876044 16234567 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Estradiol | 24.52 | 16924424 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Estrogens | 24.52 | 15341023 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Genistein | 24.52 | 16924424 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Paclitaxel | 24.52 | 16313753 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Plant Extracts | 24.52 | 18834353 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Quercetin | 24.52 | 12508355 19519916 | |
| MESH:D006528 | Carcinoma, Hepatocellular | resveratrol | 24.52 | 19321006 16227395 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Tamoxifen | 24.52 | 16924424 | |
| MESH:D006528 | Carcinoma, Hepatocellular | vinyl carbamate | 24.52 | 12371669 | |
| MESH:D002278 | Carcinoma in Situ | bisphenol A | 3.71 | 17123778 | |
| MESH:D018827 | Carcinoma, Lewis Lung | Cyclophosphamide | 7.29 | 16152834 | |
| MESH:D018827 | Carcinoma, Lewis Lung | resveratrol | 7.29 | 16675471 | |
| MESH:D002289 | Carcinoma, Non-Small-Cell Lung | gefitinib | 4.33 | 16230376 19233551 18347146 17290066 15496427 20005069 | |
| MESH:D002289 | Carcinoma, Non-Small-Cell Lung | vinyl carbamate | 4.33 | 16247446 | |
| MESH:D021441 | Carcinoma, Pancreatic Ductal | Quercetin | 3.70 | 17234771 | |
| MESH:D002292 | Carcinoma, Renal Cell | 4,4'-diaminodiphenylmethane | 6.09 | 7296757 | |
| MESH:D002292 | Carcinoma, Renal Cell | Cyclophosphamide | 6.09 | 16201981 | |
| MESH:D002292 | Carcinoma, Renal Cell | Doxorubicin | 6.09 | 16201981 1485588 | |
| MESH:D002294 | Carcinoma, Squamous Cell | decitabine | 7.70 | 19215824 | |
| MESH:D002294 | Carcinoma, Squamous Cell | Doxorubicin | 7.70 | 6189445 | |
| MESH:D002294 | Carcinoma, Squamous Cell | Plant Preparations | 7.70 | 17418620 | |
| MESH:D002294 | Carcinoma, Squamous Cell | resveratrol | 7.70 | 16227395 | |
| MESH:D002294 | Carcinoma, Squamous Cell | Tetradecanoylphorbol Acetate | 7.70 | 18922899 | |
| MESH:D002295 | Carcinoma, Transitional Cell | Raloxifene | 5.68 | 17572228 | |
| MESH:D002295 | Carcinoma, Transitional Cell | Tamoxifen | 5.68 | 17572228 | |
| MESH:D006332 | Cardiomegaly | Plant Extracts | 6.32 | 17645561 | |
| MESH:D006332 | Cardiomegaly | Quercetin | 6.32 | 19794523 | |
| MESH:D006332 | Cardiomegaly | Tetrachlorodibenzodioxin | 6.32 | 18670907 18850075 16120746 | |
| MESH:D009202 | Cardiomyopathies | Doxorubicin | 2.58 | 18627295 17519947 16269455 17007740 16651473 17382496 17351982 17924179 16364871 17308081 17329180 15476868 17131338 17928571 15792986 16455267 16952015 16242529 16278810 16612575 16731534 17974986 16109756 15505089 15811867 | |
| MESH:D002311 | Cardiomyopathy, Dilated | Doxorubicin | 3.93 | 16243910 17334414 | |
| MESH:D002311 | Cardiomyopathy, Dilated | Mercury | 3.93 | 10334427 | |
| MESH:D002318 | Cardiovascular Diseases | daidzein | 22.55 | 16332659 | |
| MESH:D002318 | Cardiovascular Diseases | Genistein | 22.55 | 16332659 | |
| MESH:D002318 | Cardiovascular Diseases | Isoflavones | 22.55 | 17689850 | |
| MESH:D002318 | Cardiovascular Diseases | kaempferol | 22.55 | 16756079 | |
| MESH:D002318 | Cardiovascular Diseases | Phytoestrogens | 22.55 | 16862667 | |
| MESH:D002318 | Cardiovascular Diseases | Plant Preparations | 22.55 | 16862667 | |
| MESH:D002318 | Cardiovascular Diseases | Raloxifene | 22.55 | 15775269 | |
| MESH:D002318 | Cardiovascular Diseases | resveratrol | 22.55 | 15458977 | |
| MESH:D016893 | Carotid Stenosis | Plant Preparations | 4.86 | 15158307 | |
| MESH:D002471 | Cell Transformation, Neoplastic | 4,4'-diaminodiphenylmethane | 8.02 | 7505956 | |
| MESH:D002471 | Cell Transformation, Neoplastic | 4-hydroxyestradiol-17 beta | 8.02 | 18226522 18566989 | |
| MESH:D002471 | Cell Transformation, Neoplastic | Cadmium | 8.02 | 17332340 | |
| MESH:D002471 | Cell Transformation, Neoplastic | Estradiol | 8.02 | 18566989 | |
| MESH:D002659 | Child Development Disorders, Pervasive | Testosterone | 3.94 | 20678186 | |
| MESH:D002659 | Child Development Disorders, Pervasive | Valproic Acid | 3.94 | 20734317 | |
| MESH:D018281 | Cholangiocarcinoma | Tetrachlorodibenzodioxin | 2.04 | 16835633 | |
| MESH:D002779 | Cholestasis | 4,4'-diaminodiphenylmethane | 7.60 | 19486331 9022650 | |
| MESH:D002779 | Cholestasis | Ethinyl Estradiol | 7.60 | 17110522 16919318 11677210 17681005 15861022 16105132 17333356 | |
| MESH:D002779 | Cholestasis | Levonorgestrel | 7.60 | 15861022 | |
| MESH:D019457 | Chromosome Breakage | Sodium Selenite | 3.50 | 15894690 | |
| MESH:D002972 | Cleft Palate | Tetrachlorodibenzodioxin | 1.41 | 8697196 15668235 12621046 15340226 16354765 | |
| MESH:D003072 | Cognition Disorders | Raloxifene | 3.37 | 15800139 | |
| MESH:D003092 | Colitis | resveratrol | 2.91 | 16474422 | |
| MESH:D003110 | Colonic Neoplasms | decitabine | 4.43 | 17616700 | |
| MESH:D003110 | Colonic Neoplasms | Genistein | 4.43 | 17182828 | |
| MESH:D003110 | Colonic Neoplasms | Quercetin | 4.43 | 11134977 15741050 19440933 16640504 17148506 17191121 19056647 | |
| MESH:D003110 | Colonic Neoplasms | resveratrol | 4.43 | 16338953 | |
| MESH:D015179 | Colorectal Neoplasms | marker/mechanism | 15954165 | ||
| MESH:D015179 | Colorectal Neoplasms | decitabine | 7.32 | 18981723 | |
| MESH:D015179 | Colorectal Neoplasms | Doxorubicin | 7.32 | 18802399 18259882 | |
| MESH:D015179 | Colorectal Neoplasms | gefitinib | 7.32 | 17594712 | |
| MESH:D015179 | Colorectal Neoplasms | Isoflavones | 7.32 | 17116718 | |
| MESH:D015179 | Colorectal Neoplasms | Paclitaxel | 7.32 | 18802399 | |
| MESH:D015179 | Colorectal Neoplasms | Polychlorinated Biphenyls | 7.32 | 15531428 | |
| MESH:D015179 | Colorectal Neoplasms | Quercetin | 7.32 | 18095365 18852136 | |
| MESH:D015179 | Colorectal Neoplasms | resveratrol | 7.32 | 16550006 | |
| MESH:D000013 | Congenital Abnormalities | DDT | 13.15 | 15095906 | |
| MESH:D000013 | Congenital Abnormalities | Dichlorodiphenyldichloroethane | 13.15 | 15095906 | |
| MESH:D000013 | Congenital Abnormalities | Tetrachlorodibenzodioxin | 13.15 | 14669216 17141729 | |
| MESH:D000013 | Congenital Abnormalities | Triclosan | 13.15 | 19283420 | |
| MESH:D003324 | Coronary Artery Disease | marker/mechanism | 20559769 | ||
| MESH:D003324 | Coronary Artery Disease | Plant Preparations | 3.35 | 15158307 | |
| MESH:D003327 | Coronary Disease | marker/mechanism | 17367797 | ||
| MESH:D003327 | Coronary Disease | Phytoestrogens | 5.80 | 17367797 | |
| MESH:D003327 | Coronary Disease | resveratrol | 5.80 | 16507316 | |
| MESH:D019465 | Craniofacial Abnormalities | Reactive Oxygen Species | 2.40 | 15736158 | |
| MESH:D019465 | Craniofacial Abnormalities | Tetrachlorodibenzodioxin | 2.40 | 15322242 10048152 20055451 | |
| MESH:D019465 | Craniofacial Abnormalities | Valproic Acid | 2.40 | 16575769 17688650 8888407 | |
| MESH:D016638 | Critical Illness | Estrogens | 4.67 | 16670151 | |
| MESH:D003456 | Cryptorchidism | Dibutyl Phthalate | 12.31 | 16037377 | |
| MESH:D003456 | Cryptorchidism | Diethylstilbestrol | 12.31 | 12952375 16002989 | |
| MESH:D003456 | Cryptorchidism | vinclozolin | 12.31 | 14966744 | |
| MESH:D003490 | Cyanosis | Endosulfan | 4.30 | 7900959 | |
| MESH:D003556 | Cystitis | Cyclophosphamide | 3.70 | 15643279 18710439 18093676 17010015 16413132 18483878 18372110 10700343 12913760 16989017 18433785 12161096 16614059 16651033 12388444 17979934 15276878 18295254 10498854 11948286 | |
| MESH:D003704 | Dementia | Polychlorinated Biphenyls | 3.53 | 16140633 | |
| MESH:D003711 | Demyelinating Diseases | Tamoxifen | 3.11 | 19031437 | |
| MESH:D003715 | Dengue | 24-hydroxycholesterol | 7.99 | 19427377 | |
| MESH:D003715 | Dengue | 27-hydroxycholesterol | 7.99 | 19427377 | |
| MESH:D003865 | Depressive Disorder, Major | Raloxifene | 3.03 | 17474826 | |
| MESH:D017449 | Dermatitis, Allergic Contact | 4,4'-diaminodiphenylmethane | 3.38 | 12868966 11298694 8156756 8970840 18759878 2524372 14531868 11906362 | |
| MESH:D017449 | Dermatitis, Allergic Contact | Mercury | 3.38 | 16823706 | |
| MESH:D003876 | Dermatitis, Atopic | Diethylhexyl Phthalate | 3.27 | 16882537 | |
| MESH:D003877 | Dermatitis, Contact | 4,4'-diaminodiphenylmethane | 6.14 | 3621924 2952479 | |
| MESH:D003877 | Dermatitis, Contact | bu-zhong-yi-qi-tang | 6.14 | 12188032 | |
| MESH:D003920 | Diabetes Mellitus | Sodium Selenite | 2.66 | 16285004 | |
| MESH:D003921 | Diabetes Mellitus, Experimental | Cyclophosphamide | 7.70 | 10990075 15331540 11751995 | |
| MESH:D003921 | Diabetes Mellitus, Experimental | Quercetin | 7.70 | 19496084 | |
| MESH:D003921 | Diabetes Mellitus, Experimental | resveratrol | 7.70 | 16873680 | |
| MESH:D003922 | Diabetes Mellitus, Type 1 | Cyclophosphamide | 3.99 | 18772604 | |
| MESH:D003922 | Diabetes Mellitus, Type 1 | Dehydroepiandrosterone | 3.99 | 16616286 | |
| MESH:D003924 | Diabetes Mellitus, Type 2 | daidzein | 4.03 | 16647724 | |
| MESH:D003924 | Diabetes Mellitus, Type 2 | Genistein | 4.03 | 16647724 | |
| MESH:D003924 | Diabetes Mellitus, Type 2 | Tetrachlorodibenzodioxin | 4.03 | 17107852 | |
| MESH:D003928 | Diabetic Nephropathies | Estradiol | 16.27 | 19279558 | |
| MESH:D003928 | Diabetic Nephropathies | Plant Extracts | 16.27 | 19706694 | |
| MESH:D003928 | Diabetic Nephropathies | Raloxifene | 16.27 | 17451421 17308373 15920148 | |
| MESH:D003928 | Diabetic Nephropathies | resveratrol | 16.27 | 16286809 | |
| MESH:D003928 | Diabetic Nephropathies | Tamoxifen | 16.27 | 19279558 | |
| MESH:D003929 | Diabetic Neuropathies | Progesterone | 3.24 | 17187935 | |
| MESH:D056486 | Drug-Induced Liver Injury | 4,4'-diaminodiphenylmethane | 15.54 | 1440618 18289764 16192314 18692083 9653073 11289319 9328219 6482804 9022650 18648102 8291058 7440962 6679447 | |
| MESH:D056486 | Drug-Induced Liver Injury | Carbon Tetrachloride | 15.54 | 15968718 3786805 19085960 7120509 7440962 9327722 16177239 6623471 10915739 15998439 21278145 17522070 16227642 4309450 19336974 6884620 15027814 2869522 7179309 10092053 3732212 11566570 | |
| MESH:D056486 | Drug-Induced Liver Injury | Chlorodiphenyl (54% Chlorine) | 15.54 | 17851650 | |
| MESH:D056486 | Drug-Induced Liver Injury | Doxorubicin | 15.54 | 17416283 | |
| MESH:D056486 | Drug-Induced Liver Injury | Drugs, Chinese Herbal | 15.54 | 15027814 | |
| MESH:D056486 | Drug-Induced Liver Injury | pyrazole | 15.54 | 12499123 | |
| MESH:D056486 | Drug-Induced Liver Injury | Silymarin | 15.54 | 14998559 | |
| MESH:D056486 | Drug-Induced Liver Injury | Sodium Selenite | 15.54 | 15131321 | |
| MESH:D056486 | Drug-Induced Liver Injury | Tetrachlorodibenzodioxin | 15.54 | 20420201 | |
| MESH:D056486 | Drug-Induced Liver Injury | Valproic Acid | 15.54 | 19641884 1733752 | |
| MESH:D004362 | Drug Toxicity | Doxorubicin | 14.74 | 18602426 | |
| MESH:D004362 | Drug Toxicity | Lamivudine | 14.74 | 15040536 | |
| MESH:D004362 | Drug Toxicity | Plant Preparations | 14.74 | 11033412 | |
| MESH:D004362 | Drug Toxicity | Tetrachlorodibenzodioxin | 14.74 | 11462148 | |
| MESH:D004362 | Drug Toxicity | Zidovudine | 14.74 | 15040536 | |
| MESH:D004417 | Dyspnea | DDT | 10.22 | 16487989 | |
| MESH:D004417 | Dyspnea | Dichlorodiphenyl Dichloroethylene | 10.22 | 16487989 | |
| MESH:D004417 | Dyspnea | Endosulfan | 10.22 | 7900959 3388749 | |
| MESH:D004421 | Dystonia | Valproic Acid | 2.85 | 1851702 | |
| MESH:D004487 | Edema | perfluorooctanoic acid | 12.44 | 17259670 12083418 | |
| MESH:D004487 | Edema | Plant Extracts | 12.44 | 12787963 | |
| MESH:D004487 | Edema | Raloxifene | 12.44 | 15860553 | |
| MESH:D004487 | Edema | resveratrol | 12.44 | 8985016 | |
| MESH:D004487 | Edema | Tetrachlorodibenzodioxin | 12.44 | 12711302 11000095 | |
| MESH:D004487 | Edema | Tetradecanoylphorbol Acetate | 12.44 | 16716910 8273558 11698051 8113982 9599246 7812673 15177302 | |
| MESH:D004489 | Edema, Cardiac | Tetrachlorodibenzodioxin | 2.61 | 18230668 15322242 16714409 | |
| MESH:D004646 | Emphysema | Endosulfan | 5.26 | 7900959 | |
| MESH:D004681 | Encephalomyelitis, Autoimmune, Experimental | 24-hydroxycholesterol | 24.74 | 17410599 | |
| MESH:D004681 | Encephalomyelitis, Autoimmune, Experimental | 27-hydroxycholesterol | 24.74 | 17410599 | |
| MESH:D004681 | Encephalomyelitis, Autoimmune, Experimental | Ethinyl Estradiol | 24.74 | 12538720 | |
| MESH:D004681 | Encephalomyelitis, Autoimmune, Experimental | Progesterone | 24.74 | 17692515 | |
| MESH:D004681 | Encephalomyelitis, Autoimmune, Experimental | Raloxifene | 24.74 | 15845917 | |
| MESH:D004681 | Encephalomyelitis, Autoimmune, Experimental | resveratrol | 24.74 | 17872969 | |
| MESH:D004681 | Encephalomyelitis, Autoimmune, Experimental | Tamoxifen | 24.74 | 19031437 | |
| MESH:D004701 | Endocrine Gland Neoplasms | decitabine | 9.75 | 19294695 | |
| MESH:D004701 | Endocrine Gland Neoplasms | trichostatin A | 9.75 | 19294695 | |
| MESH:D004714 | Endometrial Hyperplasia | Diethylstilbestrol | 18.93 | 16402032 | |
| MESH:D004714 | Endometrial Hyperplasia | Estriol | 18.93 | 16402032 | |
| MESH:D004714 | Endometrial Hyperplasia | Genistein | 18.93 | 16402032 | |
| MESH:D004714 | Endometrial Hyperplasia | Phytoestrogens | 18.93 | 16402032 | |
| MESH:D016889 | Endometrial Neoplasms | 4-hydroxytamoxifen | 28.14 | 19148513 | |
| MESH:D016889 | Endometrial Neoplasms | bu-zhong-yi-qi-tang | 28.14 | 17089059 | |
| MESH:D016889 | Endometrial Neoplasms | daidzein | 28.14 | 11473722 | |
| MESH:D016889 | Endometrial Neoplasms | Diethylstilbestrol | 28.14 | 16804899 15700306 | |
| MESH:D016889 | Endometrial Neoplasms | Doxorubicin | 28.14 | 17359293 | |
| MESH:D016889 | Endometrial Neoplasms | Estradiol | 28.14 | 18566989 11473722 19148513 | |
| MESH:D016889 | Endometrial Neoplasms | Genistein | 28.14 | 11473722 | |
| MESH:D016889 | Endometrial Neoplasms | Phytoestrogens | 28.14 | 16543667 | |
| MESH:D016889 | Endometrial Neoplasms | Tamoxifen | 28.14 | 16202921 19155303 20544844 17893378 | |
| MESH:D004715 | Endometriosis | marker/mechanism | 17625110 | ||
| MESH:D004715 | Endometriosis | Progesterone | 5.12 | 16134523 | |
| MESH:D004715 | Endometriosis | Tetrachlorodibenzodioxin | 5.12 | 9294722 10568697 | |
| MESH:D004719 | Endomyocardial Fibrosis | Doxorubicin | 9.78 | 18037988 | |
| MESH:D004719 | Endomyocardial Fibrosis | Plant Extracts | 9.78 | 15268973 | |
| MESH:D019446 | Endotoxemia | dong quai | 4.92 | 16424112 | |
| MESH:D020345 | Enterocolitis, Necrotizing | resveratrol | 3.60 | 17923197 | |
| MESH:D004802 | Eosinophilia | Cyclophosphamide | 3.02 | 11006010 | |
| MESH:D004831 | Epilepsies, Myoclonic | Valproic Acid | 2.91 | 3659116 17275665 | |
| MESH:D004828 | Epilepsies, Partial | Valproic Acid | 2.65 | 16628512 3922381 | |
| MESH:D004827 | Epilepsy | Plant Extracts | 4.15 | 19439326 19700373 | |
| MESH:D004827 | Epilepsy | Valproic Acid | 4.15 | 18234410 20417680 | |
| MESH:D004832 | Epilepsy, Absence | Valproic Acid | 2.48 | 6254150 6426943 7562514 | |
| MESH:D017029 | Epilepsy, Complex Partial | Valproic Acid | 3.05 | 7750514 | |
| MESH:D004830 | Epilepsy, Tonic-Clonic | Valproic Acid | 2.81 | 3659116 | |
| MESH:D007172 | Erectile Dysfunction | daidzein | 3.81 | 14972507 | |
| MESH:D004938 | Esophageal Neoplasms | 4,4'-diaminodiphenylmethane | 4.19 | 3581430 | |
| MESH:D004938 | Esophageal Neoplasms | Paclitaxel | 4.19 | 16481741 | |
| MESH:D004938 | Esophageal Neoplasms | Plant Preparations | 4.19 | 16510608 | |
| MESH:D005124 | Eye Abnormalities | Tetrachlorodibenzodioxin | 1.96 | 11564622 | |
| MESH:D005234 | Fatty Liver | Carbon Tetrachloride | 19.50 | 12631006 61145 15959796 16045604 12795759 19224547 17595544 16239168 | |
| MESH:D005234 | Fatty Liver | Ethinyl Estradiol | 19.50 | 15345470 | |
| MESH:D005234 | Fatty Liver | Plant Extracts | 19.50 | 15975614 | |
| MESH:D005234 | Fatty Liver | Raloxifene | 19.50 | 17473493 | |
| MESH:D005234 | Fatty Liver | Tamoxifen | 19.50 | 14986274 19224547 | |
| MESH:D005234 | Fatty Liver | Valproic Acid | 19.50 | 14986274 19224547 | |
| MESH:D005234 | Fatty Liver | Zidovudine | 19.50 | 18299183 | |
| MESH:D052776 | Female Urogenital Diseases | Diethylstilbestrol | 8.44 | 16534752 16513791 15751030 16611131 16002989 | |
| MESH:D052776 | Female Urogenital Diseases | Tamoxifen | 8.44 | 16709447 | |
| MESH:D052776 | Female Urogenital Diseases | Toremifene | 8.44 | 16709447 | |
| MESH:D005313 | Fetal Death | Tetrachlorodibenzodioxin | 2.22 | 11858732 | |
| MESH:D005315 | Fetal Diseases | Valproic Acid | 3.59 | 16575769 | |
| MESH:D005317 | Fetal Growth Retardation | Valproic Acid | 2.91 | 8888407 18558336 | |
| MESH:D005350 | Fibroma | 4,4'-diaminodiphenylmethane | 3.72 | 6705139 | |
| MESH:D018221 | Fibromatosis, Abdominal | Tamoxifen | 3.25 | 14745880 | |
| MESH:D018222 | Fibromatosis, Aggressive | Doxorubicin | 7.24 | 19069698 | |
| MESH:D018222 | Fibromatosis, Aggressive | Tamoxifen | 7.24 | 19069698 | |
| MESH:D005355 | Fibrosis | Carbon Tetrachloride | 11.23 | 18705752 | |
| MESH:D005355 | Fibrosis | Emodin | 11.23 | 19474275 | |
| MESH:D005355 | Fibrosis | Quercetin | 11.23 | 19474275 | |
| MESH:D005355 | Fibrosis | Tetrachlorodibenzodioxin | 11.23 | 20067830 | |
| MESH:D005391 | Firesetting Behavior | Testosterone | 4.56 | 7506515 | |
| MESH:D005532 | Foot Deformities, Congenital | methoxyacetic acid | 4.49 | 3652986 | |
| MESH:D030342 | Genetic Diseases, Inborn | vinclozolin | 3.66 | 16973722 | |
| MESH:D005832 | Genital Diseases, Male | vinclozolin | 4.00 | 16417039 | |
| MESH:D005833 | Genital Neoplasms, Female | Diethylstilbestrol | 3.67 | 16452187 | |
| MESH:D005909 | Glioblastoma | biochanin A | 15.25 | 16598420 | |
| MESH:D005909 | Glioblastoma | Doxorubicin | 15.25 | 17150277 | |
| MESH:D005909 | Glioblastoma | Genistein | 15.25 | 16598420 | |
| MESH:D005909 | Glioblastoma | Quercetin | 15.25 | 19804834 | |
| MESH:D005909 | Glioblastoma | Testosterone | 15.25 | 17162496 | |
| MESH:D005909 | Glioblastoma | trichostatin A | 15.25 | 18801729 | |
| MESH:D005910 | Glioma | Quercetin | 2.38 | 17643826 | |
| MESH:D018316 | Gliosarcoma | Cyclophosphamide | 4.24 | 11389073 | |
| MESH:D006042 | Goiter | 4,4'-diaminodiphenylmethane | 2.83 | 7505956 | |
| MESH:D006058 | Gonadal Disorders | Tetrachlorodibenzodioxin | 3.30 | 10696789 | |
| MESH:D006086 | Graft vs Host Disease | Cyclophosphamide | 3.78 | 15172196 11014644 16376943 | |
| MESH:D006177 | Gynecomastia | dong quai | 5.75 | 11405562 | |
| MESH:D006258 | Head and Neck Neoplasms | decitabine | 4.66 | 19215824 | |
| MESH:D006258 | Head and Neck Neoplasms | Doxorubicin | 4.66 | 15692506 | |
| MESH:D006330 | Heart Defects, Congenital | 3,4,3',4'-tetrachlorobiphenyl | 4.30 | 11294989 | |
| MESH:D006330 | Heart Defects, Congenital | Tetrachlorodibenzodioxin | 4.30 | 11294989 10048152 | |
| MESH:D006331 | Heart Diseases | Doxorubicin | 4.51 | 16144979 14766674 16244371 16244372 18674790 16495754 17888722 18006777 16707910 16879835 12587719 17875725 16330681 | |
| MESH:D006331 | Heart Diseases | Raloxifene | 4.51 | 11110106 | |
| MESH:D006333 | Heart Failure | Doxorubicin | 4.42 | 17481944 | |
| MESH:D006333 | Heart Failure | Plant Extracts | 4.42 | 18097624 | |
| MESH:D006394 | Hemangiosarcoma | Doxorubicin | 2.75 | 15692506 | |
| MESH:D006402 | Hematologic Diseases | Zidovudine | 3.51 | 12579204 | |
| MESH:D006467 | Hemophilia A | Cyclophosphamide | 4.03 | 11918545 | |
| MESH:D006470 | Hemorrhage | Endosulfan | 6.53 | 7900959 | |
| MESH:D006470 | Hemorrhage | Tetrachlorodibenzodioxin | 6.53 | 11000095 | |
| MESH:D006504 | Hepatic Veno-Occlusive Disease | Cyclophosphamide | 4.24 | 14986274 | |
| MESH:D006505 | Hepatitis | 4,4'-diaminodiphenylmethane | 16.69 | 6705139 | |
| MESH:D006505 | Hepatitis | Carbon Tetrachloride | 16.69 | 19900420 19110552 | |
| MESH:D006505 | Hepatitis | DDT | 16.69 | 16487989 | |
| MESH:D006505 | Hepatitis | Dichlorodiphenyl Dichloroethylene | 16.69 | 16487989 | |
| MESH:D006505 | Hepatitis | Drugs, Chinese Herbal | 16.69 | 18339527 | |
| MESH:D006509 | Hepatitis B | Lamivudine | 3.92 | 17703166 | |
| MESH:D019694 | Hepatitis B, Chronic | Lamivudine | 3.92 | 12044531 15631357 15274664 16476009 15309715 | |
| MESH:D006529 | Hepatomegaly | DDT | 22.11 | 2387028 | |
| MESH:D006529 | Hepatomegaly | Dicofol | 22.11 | 2387028 | |
| MESH:D006529 | Hepatomegaly | fenarimol | 22.11 | 2387028 | |
| MESH:D006529 | Hepatomegaly | fenvalerate | 22.11 | 15602828 | |
| MESH:D006529 | Hepatomegaly | isopropyl 4,4'-dibromobenzilate | 22.11 | 2387028 | |
| MESH:D006529 | Hepatomegaly | perfluorooctanoic acid | 22.11 | 3609246 | |
| MESH:D006529 | Hepatomegaly | Tetrachlorodibenzodioxin | 22.11 | 12621046 15340226 16120746 | |
| MESH:D006558 | Herpes Genitalis | Estradiol | 3.73 | 15709030 | |
| MESH:D006561 | Herpes Simplex | Plant Extracts | 5.96 | 10715843 | |
| MESH:D006561 | Herpes Simplex | resveratrol | 5.96 | 16876885 | |
| MESH:D006628 | Hirsutism | Testosterone | 4.36 | 17019078 | |
| MESH:D015658 | HIV Infections | beta Carotene | 14.02 | 16960176 | |
| MESH:D015658 | HIV Infections | Indinavir | 14.02 | 11363243 15388451 11141242 | |
| MESH:D015658 | HIV Infections | Lamivudine | 14.02 | 9296927 11141242 17530837 20032539 | |
| MESH:D015658 | HIV Infections | Plant Extracts | 14.02 | 12878215 | |
| MESH:D015658 | HIV Infections | Saquinavir | 14.02 | 15388451 11141242 | |
| MESH:D015658 | HIV Infections | Zidovudine | 14.02 | 11698656 11141242 11363243 20032539 17358032 | |
| MESH:D006689 | Hodgkin Disease | Cyclophosphamide | 4.11 | 16135485 17606976 | |
| MESH:D006689 | Hodgkin Disease | Doxorubicin | 4.11 | 17606976 18501091 15147373 | |
| MESH:D019584 | Hot Flashes | 8-prenylnaringenin | 18.65 | 17088409 | |
| MESH:D019584 | Hot Flashes | dong quai | 18.65 | 18568789 | |
| MESH:D019584 | Hot Flashes | Estradiol | 18.65 | 17088409 | |
| MESH:D019584 | Hot Flashes | Isoflavones | 18.65 | 17290160 14716179 | |
| MESH:D019584 | Hot Flashes | Plant Extracts | 18.65 | 16566672 14716179 17454163 | |
| MESH:D006849 | Hydrocephalus | Valproic Acid | 3.59 | 17688650 | |
| MESH:D006869 | Hydronephrosis | Tetrachlorodibenzodioxin | 2.75 | 8697196 16354765 15340226 18606429 16959395 | |
| MESH:D006930 | Hyperalgesia | perfluorooctanoic acid | 2.82 | 12083418 | |
| MESH:D017588 | Hyperandrogenism | Flutamide | 7.96 | 15356085 | |
| MESH:D017588 | Hyperandrogenism | Testosterone | 7.96 | 17019078 | |
| MESH:D006932 | Hyperbilirubinemia | Carbon Tetrachloride | 3.26 | 16899240 | |
| MESH:D006937 | Hypercholesterolemia | 27-hydroxycholesterol | 5.92 | 17873880 | |
| MESH:D006937 | Hypercholesterolemia | resveratrol | 5.92 | 17188708 | |
| MESH:D006943 | Hyperglycemia | kaempferol | 6.09 | 18262572 | |
| MESH:D006943 | Hyperglycemia | Quercetin | 6.09 | 11834736 18262572 | |
| MESH:D020138 | Hyperhomocysteinemia | Plant Extracts | 3.35 | 16484555 | |
| MESH:D006949 | Hyperlipidemias | Plant Extracts | 5.67 | 15975614 15268973 | |
| MESH:D006949 | Hyperlipidemias | resveratrol | 5.67 | 16873680 | |
| MESH:D006965 | Hyperplasia | 4,4'-diaminodiphenylmethane | 6.71 | 15034207 | |
| MESH:D006965 | Hyperplasia | Diethylstilbestrol | 6.71 | 12960047 14722030 | |
| MESH:D006973 | Hypertension | daidzein | 6.50 | 17169123 | |
| MESH:D006973 | Hypertension | Quercetin | 6.50 | 18356687 | |
| MESH:D006973 | Hypertension | Raloxifene | 6.50 | 15787275 17577099 | |
| MESH:D006973 | Hypertension | Tetrachlorodibenzodioxin | 6.50 | 18850075 18670907 | |
| MESH:D006975 | Hypertension, Portal | Carbon Tetrachloride | 2.84 | 15338365 | |
| MESH:D006976 | Hypertension, Pulmonary | gefitinib | 3.70 | 18424623 | |
| MESH:D017379 | Hypertrophy, Left Ventricular | resveratrol | 3.15 | 17488730 | |
| MESH:D017380 | Hypertrophy, Right Ventricular | gefitinib | 4.96 | 18424623 | |
| MESH:D007006 | Hypogonadism | Testosterone | 3.56 | 12002444 | |
| MESH:D007018 | Hypopituitarism | Testosterone | 4.90 | 17426086 | |
| MESH:D007021 | Hypospadias | Diethylstilbestrol | 7.11 | 16002989 | |
| MESH:D007021 | Hypospadias | Ethinyl Estradiol | 7.11 | 16945680 16569931 | |
| MESH:D007154 | Immune System Diseases | Cyclophosphamide | 4.04 | 16076520 | |
| MESH:D007174 | Impulse Control Disorders | Testosterone | 4.56 | 7506515 | |
| MESH:D020244 | Infarction, Middle Cerebral Artery | Progesterone | 7.35 | 15869954 | |
| MESH:D020244 | Infarction, Middle Cerebral Artery | resveratrol | 7.35 | 17600658 | |
| MESH:D007246 | Infertility | Diethylstilbestrol | 3.14 | 15036965 | |
| MESH:D007247 | Infertility, Female | Dicofol | 10.49 | 11762692 10631594 | |
| MESH:D007247 | Infertility, Female | Dieldrin | 10.49 | 10630421 | |
| MESH:D007247 | Infertility, Female | Ethinyl Estradiol | 10.49 | 12013081 | |
| MESH:D007248 | Infertility, Male | Atrazine | 42.81 | 12948887 | |
| MESH:D007248 | Infertility, Male | Chlordan | 42.81 | 9432128 | |
| MESH:D007248 | Infertility, Male | Coumestrol | 42.81 | 16892005 | |
| MESH:D007248 | Infertility, Male | Cyclophosphamide | 42.81 | 16517039 7193160 | |
| MESH:D007248 | Infertility, Male | DDT | 42.81 | 17192596 17157474 | |
| MESH:D007248 | Infertility, Male | decitabine | 42.81 | 17581917 | |
| MESH:D007248 | Infertility, Male | Dichlorodiphenyl Dichloroethylene | 42.81 | 12948891 17192596 | |
| MESH:D007248 | Infertility, Male | Endosulfan | 42.81 | 8588293 9432128 | |
| MESH:D007248 | Infertility, Male | Ethinyl Estradiol | 42.81 | 17937319 | |
| MESH:D007248 | Infertility, Male | fulvestrant | 42.81 | 11514358 | |
| MESH:D007248 | Infertility, Male | Methoxychlor | 42.81 | 16467254 11955947 | |
| MESH:D007248 | Infertility, Male | Phytoestrogens | 42.81 | 16731787 | |
| MESH:D007248 | Infertility, Male | Triclosan | 42.81 | 20821571 | |
| MESH:D007248 | Infertility, Male | vinclozolin | 42.81 | 16467254 | |
| MESH:D007249 | Inflammation | perfluorooctanoic acid | 16.22 | 12083418 | |
| MESH:D007249 | Inflammation | Plant Extracts | 16.22 | 19332304 12787963 15997105 16366677 | |
| MESH:D007249 | Inflammation | Progesterone | 16.22 | 15869954 | |
| MESH:D007249 | Inflammation | resveratrol | 16.22 | 16366677 | |
| MESH:D007249 | Inflammation | Silymarin | 16.22 | 17213517 | |
| MESH:D007249 | Inflammation | Tamoxifen | 16.22 | 19457130 | |
| MESH:D007249 | Inflammation | Tetrachlorodibenzodioxin | 16.22 | 12878042 12200463 | |
| MESH:D007249 | Inflammation | Tetradecanoylphorbol Acetate | 16.22 | 7562506 7812673 11698051 15177302 8273558 | |
| MESH:D007249 | Inflammation | Triclosan | 16.22 | 20507366 9584910 | |
| MESH:D007251 | Influenza, Human | Quercetin | 6.94 | 16624496 | |
| MESH:D007251 | Influenza, Human | resveratrol | 6.94 | 16624496 | |
| MESH:D007299 | Insect Bites and Stings | cyhalothrin | 5.41 | 15189238 | |
| MESH:D007333 | Insulin Resistance | bisphenol A | 9.78 | 16393666 | |
| MESH:D007333 | Insulin Resistance | Estradiol | 9.78 | 16393666 16627594 | |
| MESH:D007333 | Insulin Resistance | royal jelly | 9.78 | 18981581 | |
| MESH:D007333 | Insulin Resistance | Sodium Selenite | 9.78 | 14714311 | |
| MESH:D007414 | Intestinal Neoplasms | Plant Extracts | 3.47 | 12584176 12351151 12628509 | |
| MESH:D002532 | Intracranial Aneurysm | Reactive Oxygen Species | 3.86 | 19381132 | |
| MESH:D007565 | Jaundice | 4,4'-diaminodiphenylmethane | 3.72 | 9022650 8074119 | |
| MESH:D007569 | Jaw Abnormalities | Tetrachlorodibenzodioxin | 2.16 | 16580747 | |
| MESH:D007627 | Keloid | Quercetin | 3.70 | 17086741 | |
| MESH:D017492 | Keratosis, Seborrheic | alitretinoin | 4.36 | 16144296 | |
| MESH:D007674 | Kidney Diseases | Cadmium | 9.54 | 16226777 16962696 16322080 | |
| MESH:D007674 | Kidney Diseases | Doxorubicin | 9.54 | 16775033 15369732 15699352 | |
| MESH:D007674 | Kidney Diseases | Estradiol | 9.54 | 15618244 | |
| MESH:D007674 | Kidney Diseases | Mercury | 9.54 | 17934191 | |
| MESH:D007674 | Kidney Diseases | Quercetin | 9.54 | 16962696 | |
| MESH:D007676 | Kidney Failure, Chronic | Doxorubicin | 2.98 | 16707910 | |
| MESH:D007680 | Kidney Neoplasms | 4,4'-diaminodiphenylmethane | 18.53 | 6582329 | |
| MESH:D007680 | Kidney Neoplasms | Diethylstilbestrol | 18.53 | 16762066 15003126 14681315 | |
| MESH:D007680 | Kidney Neoplasms | Estradiol | 18.53 | 15610895 | |
| MESH:D007680 | Kidney Neoplasms | Estrone | 18.53 | 15610895 | |
| MESH:D007680 | Kidney Neoplasms | gefitinib | 18.53 | 18625569 | |
| MESH:D007680 | Kidney Neoplasms | Tamoxifen | 18.53 | 18625569 | |
| MESH:D007680 | Kidney Neoplasms | Zidovudine | 18.53 | 12579204 | |
| MESH:D007859 | Learning Disorders | DDT | 9.27 | 7589230 | |
| MESH:D007859 | Learning Disorders | Diethylstilbestrol | 9.27 | 17184923 | |
| MESH:D007859 | Learning Disorders | Endosulfan | 9.27 | 8157075 | |
| MESH:D007889 | Leiomyoma | Raloxifene | 3.29 | 16973256 | |
| MESH:D007896 | Leishmaniasis | fenarimol | 4.32 | 18372651 | |
| MESH:D007938 | Leukemia | Cyclophosphamide | 10.78 | 10602166 | |
| MESH:D007938 | Leukemia | decitabine | 10.78 | 19235587 18980019 | |
| MESH:D007938 | Leukemia | Genistein | 10.78 | 18980019 17468513 | |
| MESH:D007938 | Leukemia | kaempferol | 10.78 | 17468513 | |
| MESH:D007938 | Leukemia | Quercetin | 10.78 | 17468513 | |
| MESH:D004915 | Leukemia, Erythroblastic, Acute | Doxorubicin | 3.86 | 16085563 | |
| MESH:D015451 | Leukemia, Lymphocytic, Chronic, B-Cell | Cyclophosphamide | 4.47 | 17802794 17296974 17008537 18587576 17658394 18172266 | |
| MESH:D015451 | Leukemia, Lymphocytic, Chronic, B-Cell | Drugs, Chinese Herbal | 4.47 | 15802533 | |
| MESH:D007945 | Leukemia, Lymphoid | Toxaphene | 5.01 | 16132792 | |
| MESH:D015459 | Leukemia-Lymphoma, Adult T-Cell | Emodin | 6.40 | 17077332 | |
| MESH:D015459 | Leukemia-Lymphoma, Adult T-Cell | Zidovudine | 6.40 | 20370541 | |
| MESH:D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Cyclophosphamide | 3.06 | 10373061 | |
| MESH:D007951 | Leukemia, Myeloid | decitabine | 2.84 | 19117987 17236224 18454857 | |
| MESH:D015470 | Leukemia, Myeloid, Acute | decitabine | 3.60 | 18704418 17679729 18206229 18460780 19387464 19010910 | |
| MESH:D015470 | Leukemia, Myeloid, Acute | trichostatin A | 3.60 | 18206229 | |
| MESH:D015470 | Leukemia, Myeloid, Acute | Valproic Acid | 3.60 | 17596541 16294345 | |
| MESH:D015477 | Leukemia, Myelomonocytic, Chronic | decitabine | 4.16 | 18055864 | |
| MESH:D015473 | Leukemia, Promyelocytic, Acute | resveratrol | 2.63 | 16087638 | |
| MESH:D007970 | Leukopenia | Cyclophosphamide | 3.70 | 11830472 10052129 | |
| MESH:D007984 | Leydig Cell Tumor | perfluorooctanoic acid | 8.72 | 8812269 | |
| MESH:D007984 | Leydig Cell Tumor | vinclozolin | 8.72 | 16417039 | |
| MESH:D017880 | Limb Deformities, Congenital | Dichlorodiphenyl Dichloroethylene | 5.75 | 12745335 | |
| MESH:D017880 | Limb Deformities, Congenital | methoxyacetic acid | 5.75 | 15959878 12805644 | |
| MESH:D008064 | Lipidoses | Tamoxifen | 2.16 | 17567588 15342952 | |
| MESH:D008080 | Liposarcoma | Paclitaxel | 3.62 | 17353645 | |
| MESH:D008103 | Liver Cirrhosis | Carbon Tetrachloride | 11.40 | 17174718 16221502 21278145 11408273 16239168 16943688 17157831 11903743 17334410 | |
| MESH:D008103 | Liver Cirrhosis | Drugs, Chinese Herbal | 11.40 | 17163593 | |
| MESH:D008103 | Liver Cirrhosis | Plant Extracts | 11.40 | 17157831 | |
| MESH:D008103 | Liver Cirrhosis | puerarin | 11.40 | 16426832 | |
| MESH:D008103 | Liver Cirrhosis | Silymarin | 11.40 | 17213517 | |
| MESH:D008105 | Liver Cirrhosis, Biliary | 4,4'-diaminodiphenylmethane | 2.25 | 15034207 9327722 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Carbon Tetrachloride | 17.49 | 18279442 12632514 14724832 15338365 15052691 18054572 12586293 15673190 16033810 18705752 15996030 17557913 17900296 18412020 18339082 16116963 16097048 18472094 20821823 16248980 15650968 18317297 11481614 17805973 15362042 17869086 13678700 12666154 18205269 16015684 18395095 18481824 12609069 14716496 12741479 18166357 18420326 15370692 18429990 12546737 16011737 14620537 16027843 18006644 15893842 18210741 15123356 14748882 17976157 16638106 15959796 12649538 17721639 18395914 18263696 15931870 14716833 15925388 10355542 17922224 17714472 17565644 12445421 12898905 18187930 18472332 18418968 15818738 18156304 17708605 18376398 17481882 17631135 12389079 17640975 12445418 12958196 14512876 17766677 17761835 16192424 15057751 12632512 17944888 17525996 17823541 15876570 17698563 12667390 18277467 18251166 16136751 15730626 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Doxorubicin | 17.49 | 16439617 16595196 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Drugs, Chinese Herbal | 17.49 | 16610055 15864749 18371158 18237412 18606216 15339415 12632512 17881167 17629604 15849816 15744066 15763062 18567088 15818738 15754396 17036385 15383259 17666798 17348192 15641146 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Emodin | 17.49 | 15288473 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Estradiol | 17.49 | 14659978 14716833 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Genistein | 17.49 | 17823541 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | naringenin | 17.49 | 14709902 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Plant Extracts | 17.49 | 15479170 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Plant Preparations | 17.49 | 17724770 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Quercetin | 17.49 | 12741479 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | silybin | 17.49 | 16169303 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Silymarin | 17.49 | 18277467 17198567 15864749 15754394 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Tamoxifen | 17.49 | 18564211 | |
| MESH:D008106 | Liver Cirrhosis, Experimental | Tetrachlorodibenzodioxin | 17.49 | 12878042 | |
| MESH:D008107 | Liver Diseases | Carbon Tetrachloride | 10.36 | 16964402 15830285 16246199 17285989 15720792 | |
| MESH:D008107 | Liver Diseases | DDT | 10.36 | 15729006 | |
| MESH:D008107 | Liver Diseases | Drugs, Chinese Herbal | 10.36 | 17207593 | |
| MESH:D008107 | Liver Diseases | Lindane | 10.36 | 1715830 | |
| MESH:D008107 | Liver Diseases | naringenin | 10.36 | 16945181 | |
| MESH:D008107 | Liver Diseases | Plant Extracts | 10.36 | 17034775 | |
| MESH:D008107 | Liver Diseases | Silymarin | 10.36 | 17213517 | |
| MESH:D008108 | Liver Diseases, Alcoholic | Silymarin | 4.68 | 17213517 | |
| MESH:D017093 | Liver Failure | Carbon Tetrachloride | 2.92 | 15123358 | |
| MESH:D017114 | Liver Failure, Acute | Carbon Tetrachloride | 2.54 | 14706259 16899240 | |
| MESH:D008113 | Liver Neoplasms | Carbon Tetrachloride | 39.09 | 19294768 | |
| MESH:D008113 | Liver Neoplasms | Chlordan | 39.09 | 2422723 | |
| MESH:D008113 | Liver Neoplasms | DDT | 39.09 | 11948501 15975961 | |
| MESH:D008113 | Liver Neoplasms | Dehydroepiandrosterone | 39.09 | 18709148 | |
| MESH:D008113 | Liver Neoplasms | Dieldrin | 39.09 | 8742319 9539021 | |
| MESH:D008113 | Liver Neoplasms | Diethylhexyl Phthalate | 39.09 | 11940454 | |
| MESH:D008113 | Liver Neoplasms | Diethylstilbestrol | 39.09 | 16712894 15890375 | |
| MESH:D008113 | Liver Neoplasms | Drugs, Chinese Herbal | 39.09 | 18339527 | |
| MESH:D008113 | Liver Neoplasms | Heptachlor | 39.09 | 9544696 2422723 | |
| MESH:D008113 | Liver Neoplasms | Heptachlor Epoxide | 39.09 | 11246134 | |
| MESH:D008113 | Liver Neoplasms | perfluorooctanoic acid | 39.09 | 18709148 14757943 | |
| MESH:D008113 | Liver Neoplasms | Plant Extracts | 39.09 | 19168119 | |
| MESH:D008113 | Liver Neoplasms | Quercetin | 39.09 | 18980244 | |
| MESH:D008113 | Liver Neoplasms | resveratrol | 39.09 | 19073162 19812893 19321006 20405173 | |
| MESH:D008113 | Liver Neoplasms | Silymarin | 39.09 | 19168119 | |
| MESH:D008113 | Liver Neoplasms | Tamoxifen | 39.09 | 16684651 | |
| MESH:D008113 | Liver Neoplasms | Tetrachlorodibenzodioxin | 39.09 | 16984957 | |
| MESH:D008114 | Liver Neoplasms, Experimental | 4,4'-diaminodiphenylmethane | 16.79 | 598648 6587162 1399818 3712494 | |
| MESH:D008114 | Liver Neoplasms, Experimental | beta Carotene | 16.79 | 17113696 | |
| MESH:D008114 | Liver Neoplasms, Experimental | Carbon Tetrachloride | 16.79 | 12014681 15583823 | |
| MESH:D008114 | Liver Neoplasms, Experimental | Dehydroepiandrosterone | 16.79 | 8603461 | |
| MESH:D008114 | Liver Neoplasms, Experimental | Doxorubicin | 16.79 | 17085340 16842330 | |
| MESH:D008114 | Liver Neoplasms, Experimental | Polychlorinated Biphenyls | 16.79 | 1423854 | |
| MESH:D008114 | Liver Neoplasms, Experimental | Quercetin | 16.79 | 19519916 | |
| MESH:D008114 | Liver Neoplasms, Experimental | Tetrachlorodibenzodioxin | 16.79 | 12151625 | |
| MESH:D017563 | Lung Diseases, Interstitial | Valproic Acid | 2.98 | 17228818 | |
| MESH:D008175 | Lung Neoplasms | alitretinoin | 13.32 | 16413115 | |
| MESH:D008175 | Lung Neoplasms | beta Carotene | 13.32 | 16401635 | |
| MESH:D008175 | Lung Neoplasms | Doxorubicin | 13.32 | 6189445 17418594 | |
| MESH:D008175 | Lung Neoplasms | Drugs, Chinese Herbal | 13.32 | 18339527 | |
| MESH:D008175 | Lung Neoplasms | Plant Extracts | 13.32 | 20869020 | |
| MESH:D008175 | Lung Neoplasms | Quercetin | 13.32 | 16280456 | |
| MESH:D008175 | Lung Neoplasms | silybin | 13.32 | 16788158 | |
| MESH:D008175 | Lung Neoplasms | Tamoxifen | 13.32 | 18625569 | |
| MESH:D008175 | Lung Neoplasms | Tetrachlorodibenzodioxin | 13.32 | 11884234 19555203 | |
| MESH:D008175 | Lung Neoplasms | Tetradecanoylphorbol Acetate | 13.32 | 11807781 | |
| MESH:D008175 | Lung Neoplasms | vinyl carbamate | 13.32 | 17363558 16247444 15824018 12117777 15172992 16885199 17361011 17163412 12438228 12765245 11134547 14755239 11195469 | |
| MESH:D008175 | Lung Neoplasms | Zidovudine | 13.32 | 18800350 | |
| MESH:D008178 | Lupus Erythematosus, Cutaneous | Rifampin | 4.85 | 11422169 | |
| MESH:D008180 | Lupus Erythematosus, Systemic | Rifampin | 3.45 | 11422169 | |
| MESH:D008181 | Lupus Nephritis | Diethylstilbestrol | 3.87 | 15166399 | |
| MESH:D008223 | Lymphoma | Cyclophosphamide | 9.56 | 12854902 | |
| MESH:D008223 | Lymphoma | decitabine | 9.56 | 19470736 | |
| MESH:D008223 | Lymphoma | Diethylstilbestrol | 9.56 | 15700306 | |
| MESH:D008223 | Lymphoma | Doxorubicin | 9.56 | 16098063 | |
| MESH:D016393 | Lymphoma, B-Cell | Cyclophosphamide | 10.31 | 16675587 | |
| MESH:D016393 | Lymphoma, B-Cell | resveratrol | 10.31 | 17088997 | |
| MESH:D016393 | Lymphoma, B-Cell | Sodium Selenite | 10.31 | 14737004 | |
| MESH:D008228 | Lymphoma, Non-Hodgkin | Cyclophosphamide | 11.70 | 11911406 | |
| MESH:D008228 | Lymphoma, Non-Hodgkin | Doxorubicin | 11.70 | 17654614 | |
| MESH:D008228 | Lymphoma, Non-Hodgkin | Paclitaxel | 11.70 | 14749477 | |
| MESH:D008228 | Lymphoma, Non-Hodgkin | resveratrol | 11.70 | 14749477 | |
| MESH:D016399 | Lymphoma, T-Cell | Doxorubicin | 3.32 | 15621674 | |
| MESH:D052801 | Male Urogenital Diseases | Diethylstilbestrol | 4.22 | 16002989 | |
| MESH:D015674 | Mammary Neoplasms, Animal | resveratrol | 5.83 | 15688416 | |
| MESH:D015674 | Mammary Neoplasms, Animal | Tamoxifen | 5.83 | 19428831 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | Dehydroepiandrosterone | 32.88 | 16457693 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | Doxorubicin | 32.88 | 15458769 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | Drugs, Chinese Herbal | 32.88 | 14758024 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | Estradiol | 32.88 | 16891317 11408345 17203775 11807958 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | estradiol 3-benzoate | 32.88 | 15375486 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | gefitinib | 32.88 | 18375820 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | Genistein | 32.88 | 14578162 12929590 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | LY 353381 | 32.88 | 12374698 11731420 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | Progesterone | 32.88 | 17203775 11408345 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | resveratrol | 32.88 | 11606380 8985016 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | Tamoxifen | 32.88 | 19196723 14580682 19196722 11731420 16827153 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | Tetradecanoylphorbol Acetate | 32.88 | 8985016 | |
| MESH:D008325 | Mammary Neoplasms, Experimental | Triclosan | 32.88 | 15358634 | |
| MESH:D020149 | Manganese Poisoning | Estradiol | 8.37 | 19453300 | |
| MESH:D020149 | Manganese Poisoning | Tamoxifen | 8.37 | 19453300 | |
| MESH:D008545 | Melanoma | decitabine | 10.13 | 16505122 17785578 | |
| MESH:D008545 | Melanoma | Doxorubicin | 10.13 | 16827129 | |
| MESH:D008545 | Melanoma | Glucose | 10.13 | 14993021 | |
| MESH:D008545 | Melanoma | Paclitaxel | 10.13 | 12025231 12040289 16342250 | |
| MESH:D008545 | Melanoma | Reactive Oxygen Species | 10.13 | 17992120 | |
| MESH:D008545 | Melanoma | resveratrol | 10.13 | 17992120 | |
| MESH:D008545 | Melanoma | Tamoxifen | 10.13 | 12393984 19393235 | |
| MESH:D008545 | Melanoma | trichostatin A | 10.13 | 16505122 | |
| MESH:D018328 | Melanoma, Amelanotic | Tamoxifen | 2.91 | 15990972 | |
| MESH:D008546 | Melanoma, Experimental | Cyclophosphamide | 3.56 | 16388313 | |
| MESH:D008654 | Mesothelioma | Atrazine | 4.10 | 1916698 | |
| MESH:D008654 | Mesothelioma | Doxorubicin | 4.10 | 17638057 | |
| MESH:D008659 | Metabolic Diseases | resveratrol | 3.20 | 17112576 | |
| MESH:D048629 | Micronuclei, Chromosome-Defective | Zidovudine | 4.54 | 17358032 | |
| MESH:D008881 | Migraine Disorders | Phytoestrogens | 4.83 | 12224599 | |
| MESH:D008881 | Migraine Disorders | Valproic Acid | 4.83 | 18803445 18765137 | |
| MESH:D028361 | Mitochondrial Diseases | Doxorubicin | 3.31 | 15792986 | |
| MESH:D018200 | Mixed Tumor, Mullerian | Raloxifene | 4.26 | 15863610 | |
| MESH:D009062 | Mouth Neoplasms | Plant Preparations | 3.72 | 17418620 | |
| MESH:D052016 | Mucositis | Doxorubicin | 3.52 | 17415656 | |
| MESH:D009101 | Multiple Myeloma | decitabine | 11.95 | 18172295 | |
| MESH:D009101 | Multiple Myeloma | Paclitaxel | 11.95 | 14749477 | |
| MESH:D009101 | Multiple Myeloma | Raloxifene | 11.95 | 16497877 | |
| MESH:D009101 | Multiple Myeloma | resveratrol | 11.95 | 17049120 16267019 16490592 17164350 17935668 14749477 | |
| MESH:D009101 | Multiple Myeloma | trichostatin A | 11.95 | 18172295 | |
| MESH:D009134 | Muscular Atrophy, Spinal | resveratrol | 3.60 | 17962980 | |
| MESH:D009139 | Musculoskeletal Abnormalities | Valproic Acid | 2.85 | 8888407 | |
| MESH:D009145 | Mushroom Poisoning | Silymarin | 5.64 | 17213517 | |
| MESH:D009164 | Mycobacterium Infections | Indinavir | 7.35 | 21442799 | |
| MESH:D009164 | Mycobacterium Infections | Rifampin | 7.35 | 18474467 | |
| MESH:D009190 | Myelodysplastic Syndromes | decitabine | 4.47 | 16882708 19010910 19157545 18608210 | |
| MESH:D009190 | Myelodysplastic Syndromes | Valproic Acid | 4.47 | 17596541 | |
| MESH:D009203 | Myocardial Infarction | Doxorubicin | 7.31 | 19429709 15857846 | |
| MESH:D009203 | Myocardial Infarction | Genistein | 7.31 | 17141266 | |
| MESH:D009203 | Myocardial Infarction | Quercetin | 7.31 | 19595682 | |
| MESH:D009203 | Myocardial Infarction | resveratrol | 7.31 | 17015251 16525036 16456233 17188708 16317513 17125593 | |
| MESH:D017202 | Myocardial Ischemia | resveratrol | 5.38 | 17015251 17125593 | |
| MESH:D017202 | Myocardial Ischemia | Tetrachlorodibenzodioxin | 5.38 | 12213967 | |
| MESH:D015428 | Myocardial Reperfusion Injury | dong quai | 11.70 | 10815014 | |
| MESH:D015428 | Myocardial Reperfusion Injury | Estradiol | 11.70 | 16810080 | |
| MESH:D015428 | Myocardial Reperfusion Injury | Genistein | 11.70 | 17141266 | |
| MESH:D015428 | Myocardial Reperfusion Injury | Quercetin | 11.70 | 19207477 | |
| MESH:D009205 | Myocarditis | resveratrol | 3.49 | 17322642 | |
| MESH:D009232 | Myxoma | Raloxifene | 4.26 | 16343187 | |
| MESH:D009362 | Neoplasm Metastasis | 4,4'-diaminodiphenylmethane | 7.43 | 3581430 | |
| MESH:D009362 | Neoplasm Metastasis | Doxorubicin | 7.43 | 18259882 | |
| MESH:D009362 | Neoplasm Metastasis | Paclitaxel | 7.43 | 15867366 | |
| MESH:D009362 | Neoplasm Metastasis | Tamoxifen | 7.43 | 19393235 | |
| MESH:D009364 | Neoplasm Recurrence, Local | Tamoxifen | 1.92 | 19410462 | |
| MESH:D009369 | Neoplasms | alitretinoin | 33.92 | 16946489 | |
| MESH:D009369 | Neoplasms | beta Carotene | 33.92 | 17051425 | |
| MESH:D009369 | Neoplasms | Cyclophosphamide | 33.92 | 18854779 | |
| MESH:D009369 | Neoplasms | DDT | 33.92 | 8820588 | |
| MESH:D009369 | Neoplasms | decitabine | 33.92 | 19116145 17925555 19470736 | |
| MESH:D009369 | Neoplasms | Dieldrin | 33.92 | 8820588 | |
| MESH:D009369 | Neoplasms | Diethylstilbestrol | 33.92 | 15313581 | |
| MESH:D009369 | Neoplasms | fenvalerate | 33.92 | 2895627 | |
| MESH:D009369 | Neoplasms | Lindane | 33.92 | 16818664 12807735 | |
| MESH:D009369 | Neoplasms | lycopene | 33.92 | 17051425 | |
| MESH:D009369 | Neoplasms | naringenin | 33.92 | 15185748 | |
| MESH:D009369 | Neoplasms | phytoene | 33.92 | 17051425 | |
| MESH:D009369 | Neoplasms | phytofluene | 33.92 | 17051425 | |
| MESH:D009369 | Neoplasms | Quercetin | 33.92 | 15185748 | |
| MESH:D009369 | Neoplasms | Toxaphene | 33.92 | 8820588 | |
| MESH:D009374 | Neoplasms, Experimental | resveratrol | 2.80 | 8985016 | |
| MESH:D009376 | Neoplasms, Hormone-Dependent | Phytoestrogens | 7.10 | 16912569 | |
| MESH:D009376 | Neoplasms, Hormone-Dependent | Tamoxifen | 7.10 | 19200415 19189210 19196722 | |
| MESH:D009389 | Neovascularization, Pathologic | Estradiol | 2.48 | 17289903 | |
| MESH:D009401 | Nephrosis | Doxorubicin | 3.52 | 16636307 16899518 | |
| MESH:D009404 | Nephrotic Syndrome | Doxorubicin | 2.88 | 16889571 15640375 | |
| MESH:D009422 | Nervous System Diseases | Dicofol | 4.56 | 1856875 | |
| MESH:D009421 | Nervous System Malformations | bisphenol A | 18.04 | 11399458 16427766 | |
| MESH:D009421 | Nervous System Malformations | Diethylstilbestrol | 18.04 | 11399458 | |
| MESH:D009421 | Nervous System Malformations | Estradiol | 18.04 | 16427766 11399458 | |
| MESH:D009421 | Nervous System Malformations | Genistein | 18.04 | 16427766 | |
| MESH:D009421 | Nervous System Malformations | Tetrachlorodibenzodioxin | 18.04 | 14600291 | |
| MESH:D009436 | Neural Tube Defects | 4,4'-diaminodiphenylmethane | 4.04 | 6679447 | |
| MESH:D009436 | Neural Tube Defects | Valproic Acid | 4.04 | 16359493 8888407 | |
| MESH:D019954 | Neurobehavioral Manifestations | Plant Extracts | 3.93 | 17168769 | |
| MESH:D009447 | Neuroblastoma | Cyclophosphamide | 4.36 | 8761367 16115947 15176712 | |
| MESH:D009447 | Neuroblastoma | Doxorubicin | 4.36 | 15555623 | |
| MESH:D019636 | Neurodegenerative Diseases | resveratrol | 2.73 | 17652729 | |
| MESH:D017599 | Neuroectodermal Tumors | Cyclophosphamide | 3.62 | 8761367 12837982 | |
| MESH:D020078 | Neurogenic Inflammation | Quercetin | 6.71 | 17929310 | |
| MESH:D020078 | Neurogenic Inflammation | resveratrol | 6.71 | 17929310 | |
| MESH:D009503 | Neutropenia | Cyclophosphamide | 3.16 | 8291058 | |
| MESH:D052556 | Niemann-Pick Disease, Type C | perfluorooctanoic acid | 3.70 | 9802331 | |
| MESH:D009765 | Obesity | Plant Extracts | 2.71 | 20132043 19056576 | |
| MESH:D009784 | Occupational Diseases | 4,4'-diaminodiphenylmethane | 2.29 | 4026338 6482804 | |
| MESH:D009845 | Oligospermia | Cyclophosphamide | 3.46 | 16517039 | |
| MESH:D009902 | Optic Neuritis | 4,4'-diaminodiphenylmethane | 3.72 | 3988306 | |
| MESH:D010014 | Osteolysis | Paclitaxel | 3.71 | 15867366 | |
| MESH:D010024 | Osteoporosis | Genistein | 15.52 | 19401787 | |
| MESH:D010024 | Osteoporosis | Isoflavones | 15.52 | 16562857 | |
| MESH:D010024 | Osteoporosis | kaempferol | 15.52 | 16756079 | |
| MESH:D010024 | Osteoporosis | Levonorgestrel | 15.52 | 12665316 | |
| MESH:D010024 | Osteoporosis | ormeloxifene | 15.52 | 15261309 | |
| MESH:D010024 | Osteoporosis | Raloxifene | 15.52 | 17882678 15775268 19059307 | |
| MESH:D015663 | Osteoporosis, Postmenopausal | Dehydroepiandrosterone | 23.95 | 16397352 | |
| MESH:D015663 | Osteoporosis, Postmenopausal | Drugs, Chinese Herbal | 23.95 | 16548355 | |
| MESH:D015663 | Osteoporosis, Postmenopausal | Genistein | 23.95 | 16169203 | |
| MESH:D015663 | Osteoporosis, Postmenopausal | Quercetin | 23.95 | 19495926 | |
| MESH:D015663 | Osteoporosis, Postmenopausal | Raloxifene | 23.95 | 17893378 17823083 15758505 15579764 | |
| MESH:D015663 | Osteoporosis, Postmenopausal | resveratrol | 23.95 | 17513867 | |
| MESH:D012516 | Osteosarcoma | Doxorubicin | 3.02 | 15930896 | |
| MESH:D010049 | Ovarian Diseases | bisphenol A | 3.71 | 11985600 | |
| MESH:D010051 | Ovarian Neoplasms | decitabine | 15.51 | 19259094 19331143 | |
| MESH:D010051 | Ovarian Neoplasms | Estradiol | 15.51 | 19401270 | |
| MESH:D010051 | Ovarian Neoplasms | Genistein | 15.51 | 19005980 | |
| MESH:D010051 | Ovarian Neoplasms | Luteolin | 15.51 | 19005980 | |
| MESH:D010051 | Ovarian Neoplasms | Paclitaxel | 15.51 | 11161223 | |
| MESH:D010051 | Ovarian Neoplasms | Progesterone | 15.51 | 16525653 17393432 | |
| MESH:D010051 | Ovarian Neoplasms | Quercetin | 15.51 | 19005980 | |
| MESH:D010051 | Ovarian Neoplasms | trichostatin A | 15.51 | 19331143 | |
| MESH:D010146 | Pain | Cyclophosphamide | 2.66 | 18093676 12161096 | |
| MESH:D010190 | Pancreatic Neoplasms | Cyclophosphamide | 14.03 | 11332152 | |
| MESH:D010190 | Pancreatic Neoplasms | decitabine | 14.03 | 19294695 | |
| MESH:D010190 | Pancreatic Neoplasms | pendimethalin | 14.03 | 19142867 | |
| MESH:D010190 | Pancreatic Neoplasms | Quercetin | 14.03 | 16965848 | |
| MESH:D010190 | Pancreatic Neoplasms | Reactive Oxygen Species | 14.03 | 15580305 | |
| MESH:D010190 | Pancreatic Neoplasms | Tetradecanoylphorbol Acetate | 14.03 | 15976015 | |
| MESH:D010190 | Pancreatic Neoplasms | trichostatin A | 14.03 | 19294695 | |
| MESH:D010195 | Pancreatitis | Phytoestrogens | 4.09 | 17269527 | |
| MESH:D016584 | Panic Disorder | Ethinyl Estradiol | 2.48 | 11578682 | |
| MESH:D010212 | Papilloma | 4,4'-diaminodiphenylmethane | 8.59 | 7296757 | |
| MESH:D010212 | Papilloma | Plant Extracts | 8.59 | 15173996 16517061 | |
| MESH:D010212 | Papilloma | Tetradecanoylphorbol Acetate | 8.59 | 18922899 12065085 18404319 8330346 | |
| MESH:D010243 | Paralysis | fenvalerate | 4.73 | 8952708 | |
| MESH:D010300 | Parkinson Disease | Atrazine | 4.87 | 17218051 | |
| MESH:D010300 | Parkinson Disease | Dieldrin | 4.87 | 16112328 17291500 11445065 11181820 16809432 | |
| MESH:D010300 | Parkinson Disease | Polychlorinated Biphenyls | 4.87 | 16702228 | |
| MESH:D010382 | Peliosis Hepatis | Tetrachlorodibenzodioxin | 2.95 | 12520081 | |
| MESH:D016491 | Peripheral Vascular Diseases | Cadmium | 4.11 | 15687053 | |
| MESH:D010787 | Photosensitivity Disorders | 4,4'-diaminodiphenylmethane | 3.18 | 6228378 | |
| MESH:D003557 | Phyllodes Tumor | Doxorubicin | 3.86 | 17983394 | |
| MESH:D010900 | Pituitary Diseases | Diethylstilbestrol | 3.87 | 14722030 | |
| MESH:D010911 | Pituitary Neoplasms | Diethylstilbestrol | 3.42 | 15687265 16977796 | |
| MESH:D010997 | Pleural Neoplasms | Doxorubicin | 3.86 | 17638057 | |
| MESH:D011085 | Polycystic Ovary Syndrome | Flutamide | 3.84 | 15356085 | |
| MESH:D017499 | Porokeratosis | alitretinoin | 4.71 | 16144296 | |
| MESH:D017119 | Porphyria Cutanea Tarda | Tetrachlorodibenzodioxin | 2.33 | 18163543 | |
| MESH:D011230 | Precancerous Conditions | Quercetin | 2.86 | 19056647 | |
| MESH:D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Cyclophosphamide | 2.93 | 21297632 | |
| MESH:D011248 | Pregnancy Complications | Toxaphene | 4.62 | 2087686 | |
| MESH:D011297 | Prenatal Exposure Delayed Effects | bisphenol A | 26.68 | 10548101 | |
| MESH:D011297 | Prenatal Exposure Delayed Effects | Diethylstilbestrol | 26.68 | 17184923 | |
| MESH:D011297 | Prenatal Exposure Delayed Effects | perfluorooctanoic acid | 26.68 | 17132714 | |
| MESH:D011297 | Prenatal Exposure Delayed Effects | resveratrol | 26.68 | 16679765 | |
| MESH:D011297 | Prenatal Exposure Delayed Effects | Tetrachlorodibenzodioxin | 26.68 | 11118676 11896295 11222880 11399792 | |
| MESH:D011297 | Prenatal Exposure Delayed Effects | Valproic Acid | 26.68 | 20603192 | |
| MESH:D011297 | Prenatal Exposure Delayed Effects | vinclozolin | 26.68 | 18220299 19015723 18042343 | |
| MESH:D055728 | Primary Myelofibrosis | decitabine | 8.28 | 17616702 | |
| MESH:D055728 | Primary Myelofibrosis | trichostatin A | 8.28 | 17616702 | |
| MESH:D011469 | Prostatic Diseases | vinclozolin | 3.66 | 18220299 | |
| MESH:D019048 | Prostatic Intraepithelial Neoplasia | marker/mechanism | 16220300 | ||
| MESH:D019048 | Prostatic Intraepithelial Neoplasia | bisphenol A | 11.25 | 20887781 | |
| MESH:D019048 | Prostatic Intraepithelial Neoplasia | Estradiol | 11.25 | 20887781 | |
| MESH:D019048 | Prostatic Intraepithelial Neoplasia | Testosterone | 11.25 | 20887781 | |
| MESH:D011471 | Prostatic Neoplasms | marker/mechanism|therapeutic | 17639508 16220300 16921512 17132221 15046698 | ||
| MESH:D011471 | Prostatic Neoplasms | Apigenin | 21.61 | 17132221 | |
| MESH:D011471 | Prostatic Neoplasms | biochanin A | 21.61 | 12111696 | |
| MESH:D011471 | Prostatic Neoplasms | bisphenol A | 21.61 | 16740699 | |
| MESH:D011471 | Prostatic Neoplasms | Cadmium | 21.61 | 17075824 | |
| MESH:D011471 | Prostatic Neoplasms | Coumestrol | 21.61 | 16921512 | |
| MESH:D011471 | Prostatic Neoplasms | Cyclophosphamide | 21.61 | 17136230 | |
| MESH:D011471 | Prostatic Neoplasms | DDT | 21.61 | 12584743 | |
| MESH:D011471 | Prostatic Neoplasms | Dicofol | 21.61 | 12584743 | |
| MESH:D011471 | Prostatic Neoplasms | Diethylstilbestrol | 21.61 | 17136230 15846301 15046698 | |
| MESH:D011471 | Prostatic Neoplasms | Doxorubicin | 21.61 | 16888761 16729912 16868541 18437689 15897917 15749863 | |
| MESH:D011471 | Prostatic Neoplasms | equol | 21.61 | 16898868 16925846 | |
| MESH:D011471 | Prostatic Neoplasms | Estradiol | 21.61 | 16740699 | |
| MESH:D011471 | Prostatic Neoplasms | Flutamide | 21.61 | 3169114 | |
| MESH:D011471 | Prostatic Neoplasms | gefitinib | 21.61 | 16685379 17914592 15651060 | |
| MESH:D011471 | Prostatic Neoplasms | Genistein | 21.61 | 15256057 16925846 15378649 | |
| MESH:D011471 | Prostatic Neoplasms | Heptachlor | 21.61 | 12661182 | |
| MESH:D011471 | Prostatic Neoplasms | Isoflavones | 21.61 | 17571952 16365062 17219775 17374662 | |
| MESH:D011471 | Prostatic Neoplasms | Lindane | 21.61 | 14688026 12661182 | |
| MESH:D011471 | Prostatic Neoplasms | lycopene | 21.61 | 15084515 17337101 | |
| MESH:D011471 | Prostatic Neoplasms | methylselenic acid | 21.61 | 16205645 | |
| MESH:D011471 | Prostatic Neoplasms | O-desmethylangolensin | 21.61 | 16925846 | |
| MESH:D011471 | Prostatic Neoplasms | Paclitaxel | 21.61 | 17136230 16356831 16729912 17172428 | |
| MESH:D011471 | Prostatic Neoplasms | Phytoestrogens | 21.61 | 16921512 | |
| MESH:D011471 | Prostatic Neoplasms | Plant Extracts | 21.61 | 17804756 14666653 | |
| MESH:D011471 | Prostatic Neoplasms | Polychlorinated Biphenyls | 21.61 | 15721890 | |
| MESH:D011471 | Prostatic Neoplasms | Quercetin | 21.61 | 14715546 17292933 | |
| MESH:D011471 | Prostatic Neoplasms | Raloxifene | 21.61 | 15731164 16536755 16220300 | |
| MESH:D011471 | Prostatic Neoplasms | resveratrol | 21.61 | 17718901 17804756 15767336 17636462 16731767 17675339 | |
| MESH:D011471 | Prostatic Neoplasms | Sodium Selenite | 21.61 | 18760546 | |
| MESH:D011471 | Prostatic Neoplasms | Tamoxifen | 21.61 | 15067354 | |
| MESH:D011471 | Prostatic Neoplasms | trichostatin A | 21.61 | 19789329 18798265 | |
| MESH:D011472 | Prostatitis | vinclozolin | 3.66 | 18629315 | |
| MESH:D011537 | Pruritus | Ethinyl Estradiol | 5.85 | 16919318 15861022 | |
| MESH:D011537 | Pruritus | Levonorgestrel | 5.85 | 15861022 | |
| MESH:D019310 | Pseudolymphoma | Valproic Acid | 3.25 | 12752131 11422049 | |
| MESH:D011629 | Puberty, Precocious | bisphenol A | 3.51 | 10548101 | |
| MESH:D011649 | Pulmonary Alveolar Proteinosis | 27-hydroxycholesterol | 5.10 | 15466366 | |
| MESH:D011658 | Pulmonary Fibrosis | Cyclophosphamide | 5.43 | 16636934 | |
| MESH:D011658 | Pulmonary Fibrosis | Drugs, Chinese Herbal | 5.43 | 16987627 | |
| MESH:D011658 | Pulmonary Fibrosis | gefitinib | 5.43 | 18424623 | |
| MESH:D011693 | Purpura | Raloxifene | 4.26 | 15770314 | |
| MESH:D012003 | Rectal Fistula | Drugs, Chinese Herbal | 4.67 | 15043669 | |
| MESH:D051437 | Renal Insufficiency | Doxorubicin | 2.99 | 17922066 | |
| MESH:D051436 | Renal Insufficiency, Chronic | resveratrol | 4.28 | 16325855 | |
| MESH:D015427 | Reperfusion Injury | resveratrol | 2.49 | 16314181 15827377 17520802 17058453 16317513 | |
| MESH:D012135 | Respiratory Sounds | Atrazine | 3.30 | 11874814 | |
| MESH:D015619 | Respiratory System Abnormalities | Tetrachlorodibenzodioxin | 2.61 | 18990726 | |
| MESH:D012162 | Retinal Degeneration | 4,4'-diaminodiphenylmethane | 2.33 | 3692021 | |
| MESH:D012206 | Rhabdomyolysis | Lamivudine | 4.26 | 9296927 | |
| MESH:D012208 | Rhabdomyosarcoma | decitabine | 6.98 | 19155313 | |
| MESH:D012208 | Rhabdomyosarcoma | Valproic Acid | 6.98 | 19155313 | |
| MESH:D012221 | Rhinitis, Allergic, Perennial | Drugs, Chinese Herbal | 3.99 | 15015336 | |
| MESH:D012468 | Salivary Gland Neoplasms | Progesterone | 2.21 | 18045962 | |
| MESH:D012509 | Sarcoma | Doxorubicin | 2.85 | 16767912 17710206 15625365 18313854 17203757 15675481 | |
| MESH:D012512 | Sarcoma, Ewing's | Doxorubicin | 3.03 | 14601052 16326096 | |
| MESH:D012514 | Sarcoma, Kaposi | Doxorubicin | 3.52 | 17846226 | |
| MESH:D012554 | Schistosomiasis japonica | Quercetin | 4.25 | 16862918 | |
| MESH:D012559 | Schizophrenia | Valproic Acid | 1.87 | 19110320 15737665 | |
| MESH:D012595 | Scleroderma, Systemic | Cyclophosphamide | 3.62 | 16636934 | |
| MESH:D012640 | Seizures | Endosulfan | 4.63 | 7539098 10698677 | |
| MESH:D012640 | Seizures | Lindane | 4.63 | 15475178 7539098 12842176 | |
| MESH:D012640 | Seizures | Valproic Acid | 4.63 | 15475178 11044598 11738929 14763951 1511512 3137016 16876388 17978042 | |
| MESH:D018805 | Sepsis | dong quai | 4.73 | 16424112 | |
| MESH:D012735 | Sexual Dysfunction, Physiological | Testosterone | 4.90 | 16631401 | |
| MESH:D012878 | Skin Neoplasms | Doxorubicin | 11.93 | 15692506 | |
| MESH:D012878 | Skin Neoplasms | Glucose | 11.93 | 14993021 | |
| MESH:D012878 | Skin Neoplasms | Plant Extracts | 11.93 | 15173996 16517061 | |
| MESH:D012878 | Skin Neoplasms | resveratrol | 11.93 | 15837718 8985016 | |
| MESH:D012878 | Skin Neoplasms | Tetrachlorodibenzodioxin | 11.93 | 16192470 | |
| MESH:D012878 | Skin Neoplasms | Tetradecanoylphorbol Acetate | 11.93 | 18404319 8985016 8330346 11807781 12065085 | |
| MESH:D019082 | Smith-Lemli-Opitz Syndrome | 24-hydroxycholesterol | 9.23 | 11254748 | |
| MESH:D019082 | Smith-Lemli-Opitz Syndrome | 27-hydroxycholesterol | 9.23 | 11254748 | |
| MESH:D012983 | Soft Tissue Neoplasms | Doxorubicin | 3.32 | 15625365 16767912 17203757 | |
| OMIM:270800 | SPASTIC PARAPLEGIA 5A, AUTOSOMAL RECESSIVE | 27-hydroxycholesterol | 5.09 | 19812052 | |
| MESH:D013088 | Spermatocele | Diethylstilbestrol | 18.85 | 16709447 16002989 | |
| MESH:D013088 | Spermatocele | Ethinyl Estradiol | 18.85 | 16709447 | |
| MESH:D013088 | Spermatocele | Tamoxifen | 18.85 | 16709447 | |
| MESH:D013088 | Spermatocele | Toremifene | 18.85 | 16709447 | |
| OMIM:102530 | SPERMATOGENIC FAILURE 6 | Cyclophosphamide | 4.24 | 16517039 | |
| MESH:D013119 | Spinal Cord Injuries | Progesterone | 6.68 | 16503802 15862959 | |
| MESH:D013119 | Spinal Cord Injuries | Tamoxifen | 6.68 | 19457130 | |
| MESH:D016135 | Spinal Dysraphism | Valproic Acid | 2.71 | 19490988 | |
| MESH:D013226 | Status Epilepticus | Valproic Acid | 3.25 | 12833885 | |
| MESH:D013272 | Stomach Diseases | beta Carotene | 3.84 | 17638125 | |
| MESH:D013274 | Stomach Neoplasms | Butylated Hydroxyanisole | 3.44 | 3581430 1399818 | |
| MESH:D013274 | Stomach Neoplasms | decitabine | 3.44 | 19037991 | |
| MESH:D013274 | Stomach Neoplasms | Drugs, Chinese Herbal | 3.44 | 18339527 | |
| MESH:D013274 | Stomach Neoplasms | Paclitaxel | 3.44 | 18506536 18396642 | |
| MESH:D013274 | Stomach Neoplasms | Zidovudine | 3.44 | 17696246 | |
| MESH:D013276 | Stomach Ulcer | beta Carotene | 4.27 | 12500499 | |
| MESH:D013276 | Stomach Ulcer | Plant Extracts | 4.27 | 15255614 17135157 12787963 18237397 18193104 | |
| MESH:D020521 | Stroke | Raloxifene | 2.76 | 16837676 | |
| OMIM:601367 | STROKE, ISCHEMIC | resveratrol | 3.32 | 16321402 | |
| MESH:D013345 | Subarachnoid Hemorrhage | Drugs, Chinese Herbal | 4.47 | 17634840 | |
| MESH:D019966 | Substance-Related Disorders | bisphenol A | 2.74 | 16684133 16045194 | |
| MESH:D015173 | Supratentorial Neoplasms | Cyclophosphamide | 3.79 | 12837982 | |
| MESH:D013576 | Syndactyly | methoxyacetic acid | 4.40 | 1761404 1761407 | |
| MESH:D024801 | Tauopathies | Paclitaxel | 3.55 | 16930453 | |
| MESH:D013705 | Temporomandibular Joint Disorders | Plant Extracts | 4.19 | 17997062 | |
| MESH:D013733 | Testicular Diseases | methoxyacetic acid | 6.82 | 18486176 6499806 | |
| MESH:D013733 | Testicular Diseases | pyrazole | 6.82 | 6499806 | |
| MESH:D019851 | Thrombophilia | Ethinyl Estradiol | 2.42 | 11994571 | |
| MESH:D013927 | Thrombosis | Ethinyl Estradiol | 2.04 | 15669648 | |
| MESH:D013959 | Thyroid Diseases | Tetrachlorodibenzodioxin | 8.23 | 12697716 | |
| MESH:D013959 | Thyroid Diseases | Triclosan | 8.23 | 19910387 | |
| MESH:D013964 | Thyroid Neoplasms | 4,4'-diaminodiphenylmethane | 8.61 | 3712494 7505956 6582329 6587162 1399818 | |
| MESH:D013964 | Thyroid Neoplasms | decitabine | 8.61 | 17967635 | |
| MESH:D013964 | Thyroid Neoplasms | Doxorubicin | 8.61 | 16010429 17909728 | |
| MESH:D013964 | Thyroid Neoplasms | gefitinib | 8.61 | 16940797 | |
| MESH:D013978 | Tibial Fractures | Estradiol | 9.43 | 19048282 | |
| MESH:D013978 | Tibial Fractures | Raloxifene | 9.43 | 19048282 | |
| MESH:D014062 | Tongue Neoplasms | resveratrol | 3.06 | 16227395 | |
| MESH:D014178 | Translocation, Genetic | Valproic Acid | 3.94 | 17262798 | |
| MESH:D014202 | Tremor | Chlordecone | 7.56 | 6175765 | |
| MESH:D014202 | Tremor | fenvalerate | 7.56 | 8952708 | |
| MESH:D014376 | Tuberculosis | Rifampin | 3.83 | 18397238 15236969 | |
| MESH:D020194 | Unverricht-Lundborg Syndrome | Valproic Acid | 3.25 | 3119515 | |
| MESH:D001749 | Urinary Bladder Neoplasms | marker/mechanism | 16700038 | ||
| MESH:D001749 | Urinary Bladder Neoplasms | 2-phenylphenol | 24.24 | 6654951 | |
| MESH:D001749 | Urinary Bladder Neoplasms | 4,4'-diaminodiphenylmethane | 24.24 | 8074119 | |
| MESH:D001749 | Urinary Bladder Neoplasms | Butylated Hydroxyanisole | 24.24 | 1399818 | |
| MESH:D001749 | Urinary Bladder Neoplasms | Cyclophosphamide | 24.24 | 14692829 | |
| MESH:D001749 | Urinary Bladder Neoplasms | decitabine | 24.24 | 17616700 19087683 | |
| MESH:D001749 | Urinary Bladder Neoplasms | Diethylstilbestrol | 24.24 | 16452187 16712894 17306315 | |
| MESH:D001749 | Urinary Bladder Neoplasms | Doxorubicin | 24.24 | 17653716 | |
| MESH:D001749 | Urinary Bladder Neoplasms | Plant Preparations | 24.24 | 11251952 | |
| MESH:D001749 | Urinary Bladder Neoplasms | Quercetin | 24.24 | 16720314 | |
| MESH:D001749 | Urinary Bladder Neoplasms | Raloxifene | 24.24 | 17572228 | |
| MESH:D001749 | Urinary Bladder Neoplasms | Tamoxifen | 24.24 | 16712894 8653321 17572228 | |
| MESH:D014564 | Urogenital Abnormalities | Valproic Acid | 3.39 | 8888407 | |
| MESH:D014570 | Urologic Diseases | DDT | 8.45 | 16487989 | |
| MESH:D014570 | Urologic Diseases | Dichlorodiphenyl Dichloroethylene | 8.45 | 16487989 | |
| MESH:D002583 | Uterine Cervical Neoplasms | Diethylstilbestrol | 5.84 | 16175088 | |
| MESH:D002583 | Uterine Cervical Neoplasms | resveratrol | 5.84 | 17473185 | |
| MESH:D014591 | Uterine Diseases | bisphenol A | 9.53 | 14652134 | |
| MESH:D014591 | Uterine Diseases | Diethylstilbestrol | 9.53 | 14652134 | |
| MESH:D014594 | Uterine Neoplasms | Diethylstilbestrol | 9.08 | 15809267 16690809 | |
| MESH:D014594 | Uterine Neoplasms | Ethinyl Estradiol | 9.08 | 14692618 | |
| MESH:D014594 | Uterine Neoplasms | resveratrol | 9.08 | 17044934 | |
| MESH:D014604 | Uveal Neoplasms | decitabine | 3.62 | 17785578 | |
| MESH:D014623 | Vaginal Diseases | cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt | 6.41 | 16837883 | |
| MESH:D014625 | Vaginal Neoplasms | Diethylstilbestrol | 7.01 | 16002989 16513791 | |
| MESH:D014625 | Vaginal Neoplasms | Zidovudine | 7.01 | 12579204 | |
| MESH:D054079 | Vascular Malformations | Tetrachlorodibenzodioxin | 3.30 | 12125929 | |
| MESH:D054556 | Venous Thromboembolism | Raloxifene | 3.91 | 16837676 | |
| MESH:D020246 | Venous Thrombosis | Ethinyl Estradiol | 6.87 | 15869587 14671159 | |
| MESH:D020246 | Venous Thrombosis | Levonorgestrel | 6.87 | 15869587 | |
| MESH:D018487 | Ventricular Dysfunction, Left | Doxorubicin | 10.11 | 17678736 17638931 16364871 17334414 | |
| MESH:D018487 | Ventricular Dysfunction, Left | Plant Extracts | 10.11 | 18097624 | |
| MESH:D018487 | Ventricular Dysfunction, Left | resveratrol | 10.11 | 17488730 | |
| MESH:D020257 | Ventricular Remodeling | Plant Extracts | 4.04 | 18097624 | |
| MESH:D014846 | Vulvar Neoplasms | Raloxifene | 4.26 | 16343187 | |
| MESH:D019282 | Wasting Syndrome | Tetrachlorodibenzodioxin | 2.95 | 15886252 | |
| MESH:D014947 | Wounds and Injuries | Drugs, Chinese Herbal | 8.16 | 16313111 | |
| MESH:D014947 | Wounds and Injuries | Estrogens | 8.16 | 11172683 | |
| MESH:D014947 | Wounds and Injuries | Plant Extracts | 8.16 | 19894650 20213670 |
| Pathway ID | Pathway Name |
|---|---|
| REACT:71 | Gene Expression |
| Drugbank ID | Action | Drug Name | Description |
|---|---|---|---|
| DB00255 | agonist | Diethylstilbestrol | Antineoplastic Agents, Hormonal;Carcinogens;Estrogens, Non-Steroidal |
| DB00481 | agonist | Raloxifene | Antihypocalcemic Agents;Osteoporosis Prophylactic;Selective Estrogen Receptor Modulators;Estrogen Antagonists;Bone Density Conservation Agents |
| DB00675 | other/unknown | Tamoxifen | Antineoplastic Agents, Hormonal;Selective Estrogen Receptor Modulators;Estrogen Antagonists;Bone Density Conservation Agents |
| DB00783 | agonist | Triquilar 21 | Anticholesteremic Agents;Estrogens;Anti-menopausal Agents |
| DB01108 | allosteric modulator | Trilostane | Antiadrenal;Anticorticosteroids |
| DB01196 | other/unknown | Estramustine | Antineoplastic Agents;Antineoplastic Agents, Hormonal;Radiation-Protective Agents;Antineoplastic Agents, Alkylating |
| DB01645 | - | Genistein | Antineoplastic Agents;Enzyme Inhibitors;Growth Inhibitors;Anticarcinogenic Agents;Protein Kinase Inhibitors;Phytoestrogens |
| DB02983 | - | Para-Mercury-Benzenesulfonic Acid | |
| DB03860 | - | N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide | Estrogen Antagonists |
| DB04020 | - | 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol | |
| DB04184 | - | Acetate Ion | Indicators and Reagents |
| DB04573 | agonist | Estriol | Estrogens |
| DB04574 | agonist | Estropipate | Hormone Replacement Agents;Estrogens |
| DB06832 | - | 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL | |
| DB06875 | - | 3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE | |
| DB06927 | - | [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE | |
| DB06937 | - | 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL | |
| DB07009 | - | 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL | |
| DB07032 | - | 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL | |
| DB07036 | - | (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol | |
| DB07119 | - | 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL | |
| DB07150 | - | 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME | |
| DB07198 | - | 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE | |
| DB07230 | - | 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE | |
| DB07236 | - | 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL | |
| DB07638 | - | (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL | |
| DB07702 | - | (16ALPHA,17ALPHA)-ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL | |
| DB07757 | - | (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one | |
| DB07933 | - | (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL | |
| DB08020 | - | (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL |
| No data |
| No data |
| No data |